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SUMMARY 
 
 
 
ClC proteins encompass a large protein family consisting of both voltage-
dependent chloride channels and chloride/proton exchangers that are found in both 
eukaryotes and prokaryotes. These proteins mediate Cl- flux across the plasma membrane 
or intracellular membranes of many cell types including neurons, epithelial cells, and 
skeletal muscle in mammals. In prokaryotic systems they are thought to be critical for 
extreme acid resistance. Mutations in genes encoding these proteins underlie several 
human genetic diseases including myotonia, epilepsy, Bartter’s syndrome, and Dent’s 
disease. Much of the research devoted to ClC proteins has focused on understanding ion 
conduction and gating of only a few members of the family, with ClC-0 and ClC-1 being 
the most prominent. Unlike other ion transport proteins, ClC proteins are homodimeric, 
“two pore”, proteins with each subunit containing 18 helical domains, as well as large 
intracellular domains in the eukaryotic members. For the ion channel members of the ClC 
family, chloride conduction through these channels is regulated by two separate gating 
mechanisms; a fast gating mechanism which independently controls conduction through 
each pore, and a slow gating mechanism which controls both pore simultaneously. While 
structure/function studies, coupled with a crystal structure of a bacterial ClC transporter, 
have led to improved understanding of some aspects of ClC fast gating and conduction, 
many issues remain unresolved including the nature of slow gating, and the differences 
that underlie ion transport through ClC channels versus ClC transporters. This has been 
hampered by the lack of selective, potent inhibitors of this family of proteins that could 
be used for structure/function studies.  
 xix
 In the cation channel field highly potent and selective inhibitors exist that have 
been very useful for structure/function studies. Some of the most useful of these 
compounds have been peptide toxins isolated from venomous animals such as scorpions, 
spiders, and cone snails. These proteins typically interact very high affinity, usually in the 
nM or pM range, and are very selective for their particular targets. Peptide toxins have 
been critical for elucidation of mechanisms underlying gating and ion conduction of 
various voltage-gated and ligand-gated cation channels. However, no peptide toxins have 
been discovered that interact with any member of the ClC family, and only one has been 
identified which inhibits a chloride channel of known molecular identity. Georgia anion 
toxin 1 (GaTx1), isolated from the venom of Leiurus quinquestriatus hebraeus (Lqh), 
inhibits the cystic fibrosis transmembrane conductance regulator  (CFTR) chloride 
channel. Identification and characterization of a peptide toxin capable of selectively 
inhibiting a member of the ClC protein family would open a new avenue of 
structure/function studies of these proteins, as well as help answer critical questions 
regarding the physiological role that some of these proteins play. Preliminary 
experiments from Dr. McCarty’s lab suggested that Lqh venom contained a component 
capable of inhibiting the ClC-2 chloride channel. Results shown in Chapters 2 - 9 
describe the initial characterization of the activity of Lqh venom, and isolation and 
characterization of the active toxin.  
 The first goal of this project was to characterize the activity of Lqh venom against 
members of the ClC protein family, and to determine if the active component was a 
peptide. We found that venom contained a component that selectively inhibited the ClC-2 
chloride channel when applied to the extracellular face of the channel. Further 
 xx
characterization of the active component revealed that the inhibitory nature of the active 
component could be abolished by treatment with trypsin, suggesting that this component 
was indeed a peptide. Finally, investigation into the mechanism of inhibition suggested 
that the active component of Lqh-venom acted as a gating modifier, slowing channel 
opening, and shifting the voltage-dependence of inhibition to more hyperpolarizing 
membrane potentials.  
 Our second goal was to purify the active toxin from venom, determine the 
primary amino acid sequence, and perform a more detailed characterization of the 
inhibitory activity against ClC-2. From venom, we isolated a peptide with a molecular 
mass of 3.2 kDa using reversed-phase HPLC, which we named Georgia anion toxin 2 
(GaTx2). Sequence analysis revealed that this toxin had been previously isolated in 1997, 
although no target was identified. Our worked showed that GaTx2 is the highest affinity 
inhibitor available for any chloride channel, inhibiting ClC-2 with a KD in the low pM 
range. Like venom, GaTx2 also appeared to slow channel opening. Finally, our data 
suggest that GaTx2 is specific for ClC-2; it was unable to inhibit currents mediated by 
other members of the ClC family, CFTR, other major chloride channels, and voltage-
dependent potassium channels.  
 Our results demonstrate the existence of a peptide toxin that is capable of 
inhibiting the ClC-2 voltage-gated chloride channel. This toxin is the first peptide toxin 
inhibitor of any ClC protein, and is the highest affinity inhibitor of any chloride channel 
identified to date. This toxin will provide a new tool for structure/function studies of ClC-
2, and will hopefully serve as only the first toxin inhibitor available for this protein 
family.  
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CHAPTER 1 
 
 
 
INTRODUCTION 
 
 
 
ClC proteins form a family of chloride transport proteins that are expressed in 
nearly all phyla. These proteins may be separated into two functional groups: those which 
form voltage-gated chloride channels, and those which form Cl-/H+ exchangers (Fig. 1). 
While evolutionarily these proteins are very similar, the basic mechanisms by which they 
perform their functions are very different. The functional unit of the ClC protein family is 
generally homodimeric, although heterodimers can form, with the mammalian proteins 
bearing a large intracellular domain that is absent in bacterial homologs. ClC channels 
generally show a halide permselectivity and conductivity sequence of Cl- >Br- >I-, and 
are impermeable to cations; ClC transporters exchange 2 Cl- ions for 1 H+ during their 
transport cycle. There are nine mammalian members of the ClC family, with 
representatives from both functional groups. In mammalian systems, ClC proteins 
mediate chloride transport across the plasma membrane and intracellular membranes in 
nearly all cell types. The functional effect of this chloride transport is the maintenance of 
resting membrane potential, cell volume regulation, and acidification of intracellular 
compartments such as endosomes. We will discuss, in detail, the properties of each of the 
mammalian ClC proteins, as well as ClC-0 from Torpedo electric organ, which was the 
first cloned ClC family member. We will also dissect the ClC protein structure, and the 
insights into channel gating that can be inferred from the available crystal structures, as 
well as the limitations of these structures. Finally, we will discuss the available 
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pharmacological tools for ClC proteins, as well as the lack of high affinity probes such as 
those available for cation channels.  
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Figure 1: ClC protein phylogeny. This phylogenetic tree is constructed from protein 
sequences of ClC protein representatives from Homo sapiens (red), C. elegans (black), 
Arabadopsis (green), and bacteria (blue).   
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1.1 Properties and physiology of ClC channels 
 ClC channels are mainly voltage-gated chloride channels that mediate chloride 
transport across the plasma membrane of many cell types. In mammals, there are 4 
channel subtypes of the ClC family: ClC-1, -2, -Ka, -Kb (Table 1). The canonical ClC 
channel to date, however, has been ClC-0, cloned from the electric organ of the Torpedo 
electric ray. As will be discussed below, many of the biophysical characteristics of these 
channels are quite similar, although they mediated vastly divergent physiological roles.  
 
1.1.1 ClC-0 
 The first member of the ClC family to be identified was the ClC-0 voltage-gated 
chloride channel from the electroplax of the Torpedo electric ray. This conductance was 
identified functionally by White and Miller in 1979, during attempts to insert membrane 
vesicles containing the nicotinic acetylcholine receptor (nAChR) from electroplax into 
planar lipid bilayers [1]. The insertion of membrane vesicles into bilayers showed a very 
weakly voltage-dependent conductance that was nearly perfectly anion selective, and 
inhibited by the non-selective chloride channel blockers SITS and DIDS. Also derived 
from this study was the realization that the nAChR and this voltage-dependent chloride 
channel localize to different parts of the electroplax membrane. The nAChR in 
electroplax is found at high density in the innervated membrane, while ClC-0 is localized 
to the non-innervated membrane [2]. Thousands of electroplax cells are then arranged in 
stacks similar to batteries placed in series. This arrangement allows for the high 
voltage/large current discharges that these animal use to stun or kill prey. 
 5
Table 1: Properties of ClC Chloride Channels. Members of the ClC protein family that act as voltage-dependent chloride channels 
are listed with decriptions of basic biophysical properties, tissue expression, physiological role, and associated pathophysiology.  
 
Table 1: Properties of ClC Chloride Channels 
 
 Function Expression Physiological Role Pathophysiology and 
Knockout 
 
  Tissue Cellular Localization    
ClC-0 Voltage-gated 
channel 
Slow gate: Hyperpol. 
Fast gates: Depol. 
Cl- >Br- >I- 
Torpedo electric 
organ 
Non-innervated PM Stabilization of membrane 
potential 
  
       
       
ClC-1 Voltage-gated 
channel 
Slow and Fast gates: 
Depol. 
Cl- >Br- >I- 
Skeletal muscle Sarcolemmal PM Stabilization of membrane 
potential, Primary Cl- 
conductance of skeletal 
muscle 
Generalized myotonia 
Myotonia congenita 
Myotonic dystrophy 
 
       
       
ClC-2 Voltage-gated 
channel 
Slow and Fast gates: 
Hyperpol 
Cl- >Br- >I- 
Ubiquitous Epithelial Apical or 
Basolateral PM, 
PM of VSMC, 
PM of Pyramidal Neurons 
Transepithelial transport,  
Cell volume regulation, 
Stabilization of membrane 
potential 
Epilepsy 
Degeneration of Testis and 
Retina (KO) 
Leukoencephaolopathy (KO) 
 
       
       
ClC-Ka/b 
+ Barttin 
Voltage-independent 
channel 
Cl- >Br- >I- 
Kidney Basolateral membrane Transepithelial transport Bartter’s Syndrome 
Diabetes insipidus (KO) 
 
       
 6
Prior to the cloning of the ClC-0 gene, much work was performed on single 
voltage-dependent chloride channels isolated from Torpedo membranes. The first studies 
of single Torpedo voltage-dependent chloride channels showed very interesting behavior. 
When these channels were observed at the single channel level, two equidistant 
conductance levels were always present during the recording, suggesting that more than 
one channel had been inserted into the bilayer [3, 4]. However, Miller and White showed 
that these conductance levels were always observed together as discrete bursts that were 
separated by long quiescent periods [3], suggesting that the conductance levels arose 
from a single protein. Analysis of the burst behavior showed that the distribution of 
conductance levels between closed, open level 1, and open level 2 exhibited a binomial 
distribution, suggesting that each conductance level was independent of the other during 
an open burst. The separation of these bursts by long quiescent periods indicated that a 
separate process was capable of simultaneously regulating channel activity. Taken 
together, it was suggested that the oligomeric structure of the voltage-dependent chloride 
conductance from Torpedo was that of a two-pored ion channel, possessing at least two 
separate gating processes [3, 5]. This “double-barreled” open channel behavior and 
complex gating behavior appears to be conserved among ClC channels (Fig. 2). 
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Figure 2: ClC single channel behavior. (A) Typical single channel recording of the ClC-
2 channel. Like other ClC proteins, ClC-2 transitions rapidly from the closed state (c) to 
two conducting states (O1, O2). Rapid transistions between O1 and O2 are regulated by 
the fast gates, while the long closures (> 1 second) represent closures of the slow gate. 
(B-D). Dwell time histograms of the closed state (B), and the two open states (B, D). The 
closed dwell time histograms shows two distinct closed states, brief closures consistent 
with closures of the fast gate, and long closures consistent with closures of the slow gate. 
Each open time histogram is best described by the sum of two exponential functions, as 
would be expected from the closure of two independent fast gates. (E). Transition 
diagram showing the probability of the channel transitioning from one state to any other.  
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The ClC-0 channel is encoded by a mature transcript of 2673 bases that is 
translated into an 805 amino acid protein with a mass of 89 kDa [6]. When cRNA of the 
ClC-0 clone was injected into Xenopus oocytes, currents with macroscopic behavior 
similar to that of the voltage-dependent chloride conductance from Torpedo were 
observed. These currents showed similar sensitivity to the chloride channel inhibitors 
DIDS and DPC [1, 2, 7]. Also similar to the chloride channel from electric organ, the 
cloned voltage-gated chloride channel showed double-barreled behavior, with two 
equidistant conductance levels exhibiting the same single channel conductance as 
channels isolated directly from the electric organ, ~10 pS for open level 1 and 20 pS for 
open level 2, suggesting that the cloned channel provides the voltage-dependent chloride 
conductance observed for the electric organ [8-10].  
 Since its cloning in 1990, ClC-0 has served as the canonical member of this large 
family of voltage-dependent chloride channels. In fact, much of the knowledge of ClC 
channel biophysics has come from studies initially performed on ClC-0. Early studies of 
the voltage-dependent Cl- conductance isolated from Torpedo and reconstituted into 
planar lipid bilayers suggested that the functional unit contained two independent 
chloride conduction pathways. The architecture of ClC-0 was further refined in 1996, 
when two independent studies suggested that ClC-0 was a homodimeric structure, with 
two separate pores [11, 12]. Middleton and coworkers tested the homodimeric model of 
the ClC-0 protein by introducing a point mutation into the protein that altered single 
channel conductance. The cRNA encoding the mutant channel was then co-injected with 
cRNA encoding wild-type ClC-0 into Xenopus oocytes. Single channel recording was 
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then performed and the transitions between conductance levels were observed. Three 
populations of openings were observed. Two populations showed 3 equidistant 
conductance levels consistent with WT-WT and mutant-mutant dimers. However, one 
population showed openings to 4 distinct conductance levels: closed, an opening to a 
single WT pore, an opening to a single mutant pore, and an open level with the summed 
conductance of the WT and mutant pore [12]. This model was separately tested by Pusch 
and coworkers in a separate study in which concatameric channels were created between 
WT and mutant subunits, which showed similar single channel behavior as described 
above for mixtures of WT and mutant cRNAs, with four conductance levels [11]. Both 
studies confirmed the homodimer nature of the ClC-0 protein. 
 Gating of ClC-0 channels is a very complicated process. Single ClC-0 channels 
show bursting behavior in which both pores independently conduct ions. During open 
bursts channels rapidly transition between the closed level and open levels 1 and 2 [9, 
13]. These rapid transitions are controlled by a process known as fast gating, with each 
pore controlled by its own fast gate; the main contributor to fast gating appears to be a 
conserved glutamate residue that resides within the pore domain of each subunit [14]. 
These channel bursts are separated by long periods with no channel activity. The long 
closures are controlled by a separate gating process known as slow-gating; the molecular 
determinants of this process are only now beginning to come into focus. On the single 
channel level the fast and slow gating processes are easily distinguished based on the 
time scales on which they act; there is a large amount of data characterizing these 
processes at both the macroscopic and single channel levels, which will be discussed. 
Both fast and slow gating processes are temperature dependent; the Q10 of fast gating is 
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~1.4, while the Q10 of slow gating is ~40, suggesting a major conformational change is 
associated with slow gating, and only a modest change is associated with fast gating [15]. 
The structural determinants of these gating processes will be discussed in further detail in 
section 1.4.  
 For ClC-0, both the fast and slow gating processes are voltage-dependent, with 
the slow gate being opened slowly by membrane hyperpolarization, and the fast gates 
being opened rapidly by membrane depolarization [10, 11], which results in the 
macroscopic behavior as shown in Figure 3. Analysis of the primary structure of ClC-0, 
and in fact all ClC channels, reveals no region of localized charge that may act as a 
voltage sensor, similar to the S4 helix in voltage-gated cation channels (Fig. 4A) [7, 16]. 
The calculated gating charge for ClC-0 is ~1, whereas the gating charge for a voltage-
gated K+ channel is ~14 [16]. Pusch and colleagues determined that the gating of ClC-0 is 
very dependent on the permeant ion by investigating the effects of altering the external 
[Cl-]. ClC-0 exhibited shifts in the V1/2 that were dependent on the external [Cl-], as well 
as effects on the V1/2 for fast-gating associated with anomalous mole fraction behavior 
with mixtures of Cl- and NO3-, suggesting that the permeant ion itself acts as the gating 
charge [11]. Analysis of single ClC-0 channels showed that there is a high degree of 
asymmetry in the transitions to and from the slow-gate closed state from a conducting 
state. Open bursts tended to begin with a transition from the slow-gate closed state to 
open level 2, and to return to the slow-gated closed state from open level 1. The transition 
pattern observed by Richard and Miller implied that ClC-0 gating is cyclical, 
preferentially transitioning from C→2→1→C. A gating cycle that exists in 
thermodynamic equilibrium should be able to open to either 1 or 2 with equal probability, 
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likewise for channel closing. Therefore, the transition pattern observed by Richard and 
Miller suggests that ClC-0 gating is a non-equilibrium process. This asymmetry was also 
shown to be dependent on the electrochemical gradient for Cl- [9]. It was further reported 
that the non-equilibrium gating of ClC-0 predicts that the closed state of the channel may 
differ structurally depending on whether Cl- is bound to the channel. It was shown 
experimentally that the Cl- bound closed state opens at a much higher rate than the 
unbound state [17]. The suggestion that Cl- itself acts as the gating charge, and the 
recognition that the Cl- bound state of the channel opens at a higher rate, implies a very 
strong link between permeation and gating in ClC-0: the voltage-dependence of gating is 
derived from the voltage-dependent movement of Cl- within the pore [17]. Other work 
has suggested that this is also the case for other ClC channels as well [18]. Fast-gating of 
ClC-0 is only weakly controlled by internal Cl-. Raising [Cl-]int to non-physiological 
concentrations (i.e. > 150 mM) reduced the closing rate of the channel, having no effect 
on the opening rate [17, 19]. Given the very high concentrations required to modulate 
fast-gating, it is likely that this type of regulation is not physiologically relevant.  
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Figure 3: Typical macroscopic behavior of ClC channels. (A-C). Typical macroscopic 
two-electrode voltage clamp recordings of ClC-0 (A), ClC-1 (B), and ClC-2 (C) in 
response to specific voltage protocols. (D-F) Open probability versus voltage curves for 
the corresponding trace for ClC-0 (D), ClC-1 (E), and ClC-2 (F). Both ClC-0 and -1 are 
activated by membrane depolarization, as indicated by high open probability at positive 
membrane potentials. ClC-2 is activated by hyperpolarization. Note that the ClC-2 
activation curve never truly saturates, so the true open probability can only be estimated.  
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In addition to regulation of channel activity by the membrane potential, ClC-0, as 
well as other ClC channels, is dependent on pH. Hanke and Miller showed before the 
cloning of the ClC-0 gene that channel activity was dependent on pH, with activity 
increasing as the external pH decreases [4]. At very negative potentials, protonation of 
the channel increases the opening rate of the fast-gate, yet has no effect on the closing 
rate [4, 20], and increases the minimum PO of the fast-gate to ~0.6 [20]. The effect of 
protonation is independent of Cl- concentration, suggesting that the Cl- dependence and 
pH dependence of channel activation arise from different regions of the protein [20].  
 As discussed earlier, ClC channel activity is controlled by two gating 
mechanisms, a fast gate and a slow gate. Of the two, slow gating is less well understood. 
While the fast gate controls ion conduction through both channel pores individually, slow 
gating controls both pores simultaneously. During attempts to discover a peptide inhibitor 
of ClC-0, Chen found that Zn2+ inhibits ClC-0 current in a reversible manner by 
facilitating the closure of the slow gate [21]. Mutation of residue C212 to serine (C212S) 
rendered channels insensitive to inhibition by Zn2+, and eliminated the long closed 
durations associated with closure of the slow gate [22]. Slow gating can also be abolished 
by the point mutations H736A and E763K, which reside in the intracellular C-terminal 
domain, specifically in the cystathione β-synthase 2 (CBS2) domain [23]. Investigation 
into the chloride dependence of slow gating revealed that upon reduction on intracellular 
[Cl-], slow-gate activation shifted to more hyperpolarizing potentials, reducing the 
maximal activation of ClC-0 channels [18].  
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Macroscopic ClC-0 currents are typified by rapid channel deactivation at very 
negative membrane potentials, with “crossover” current in this same voltage range (Fig. 
3) [11]. However, in some cases atypical behavior is observed, which lacks crossover at 
hyperpolarizing membrane potentials, especially when ClC-0 channels are expressed in 
Xenopus oocytes and recorded using two-electrode voltage clamp (TEVC). Li and 
coworkers showed that these atypical currents are related to the oxidation state of the 
channel; pre-incubation of cells in a reducing agent such as DTT restores typical channel 
behavior, while incubation in an oxidizing agent can induce abnormal behavior [24]. The 
same study concluded that the effect of oxidation is on channel slow-gating; channels 
bearing the C212S mutation are insensitive to the effect of oxidation. It was postulated 
that channel oxidation reduces the ability of ClC-0 to recover from a state in which the 
slow gate is closed.  
 Over the years, ClC-0 has served as the prototype ClC channel, with much of the 
biophysical knowledge of all ClC channels being derived from these studies. However, 
there are important biophysical differences between the members of this family which 
will be discussed in further detail.  
 
1.1.2 ClC-1 
1.1.2.1 Biophysical Characteristics of ClC-1 
The first mammalian ClC channel that will be discussed is ClC-1. ClC-1 is the 
main chloride channel present in skeletal muscle plasma membrane, providing greater 
than 80% of the normal resting membrane conductance [25]. Defects in this channel lead 
to generalized myotonia and myotonia congenita, which will be discussed further in 
 15
section 1.1.2.2 [26-28]. The cDNA encoding the rat skeletal muscle chloride channel, 
named ClC-1, was identified by homology screening to the Torpedo voltage-dependent 
chloride channel ClC-0. The cDNA encoding rat ClC-1 yields a 994 amino acid protein 
that is 54% identical to ClC-0 [25, 29]. The human ClC-1 clone was identified by a 
homology screen to the rat ClC-1, and was localized to chromosome 7 [26].  
Macroscopic ClC-1 currents are very similar to those of ClC-0 (Fig. 3B), with a 
similar PO/V curve (Fig. 3E), and as will be discussed below, are mediated by both fast 
and slow gating processes. Channels rapidly deactivate at strongly hyperpolarizing 
potentials, with PO increasing as the membrane becomes more depolarized. Unlike ClC-0, 
it is very difficult to perform ClC-1 single channel recordings due to the very small single 
channel amplitude. When ClC-1 is transfected into HEK-293 cells, the macroscopic 
current is very similar to that shown in Figure 3B, albeit with faster gating kinetics. 
However, non-stationary noise analysis revealed that the single pore conductance of ClC-
1 is only ~1pS, approximately 10 fold lower than the single pore conductance of ClC-0 
[30]. Therefore, determination of the oligomeric structure of ClC-1 was not initially 
feasible by site directed mutagenesis in conjunction with single channel recording. 
Instead, the oligomeric structure of ClC-1 was determined by analysis of dominant 
negative ClC-1 mutations associated with myotonia congenita [31]. In principle, currents 
mediated by ClC-1 should be reduced by incorporation of mutant subunits with altered 
conductance properties into the functional unit of the channel, and the degree to which 
activity is reduced should depend on the number of mutant subunits incorporated into the 
channel. The functional unit of channels incorporating G230E subunits appears to be a 
dimer, reducing channel current to ~35% of WT channels, while P480L subunits tend to 
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incorporate into tetrameric channels , reducing current to <10% that of WT [31]. Other 
studies utilizing chemical modifying methanethiolsulfonate (MTS) reagents suggested 
that ClC-1 was composed of just a single pore [32]. Single channel experiments in 
Xenopus oocytes performed by Saviane and coworkers showed that ClC-1 displayed 
double-barreled activity similar to ClC-0 [33]. These experiments very beautifully 
illustrated the two-pore behavior of ClC-1 channels, despite the single pore conductance 
of just 1.2 pS, and this behavior was well described by a model incorporating a single 
protein with two independent conductance pathways [33].   
Like ClC-0, ClC-1 channels are voltage-dependent channels with very shallow 
voltage-dependence, z ~ 0.9 [30]. Indeed, as previously stated, the macroscopic behavior 
of ClC-1 is very similar to ClC-0 currents isolating currents mediated by fast gating when 
the slow gate PO ~ 1(Fig. 3). Also analogous to ClC-0, ClC-1 channels show complicated 
gating behavior, possessing both a fast and slow gate, although the two gating behaviors 
are not easily separable, as they are in ClC-0. Unlike ClC-0, CLC-1 channels lack a 
hyperpolarization-activated slow gate; instead, slow-gating is activated by membrane 
depolarization. Channel deactivation at very hyperpolarizing potentials is best described 
by bi-exponential fits, which presumably correspond to the fast and slow-gating 
processes. These gating processes were initially described by Fahlke and coworkers, who 
suggested that one gating process acted on the microsecond time-scale, with each pore 
possessing a single residue, titratable by protons, acting as a voltage sensor, and a 
separate process acting on the millisecond time-scale [34], both of which were activated 
by membrane depolarization. The time constants for these gating processes are separated 
by a factor of ~10, but according to Fahlke and coworkers there is no voltage-dependence 
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of these gating processes over a voltage range of -195 to -45 mV. Later studies by 
Rychkov , however, suggested that the fast component of channel deactivation was 
weakly voltage-dependent, while the slower component was strongly voltage-dependent 
[35]. Both of these studies were corroborated by Accardi and Pusch [36], showing that at 
very negative potentials the time constants for fast and slow gating were ~10 fold 
different, and not voltage dependent, but as membrane potential increased, the gating 
processes showed strong voltage-dependence with ~100-fold difference in time constants. 
Moreover, the voltage dependence of ClC-1 gating was qualitatively very similar to that 
of the fast gating process of ClC-0. Both fast and slow gating processes had Q10 values of 
~4 – 5, which would suggest a modest structural rearrangement during both gating 
processes, while shared voltage-dependence would suggest that these gating processes 
may be coupled [37].  
 ClC-1 is also regulated by external [Cl-], and by changes in both external and 
internal pH. Lowering the extracellular [Cl-] substantially speeds channel deactivation at 
negative potentials, and reduces the overall steady-state current level at all voltages [35, 
36]. This decrease in current is due to a drastic rightward shift in the PO/V curve, making 
stronger depolarization necessary for channel opening [35, 36]. Under normal conditions, 
the minimum PO of the slow gate is >0.6; however, upon lowering of [Cl-]ext, minimum 
PO is reduced by ~50%, and is accompanied by a > 40 mV rightward shift in the PO/V 
curve of the slow gate. This would suggest that current is reduced primarily by increasing 
the closed duration of the slow gate. Like ClC-0, the cytosolic CBS domains may also 
play a role in common gating [38], as does residue C277, which when mutated to serine 
shows complete loss of common gating, similar to the C212S mutation in ClC-0 [39, 40].  
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 Regulation of ClC-1 channels by pH is complex, being affected by both internal 
and external pH. The effects of internal pH may be further complicated by the presence 
of ATP. When extracellular pH is decreased, the degree of channel deactivation at 
hyperpolarizing potentials is decreased, leading to larger steady-state currents according 
to Rychkov and colleagues. Similar to the effect of low bath pH on ClC-0 activation, low 
pH leads to an increase in the minimum PO of ClC-1, raising it from near 0 to ~0.5 [35]. 
This suggests that ClC-0 and ClC-1 are regulated by pH via a similar mechanism, with 
the effect of protonation being independent of [Cl-]ext for both channels [20, 35]. 
However, these results contradict studies from whole muscle fibers, which showed that 
GCl decreased upon extracellular acidification [41, 42]. These disparate results have not 
currently been reconciled, though the differences between the in vitro setting of cultured 
cells and the in vivo environment of intact muscle fibers is likely to play a significant 
role.  
Likewise, regulation of ClC-1 current by intracellular changes in pH is currently a 
controversial topic. Intense muscle activity is generally associated with intracellular 
acidification of muscle fibers that stems from the build-up of lactic acid within the cell 
[41], leading to muscle fatigue and a reduced ability to conduct action potentials. 
However, it was recently found that this acidification-induced fatigue was counteracted 
by decreased chloride permeability, thereby making the muscle hyper-excitable [43]. This 
contradicts previous results by Accardi and Pusch, showing that when ClC-1 is expressed 
in a heterologous system, reduction of intracellular pH increased ClC-1 current by 
shifting the PO/V curve of both the fast and slow gating processes to more 
hyperpolarizing potentials [36]. However, this was later challenged by Bennetts, who 
 19
showed that intracellular acidification shifted slow gating to more depolarized potentials, 
while fast gating was shifted to more hyperpolarized potentials [44, 45]. Both studies, 
however, show an increase in steady state current. It is possible that these slightly 
disparate results are byproducts of experimental systems, as Accardi and Pusch utilized 
the Xenopus expression system, while Bennetts et al. performed whole-cell recording of 
HEK-293 cells. This controversy is further complicated by the notion put forth that 
inhibition of ClC-1 by binding of ATP, presumably to the cytosolic CBS domains, is 
greatly enhanced by intracellular acidification [46]. Inhibition of ClC-1 currents by ATP 
+ low pH has been shown in HEK-293 cells by Bennetts and coworkers, as well as 
Xenopus oocytes by Tseng and colleagues [44-46]. However, Zifarelli and Pusch were 
unable to recapitulate these results in Xenopus oocytes using the exact same voltage 
protocols, clone, and ATP from the same manufacturer [47], and further suggested that 
ATP has an indirect effect on ClC-1 behavior. Given this current controversy, it is 
unclear how intracellular acidification may regulate ClC-1 conductance, although it 
seems likely that the combination of intracellular acidification during exercise and the 
high [ATP] concentration in cells plays a significant physiological role.  
 
1.1.2.2 Physiological role of ClC-1 and associated pathophysiology 
 As stated above, ClC-1 provides >80% of the membrane conductance of skeletal 
muscle tissue. Northern blot analysis revealed that ClC-1 was highly expressed in skeletal 
muscle, with virtually no expression in other tissues including brain, lung, kidney, and 
heart [25]. Early experiments, prior to the molecular identification of ClC-1, attempted to 
determine the localization of the major skeletal muscle Cl- (GCl) and K+ (GK) 
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conductances by disruption of the transverse tubular network by equilibrating the fiber in 
hypertonic glycerol, then returning the preparation to isotonic Ringer’s solution. This 
treatment induced a large reduction in GCl, while leaving GK largely intact, suggesting 
that GCl is localized to the T-tubules, while GK resides in the sarcolemma [42]. However, 
immunofluorescence experiments later showed that ClC-1, the major determinant of GCl, 
is distributed along the sarcolemmal surface, and could be immunoprecipitated from 
sarcolemmal preparations [48]. Furthermore, this expression was not uniform across the 
sarcolemma, and Papponen and coworkers suggested that expression of ClC-1 at the 
sarcolemmal surface may be dependent on phosphorylation/dephosphorylation signals, 
with surface expression of ClC-1 being increased by incubation of cells with the kinase 
inhibitor staurosporine [49].  
Unlike neuronal tissues, which utilize K+ current to repolarize the cell following 
an action potential, skeletal muscle fibers rely on Cl- current mediated by ClC-1 to 
repolarize the membrane. This is an important physiological feature considering that 
repolarization of muscle via outward-directed K+ conductance would lead to K+ 
accumulation in the small spaces of muscle fiber and would induce membrane 
depolarization. This is not an issue if Cl- currents are the major component of the 
repolarization phase. However, disruption of ClC-1 mediated Cl- current is the basis for 
the genetic disease myotonia.  
 Myotonia is characterized by muscle “stiffness” which can stem from defects in 
genes encoding voltage-gated sodium channels and the voltage-gated chloride channel 
ClC-1 [50]. Mutations in genes encoding these channels are fundamentally different in 
that mutations in sodium channel genes associated with myotonia are generally gain-of-
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function mutations, increasing sodium conductance, while mutations in ClC-1 are loss-of-
function mutations, leading to decreased chloride conductance [50. These alterations in 
channel conductance lead to hyperexcitability of the muscle, which can lead to trains of 
action potentials stemming from a single nerve stimulation, known as “myotonic runs”, 
51, 52]. Myotonia resulting from defects in the ClC-1 channel can be passed on through 
multiple modes of inheritance; it can be either dominant (myotonia congenita, Thomsen’s 
disease) [26, 50, 53], or recessive (generalized myotonia, Becker-type myotonia) [26, 50, 
53], with specific genotypes varying the severity of the disorder. Clinically, recessive 
myotonia is more severe than dominant myotonia, as patients with recessive myotonia are 
homozygous for mutant ClC-2 alleles, which could almost completely knockout chloride 
conductance in skeletal muscle [53]. Myotonia is also one of the main symptoms of 
myotonic dystrophy, a multi-systemic disorder, which shows a drastic reduction in the 
amount of RNA encoding ClC-1 [54, 55].  
 Specific myotonia-causing mutations associated with ClC-1 were first identified 
in mice, where it was shown that the gene encoding ClC-1 had been incorrectly spliced to 
a member of the ETn family of mouse transposons [27, 29]. Subsequently, mutations in 
human ClC-1 were identified through screening of families showing symptoms of 
generalized myotonia [26]. Mutations have since been identified in goats [56] and dogs 
[57], as well. In total, more than 60 myotonia causing mutations in the ClC-1 gene have 
been identified, the vast majority of which show an autosomal recessive mode of 
inheritance [50]. These mutations may lead to decreased surface expression of the 
channel, but many show alterations in channel behavior. For example, Fahlke and 
coworkers showed that the mutation D136G caused recessive generalized myotonia, and 
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changed ClC-1 channel biophysics such that instead of fast deactivation at hyperpolarized 
potential, channels activated very slowly at these potentials, creating an inwardly 
rectifying current [58]. The mutations I290M, R317Q, P480L, and Q552R, associated 
with dominant myotonia, drastically shift channel gating to more positive potentials, 
generally reducing channel PO within the physiological voltage range [58, 59]. Finally the 
mutation G230E shows altered permeability, with an increase in Na+ conductance, and 
overall reduction in Cl- conductance [31].  
As has been illustrated above, ClC-1 plays a critical role in muscle physiology. 
This channel is essential to normal muscle function, plays a role in the onset and recovery 
from muscle fatigue, and is mutated in the genetic disease myotonia. As will be described 
in section 1.4, knowledge gained from studying both the physiological role of WT 
channels, and understanding the biophysical characteristics of both the WT and mutant 
channel have provided invaluable insights into ClC channel structure and dynamics. 
 
1.1.3 ClC-2 
1.1.3.1 Biophysical characteristics of ClC-2 
The second mammalian member of the ClC family to be identified was ClC-2. 
Like ClC-1, mRNA encoding ClC-2 was identified by screening cDNA libraries using a 
cDNA encoding the rat skeletal muscle channel ClC-1 as a probe [60].  Initial 
screening identified an identical novel Cl- channel encoding mRNA in both rat heart and 
brain. Sequencing revealed a 3217 bp transcript encoding a 907 amino acid protein with a 
predicted molecular mass of ~99 kDa [60]. Additionally, Northern blot analysis revealed 
that ClC-2 mRNA was found nearly ubiquitously, being present in skeletal muscle, heart, 
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lung, kidney, pancreas, stomach, intestine, and liver [60]. ClC-2 was also identified in 
multiple human cell lines that are regularly used as model experimental systems. 
Comparison of the amino acid sequence revealed that ClC-2 is 49% identical to ClC-0 
and 55% identical to ClC-1 [60] (Fig. 1).  
Initial biophysical characterization of ClC-2 currents was performed by 
expression of rat ClC-2 in Xenopus oocytes, with currents recorded via TEVC. Like other 
channel members of the ClC family, ClC-2 is a voltage-gated Cl- channel. However, 
Thiemann and colleagues showed that, unlike both ClC-0 and ClC-1, ClC-2 currents were 
activated very slowly upon membrane hyperpolarization, but only when potentials were 
stronger than -50 mV (Fig 3C) [60]. Full activation of ClC-2 at very hyperpolarizing 
potentials took longer than 20 seconds. Almost no activation was observed at more 
physiological potentials, and channel deactivation was observed upon stepping to a non-
activating potential (e.g. +40 mV) immediately following channel activation, as shown in 
Figure 3C. Analysis of the PO/V curve obtained from TEVC experiments in Xenopus 
oocytes shows that ClC-2 never achieves maximal activation in this experimental system, 
even at very negative membrane potentials, and a PO ~1 is never reached within the 
voltage range that can accurately be applied to an oocyte. Ion selectivity of ClC-2 is also 
similar to other ClC channels, maintaining both a permeability and conductance sequence 
of Cl- > Br- > I- [60, 61]. ClC-2 gating is very complex. In addition to being a voltage-
gated Cl- channel, gating is also modulated by other factors including external pH and 
cell swelling upon exposure to hypotonic conditions [62].  
The basic architecture of the ClC-2 channel was initially suspected to be 
homodimeric, based on the high degree of homology to both ClC-0 and ClC-1, which had 
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been shown to be double barreled ion channels via single channel recordings [10, 33], 
and a shared predicted membrane topology [7, 25]. Early characterization of purified 
ClC-2 from Sf9 membranes reconstituted into lipid bilayers by Ramjeesingh et al., 
suggested that ClC-2, like ClC-0, showed double-barreled open channel activity, with the 
minimum functional unit being ClC-2 dimers [63]. However, it was also suggested that 
activity of a ClC-2 dimer resembled a single pore, with double-barreled activity 
becoming apparent only when a ClC-2 tetramer was formed. Additionally, the unitary 
conductance was calculated to be 32 and 64 pS for each open level [63]. A number of 
investigators now have shown these conclusions to be incorrect, and may have been a 
byproduct of the expression system. Recording of ClC-2-like current in astrocytes [64], 
ClC-2/ClC-2 concatamers [65], and single channel recording of WT ClC-2 channels in 
Xenopus oocytes (Fig. 2A), have shown that ClC-2 channels do indeed show double-
barreled activity as a dimer, with a unitary conductance of ~3 and 6 pS, 10-fold lower 
than the calculated values from Sf9 membranes fused to lipid bilayers [63]. Furthermore, 
inspection of ClC-2 single channel currents reveals that similar gating mechanisms exist 
for the ClC-2 channel, i.e. channels possess both a fast gate and a slow gate, as indicated 
by both long closured between bursts, and rapid transitions between conductance levels 
within a burst (Fig. 2A) [64, 65]. However, like ClC-1, the low conductance of ClC-2 
channels has thus far precluded highly analytical single channel analysis. Thus analysis 
of ClC-2 gating has relied on other techniques.  
The detailed gating mechanisms of ClC-2 have only recently been elucidated. It 
has long been known that the time course of activation of ClC-2 is best described by the 
sum of two exponentials [60, 61]. The proposal that ClC-2 possesses both fast and slow 
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gating processes is supported by mutational studies performed initially in the lab of F. 
Sepulveda. In ClC-0, two specific point mutations have been identified that 
independently affect either fast or slow gating; E166A, which eliminates fast-gating [14], 
and C212S, which eliminates slow gating [22]. Equivalent mutations were made in ClC-2 
channels, E217A and C256S, and analysis of macroscopic current revealed constitutively 
active channels with altered channel kinetics, altered dependence on external pH, and 
reduced the inhibitory effect of Zn2+, suggesting the presence of two gating mechanisms 
in ClC-2 channels [66, 67]. De Santiago and coworkers examined fast and slow gating 
using voltage protocols specifically designed to separate these two gating processes [68]. 
These experiments revealed that fast and slow gating share the same voltage-dependence, 
with about a 10-fold separation of the time constants for these processes [68]. 
Interestingly, the amplitudes of these gating steps show opposite voltage-dependence, 
with fast gating showing diminished contribution at more depolarizing potentials, while 
fractional contribution of slow gating increased. Open probability of the fast-gate reaches 
a PO of 0 at depolarizing membrane potentials, while the minimum PO of slow gating is 
~0.6 . De Santiago further analyzed the specific effects of the gating mutations described 
above. While those equivalent mutations only affect either fast or slow gating in ClC-0, 
in ClC-2 they affect both gating processes simultaneously [68], suggesting that not only 
are fast and slow-gating linked in terms of voltage-dependence, but they may also share a 
physical link. Like ClC-1, the Q10 values for both fast and slow gating for ClC-2 are ~4 – 
5, consistent with a similar degree of structural change. Additionally, the mutation 
H811A located in the CBS2 domain, the equivalent of which was shown to remove slow 
gating in ClC-0, alters both fast and slow gating in ClC-2 channels [69]. The theory of a 
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physical coupling between fast and slow gating has not been rigorously tested, but also 
seems likely given lack of a mutation in ClC-2 that singularly effects either fast or slow-
gating.  
 As stated above, ClC-2 currents are activated by membrane hyperpolarization, 
and can be further activated by hypotonicity, which shifts the voltage-dependence of 
activation to more depolarizing potentials and increases the activation rate of the channel. 
Through the use of channel chimeras constructed from ClC-2 and either ClC-0, or -1, 
Grunder and coworkers determined that the N-terminal domain, localized to a region 
between residues 16-61, is responsible for swelling-induced currents, as well as voltage-
dependence of channel activation [70]. However, the effect of this N-terminal deletion on 
voltage-dependence of activation is still unclear; when currents from this construct are 
recorded using inside-out macropatches, they appear to still be both voltage- and time-
dependent [67]. Further evaluation of the contribution of the N-terminal domain to 
channel gating is needed in order to clarify this apparent contradiction.  
 Similar to other ClC channels, ClC-2 currents can also be potentiated by 
extracellular acidification. Acidification of the bath solution to just pH 6.5 led to a large 
population of channels that were constitutively active at -38 mV, which was not observed 
at pH 7.5 [62, 71]. This is of particular importance because this shifts the voltage-
dependence of activation to well within the physiological voltage range. Also, raising the 
pH to 8.0 inhibited ClC-2 currents by shifting the voltage-dependence of activation to 
more hyperpolarizing potentials [62]. Further analysis of the effect of protonation state on 
ClC-2 currents revealed a bimodal dependence on proton concentration. A very high 
proton concentration associated with a pH of 5.5 inhibited channel currents, rather than 
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potentiated them [72]. Early quantitation of this phenomenon suggested that ClC-2 
contains multiple protonation sites, one which activates the channel with a pK of 7.3, and 
a second one with a pK of 6.0, where protons inhibit channel activity . Furthermore, the 
effect of channel protonation is dependent on the state of channel activity; if the pH is 
decreased to 5.5 when the channels are in the closed state, current is reduced upon 
channel reactivation. However, if pH is decreased to 5.5 while the channels are in the 
open conformation, current is transiently increased, then slowly returns to the basal 
current level obtained at pH 7.4 [72]. This type of state-dependence is not observed if the 
pH is raised above 7.4, suggesting the protonation of the second site is dependent on 
channel conformation. Interestingly, according to Grunder, deletion of the N-terminal 
region between residues 16 – 61 also removes the pH dependence of ClC-2 channel 
activation, although experiments performed by Varela and coworkers using whole-cell 
recording of HEK-293 cells expressing ClC-2 suggests that this may not be the case [70]. 
The differences in experimental system between oocytes and HEK cells may be an 
important factor, as HEK cells more likely represent a more physiologically relevant 
environment, although the recording technique is usually associated with complete 
dialysis of cell contents, possibly removing vital cellular factors. Regulation of ClC-2 by 
pH appears more complicated than for other members of the ClC family, with multiple 
proton binding sites, which may reflect the wide array of tissues in which ClC-2 is 
expressed.  
 A well-characterized trait of ClC gating is its regulation by the permeant ion. For 
ClC-0 and -1, gating is regulated by changes in the extracellular chloride concentration 
[11, 20, 35]. ClC-2 activity, however, is only modestly controlled by the extracellular 
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anion concentration. Reduction of [Cl-]ext to 1 mM increased ClC-2-mediated inward 
currents in Xenopus oocytes by increasing the number of active channels at the holding 
potential, presumably by shifting channel activation to more depolarized potentials [18]. 
This is in contrast to both ClC-0 and ClC-1, which exhibited reduced macroscopic 
currents upon reduction of the extracellular Cl- concentration [20, 35]. Changing in the 
intracellular chloride concentration, which had no significant effect on currents mediated 
by either ClC-0 or -1, can drastically alter ClC-2 channel gating. Pusch and coworkers 
showed that increases in [Cl-]int dramatically shifted the channel activation to more 
depolarizing potentials [18]. However, it is unknown which gating process is affected by 
changes in chloride concentration, because fast and slow gating only recently have been 
separately biophysically characterized. This opposite dependence of channel gating on 
[Cl-] may be related to the fact that ClC-0 and ClC-1 mediate mainly chloride influx, 
while ClC-2 serves as a chloride efflux pathway.  
 It is now coming into focus that ClC-2 channels are dependent on the nature of 
the lipid environment in which they are expressed. Vastly different activation kinetics 
may be observed if you express ClC-2 in oocytes, which displayed very slow activation 
kinetics, versus mammalian cell systems, where ClC-2 is activated much more rapidly 
[60, 61, 67, 68]. Hinzpeter and colleagues showed that channel kinetics may be 
significantly slowed in HEK-293 cells upon enrichment of the cell membrane with 
cholesterol [73]. Likewise, channel activation kinetics may be enhanced upon depletion 
of cholesterol. Regulation of ion channel activity by membrane composition is now 
becoming a common theme among many types of ion channel families; it is therefore no 
surprise to find that members of the ClC family are likewise regulated [74].  
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1.1.3.2 Physiological role of ClC-2 and associated pathophysiology 
 The precise physiological role of ClC-2 is largely still unknown. As stated above, 
this channel is expressed nearly ubiquitously [60, 75]; however, the subcellular 
localization is a matter of contention in the field. ClC-2 has been identified on the apical 
membrane in intestinal tissue of mice and humans [76, 77], as well as lung epithelia [78, 
79], where it may participate in Cl- secretion. Expression of ClC-2 at the apical 
membrane of the lung epithelia, where it may participate in Cl- efflux, where it may exist 
along side the cystic fibrosis transmembrane conductance regulator (CFTR) is an 
attractive hypothesis [79], because defects in CFTR alter Cl- conductance in lung 
epithelia, leading to the devastating disorder cystic fibrosis. However, other studies have 
proposed a basolateral localization of ClC-2 in rat small intestine and guinea pig colon [6, 
80, 81], where it would play a substantial role in NaCl absorption by mediating Cl- exit 
across the basolateral membrane. Convincing data have been provided by Pena-
Munzenmayer and colleagues, showing that native ClC-2 was exclusively localized to the 
basolateral membrane of surface colonic cells, as well as in MDCK and Caco-2 cell lines 
when transfected with a construct encoding human ClC-2-GFP [81]. Furthermore, 
localization to the basolateral membrane was mediated by a dileucine motif (L812/L813); 
mutation of these residues to alanine altered ClC-2 localization such that it was expressed 
on the apical membrane [81]. Indeed, localization of ClC-2 in epithelial cell has become a 
hotly debated topic. The possibility has not been addressed that ClC-2 may have altered 
membrane localization which is dependent on the specific cell type in which it is 
expressed. It has been shown that ClC-2 interacts with the heat shock proteins Hsp70 and 
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Hsp90 in vitro, and with Hsp90 in mouse brain, and that this interaction may play a role 
in ClC-2 trafficking [82]. Interaction with specific chaperones in certain cell types would 
suggest that cell type specific trafficking may be likely.  
 In addition to being expressed in cell types of epithelial origin, ClC-2 is also 
expressed in cardiac tissues. RT-PCR analysis has shown that ClC-2 mRNA is present in 
atrial and ventricular cardiac tissue, while immunohistochemistry confirms protein 
expression in these tissues with a distribution in the sarcolemmal membranes [75, 83]. 
One proposed role of ClC-2 in cardiac cells is cell volume regulation [83]. Proliferation 
of vascular smooth muscle cells requires high rates of both mitosis and migration, which 
require changes in cell volume. Consistent with this, Cheng and coworkers showed that 
IGF-I induced proliferation of these cells is suppressed by the Cl- channel inhibitor 
NPPB, but not DIDS, consistent with ClC-2 mediated Cl- currents. Proliferation of 
vascular smooth muscle cells was also inhibited by siRNA treatment directed against 
ClC-2 [84]. Indeed, novel cardiac ClC-2 splice variants have been identified in both rat 
and guinea pig [75]. Britton and coworkers showed that these alternately spliced ClC-2 
variants encode proteins with deletions of either 15 amino acids (Δ509-523) in rats, or 35 
amino acids (Δ509-543) in guinea pigs. These channels activated with properties similar 
to full length channels, and are inhibited by anti-ClC-2 antibodies, which was critical for 
the identification of these currents as bona fide ClC-2 mediated currents [75].  
 It has been postulated that ClC-2 channels may be involved in signal transduction 
cascades. Tewari and colleagues suggested that ClC-2 channels are activated by cAMP-
dependent protein kinase A (PKA), and arachadonic acid when expressed in HEK-293 
cells, as well as in cell lines in which ClC-2 is endogenously expressed [85]. In addition 
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to activation by PKA, Cuppoletti has proposed that ClC-2 is activated by the bicyclic 
fatty acid lubiprostone when expressed in T84 cells, an intestinal cell line, which the 
authors propose would increase Cl- secretion, and reduce constipation [86]. These results 
are highly questionable considering that the currents obtained by whole-cell recording in 
these cell types show no resemblance to typical ClC-2 mediated currents; they show no 
inward rectification, lack time-dependent activation at hyperpolarizing potentials, and 
have an incorrect permeability sequence (I- >Cl-). The lubiprostone data are additionally 
suspect considering the fact that ClC-2 showed basolateral localization in the intestine. 
Activation of ClC-2, if localized to the basolateral membrane, would lead to increased Cl- 
uptake, exacerbating constipation. It is also unlikely that lubiprostone directly acts on its 
target, as its effects take >20 minutes to be observed.  
Northern blot analysis also has shown ClC-2 mRNA to be present in brain tissue 
[60]. A hyperpolarization-activated current with properties similar to ClC-2 was 
identified in hippocampal pyramidal neurons. In situ hybridiztion confirmed that ClC-2 is 
expressed in these neurons, as well as in Purkinje neurons and in the epithelium of the 
choroid plexus [87]. In these neurons, ClC-2 functions as a chloride efflux pathway in 
order to stabilize ECl below the resting membrane potential [87]. The physiological role 
for this channel was confirmed in dorsal root ganglion (DRG) neurons by de novo 
expression of ClC-2. Over expression of ClC-2 in these neurons had no significant effect 
on the resting membrane potential, but reduced the amplitude of the GABA mediated 
response, and completely eliminated action potential firing, which is consistent with the 
notion that ClC-2 stabilizes ECl such that GABA receptor activation produced an 
inhibitory post-synaptic response in pyramidal neurons [88]. Furthermore, ClC-2 is only 
 32
expressed in a subset of neurons, suggesting a highly regulated role in neuronal 
physiology. 
In large part, the physiological role of ClC-2 is still largely undefined due to the 
fact that the phenotype of ClC-2 knockout animals does not echo the diverse expression 
pattern of ClC-2. Complete knockout of ClC-2 leads to severe retinal and testicular 
degeneration [89], as well as leukoencephalopathy [90]. Knockout of ClC-2 led to altered 
morphology of Sertoli cells and disruption of the retinal pigment epithelium [6]. 
Homozygous knock-out of ClC-2 also led to the formation of fluid filled vacuoles 
between myelin sheets of central neurons [90]. In all cases, elimination of ClC-2 led to 
the disruption of the blood-testes barrier, blood-retina barrier, and the blood-brain barrier. 
It was proposed that ClC-2 regulated ion homeostasis in narrow extracellular spaces [89-
91]. However, it should be pointed out that complete knockout of a nearly ubiquitously 
expressed protein may lead to unexpected consequences.  
A number of mutations in the gene encoding ClC-2 have been identified which 
are associated with idiopathic generalized epilepsy, although the role of ClC-2 mutations 
as causative to an epileptic phenotype is controversial. Originally, three epilepsy-
associated mutations were identified in the ClC-2 gene [92]. Two mutations were 
truncation mutations; one introduced a stop codon in transmembrane helix F 
(M200fsX231) (Fig. 4), while another was a deletion of most of helix B (Δ74-117). 
Neither ClC-2 mutation produced functional channels, although both were localized to 
the plasma membrane of tSA-201 cells. Non-functional ClC-2 channels would thus lead 
to intracellular chloride accumulation, and push ECl toward threshold potential, and could 
result in excitatory, rather than inhibitory GABA responses . However, expression of 
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these truncation mutations at a 1:1 ratio with WT ClC-2 subunits in HEK cells did not 
reduce current density compared to expression of just WT subunits. Additionally, 
confocal microscopy of HEK-293 cells expressing just the truncation mutants showed 
that they do not reach the plasma membrane [93]. The difference between the tsA-210 
cell data and HEK cell data have not currently been addressed. Niemeyer and coworkers 
suggest that haploinsufficiency may one mechanism by which these mutations are 
associated with epilepsy. The third mutation identified was a point mutation, G715E, 
which led to a depolarizing shift in the channel PO/V curve, such that more channels 
would be open at less hyperpolarizing potentials [92]. This mutation would result in 
errant chloride efflux during membrane repolarization, and thus hyperexcitability that 
could result in increased seizure frequency. In HEK cells, however, the effects of this 
mutation on channel gating could not be recapitulated [93]. Additionally, ClC-2 knock-
out animals do not show increased seizure susceptibility, as would be expected from the 
loss-of-function mutations described above, suggesting that mutations in the ClC-2 gene 
may not be causative to epilepsy, but may possibly be part of a polygenic mutational 
epileptic disorder [90]. Mutations in the ClC-2 gene associated with epilepsy are 
extremely rare, but may act as a susceptibility locus [94, 95].  
Finally, data suggesting that ClC-2 is expressed at the apical membrane of lung 
epithelial cells has generated much interest in the possibility that ClC-2 may act as an 
alternate Cl- efflux pathway for patients afflicted with the genetic disorder cystic fibrosis 
(CF) [79], which results from mutations in the CFTR chloride channel. CF is a disease 
characterized by severe lung, pancreas and intestinal symptoms, including chronic lung 
inflammation and infection, as well as intestinal blockage [96]. This disease is the most 
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common lethal autosomal recessive disorder among Caucasians [96], with the most 
common mutation being a deletion of F508 (ΔF508), which leads to misfolded CFTR that 
does not reach the plasma membrane in humans [97]. Advances in therapeutics have 
reduced the severity of the intestinal symptoms, and as a result, mortality results from 
complications from the lung disorder. CF leads to reduced volume of the airway surface 
liquid (ASL) stemming from reduced chloride secretion through CFTR [96, 98]. The 
reduction in volume of the ASL leads to the formation of thick mucus at the lung 
epithelium, and reduced mucociliary clearance, which results in chronic infection from 
colonization by Pseudomonas aeruginosa . It was proposed that ClC-2 may act as an 
alternate Cl- efflux pathway, leading to increased ASL volume, and relieve the CF 
phenotype. Zdebik and coworkers postulated that knockout of ClC-2 in a ΔF508 
homozygous background should increase the death rate in mice if ClC-2 acted as an 
alternate Cl- transport pathway in the lung. These mice did not show a higher death rate 
than CFTR ΔF508 mice alone; in fact, survival was marginally better in the double 
mutant, leading to the speculation that ClC-2 is localized to the basolateral membrane, 
and would not serve as an alternate Cl- efflux pathway [99]. However, it should be 
pointed out that mice bearing the ΔF508 mutation do not suffer from a lung disorder, and 
that functional ΔF508 is able to reach the plasma membrane in murine cells [97]. 
Therefore, the possibility remains that activation of ClC-2 in a human CF patient may 
provide some benefit.  
Given the nearly ubiquitous expression of ClC-2, it is likely that this channel 
plays a vital role in many cellular processes. It has been shown to play a critical role in 
neuronal physiology, and is suspected to play a major role in epithelial cells and cell 
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volume regulation. However, many basic aspects of ClC-2 physiology are still undefined, 
as are many of the biophysical characteristics of the channel.  
  
1.1.4 ClC-K 
1.1.4.1 Biophysical characteristics of ClC-K channels 
 Two research groups nearly simultaneously cloned the two members of the ClC-K 
subfamily. Uchida and coworkers cloned the first isoform from rat kidney, ClC-K1, via 
an RT-PCR cloning strategy using primers designed against regions of cDNAs encoding 
ClC-0, -1 and -2 that are completely conserved [100]. Kierferle and colleagues, utilizing a 
similar cloning strategy, likewise identified ClC-K1, but also cloned another isoform 
named ClC-K2 from rat; highly related human homologues were also identified in this 
same study, named ClC-Ka and ClC-Kb [101]. Evolutionarily, the ClC-K channels 
represent a ClC subfamily, having diverged from ClC-0 prior to the divergence of ClC-1 
and -2 from ClC-0 (Fig. 1). Rat ClC-K1 and -K2 are 80% identical to each other, while 
the human isoforms bear 90% identity to each other [100, 101]. Sequence analysis has 
revealed that ClC-K1 corresponds to the human ClC-Ka, while ClC-K2 is equivalent to 
ClC-Kb. Northern blot and RT-PCR analysis showed that both ClC-K isoforms are 
predominantly expressed in the kidney [100-102], although some expression was later 
identified in the ear.  
 Quantitative biophysical characterization of ClC-K channel isoforms has lagged 
far behind that of other ClC channels. Initial characterization of these channels was very 
limited shortly after the channels were cloned, as only ClC-K1 produced currents that 
were distinguishable from endogenous channels when injected into Xenopus oocytes 
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[100, 101]. Unlike any other ClC channel characterized, ClC-K1 showed only slight 
outward rectification, and almost no time-dependent component to channel activation 
[100]. Because of the lack of time-dependent activation, and the near linearity of channel 
currents, the ClC-K subfamily is largely considered voltage-independent, although some 
studies suggest the voltage-dependence of activation may be shifted out of the 
physiological voltage range [53, 103]. In fact, of all the ClC proteins, the ClC-K isoforms 
are the only members of the ClC family that lack the glutamate residue which is thought 
to the major determinant of fast gating; this residue is substituted by valine in the ClC-K 
subfamily [103]. Waldegger and Jentsch showed that introduction of this fast-gate 
glutamate residue, by making the V166E mutation in ClC-K1, drastically altered channel 
gating. V166E-ClC-K1 channels were time-dependent, showing very slow activation 
upon membrane hyperpolarization [103]. Thus, introduction of this conserved glutamate 
residue into the ClC-K1 channel at a site homologous to that of the conserved glutamate 
in ClC-0 was enough to introduce voltage-dependent gating.  
The regulation of other ClC channel family members by the extracellular milieu 
has been well described, especially regulation by extracellular pH and chloride 
concentration, as described in the previous sections. Uchida and coworkers showed that 
ClC-K1, like other members of the ClC channel family, is regulated by extracellular pH. 
However, unlike other CLC channels, which are inhibited by extracellular alkalinization 
and potentiated by extracellular acidification, ClC-K1 was inhibited by acidification and 
potentiated by alkalinization [104]. The molecular determinants by which ClC-K1 is 
regulated by extracellular pH current are not known; the V166E mutation had no 
significant effect on pH-dependent regulation of these channels [18]. Surprisingly, 
 37
Uchida and coworkers showed that ClC-K1 is potentiated by the presence of extracellular 
Ca2+; complete removal of Ca2+ from the bath solution reduced current density in 
Xenopus oocytes expressing ClC-K1. Injection of EGTA into the oocyte, effectively 
reducing [Ca2+]int to 0, had no effect on ClC-K1 mediated currents, indicating that the 
effect of Ca2+ is restricted to the extracellular face of the channel [104]. Further 
investigation into this matter by Waldegger and Jentsch showed that increasing [Ca2+] up 
to 5 mM increased ClC-K1 mediated currents [103]; this effect was not a non-specific 
effect of divalent cations, as addition of 5 mM Mg2+ or Ba2+ had no effect. The V166E 
mutation likewise has no effect on Ca2+ regulation of ClC-K1 mediated currents. No 
other member of the ClC family has been shown to be directly regulated by extracellular 
Ca2+.  
Interestingly, injection of cRNA encoding ClC-K1 into oocytes yielded no current 
unless a 5’-untranslated sequence from ClC-0 replaced the first ATG in the ClC-K1 
sequence [100]. Injection of cRNA encoding other ClC-K isoforms yielded currents that 
were indistinguishable from currents endogenously found in oocytes [101]. Keiferle and 
coworkers found, via immunoprecipitation, that all ClC-K proteins were made by the 
oocyte, but were not conductive, suggesting that an auxiliary subunit may be required for 
proper channel function [101]. This β-subunit was identified by Estevez and colleagues 
by positional cloning, and named barttin [105]. Barttin is a 320 amino acid integral 
membrane protein with two transmembrane helices, a relatively short cytosolic N-
terminus, and a large C-terminal domain that contains a PY motif [105]. Co-expression of 
ClC-Ka or –Kb with barttin induced large currents with conductance sequences of Cl- 
>Br- >I- for both channels [105]; expression of just barttin alone did not induce currents 
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larger than endogenous background current, nor did barttin have any effect on ClC-1 or 
ClC-2 mediated currents [105]. ClC-K1 currents also were enhanced by co-expression of 
barttin [105, 106]. As for ClC-K1, ClC-Ka and -Kb currents were potentiated as 
extracellular pH is increased when these channels were co-expressed with barttin. 
Currents mediated by these channels also were increased by elevated [Ca2+]ext. 
Interestingly, deletion of the PY motif by truncation of the C-terminus destroys barttin 
function [105]. Scholl and coworkers have found that barttin serves to control both 
trafficking and conduction properties of ClC-K channels. The transmembrane region of 
barttin promotes surface expression of ClC-K, while the large C-terminus is important for 
controlling unitary conductance and open probability [107]. Interestingly, a common 
polymorphism in the ClC-Kb channel, T481S, shows large currents in the absence of 
barttin; mutation of the equivalent residue in both ClC-Ka and ClC-K1 also led to large, 
barttin independent currents [108]. The authors suggested that increased current mediated 
by this channel may be a result of increased open probability, due to the fact that the 
change in surface expression is not enough mediate such a large change in current density 
[108]. 
Unlike other ClC channels, there is thus far no consensus regarding the unitary 
conductance of any of the ClC-K channels. This is largely due to the lack of convincing 
single channel data of any ClC-K channel, either in the absence or presence of barttin. 
ClC-K1 currents have been purportedly obtained from reconstitution of vesicles from 
rabbit distal tubules into lipid bilayers; a 14 pS conductance was observed that was 
inhibited by extracellular acidification [109]. This channel also was potentiated by 
increases in [Ca2+]ext, although regulation of this current by Ca2+ did not occur within the 
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same concentration range as observed for ClC-K1 expressed in heterologous systems, as 
no effect was observed until the Ca2+ concentration was raised above 20 mM in the 
bilayer system [109]. Lourdel and coworkers examined a chloride conductance isolated 
from mouse distal convoluted tubule. This current showed a single channel conductance 
of 9 pS, and also was inhibited by extracellular acidification and potentiated by 
extracellular alkalinization [110]. The molecular identity of this channel was unknown, 
with no accompanying biochemical data, although both ClC-K1 and -K2 are expressed 
the distal convoluted tubule [110]. Scholl and colleagues performed non-stationary noise 
analysis on V166E-ClC-K1, and calculated a unitary conductance of 6.5 pS in the 
absence of barttin, and 19.4 pS in the presence of barttin [107]. It is possible that these 
data all represent single channel currents from ClC-K channels under various conditions; 
it is likely that recording obtained from kidney tissue represents both the channel and 
barttin. None of these studies showed the presence of clear double-barreled activity 
associated with other ClC channels, however. Clear characterization of this channel at the 
single channel level, from heterologous systems, is needed in order to clarify the 
properties of the channel, including conductance properties, gating behavior, and 
oligomeric structure.  
 
1.1.4.2 Physiological role of ClC-K and associated pathophysiology 
 The ClC-K channels have a well defined role in renal physiology. Both the rat and 
human homologues were cloned from kidney, and have been localized in rodents to both 
the thin ascending limb of Henle’s loop (ClC-K1, -Ka), and the medullary thick 
ascending limb of Henle’s loop and distal collecting duct (ClC-K2, -Kb) [100-102, 104]. 
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Uchida and colleagues showed that ClC-K1 is expressed on both the apical and 
basolateral membrane, where it provides transepithelial chloride conductance across the 
kidney epithelium in the thin ascending limb, which bears the highest chloride 
permeability of any of the nephron segments [104]. Kobayashi and coworkers showed 
that expression of ClC-K1 is very highly developmentally regulated. In the early prenatal 
stage, ClC-K1 not was present in the thin ascending limb of Henle’s loop, but it started to 
appear five days after birth, which coincided with increased urine concentrating ability 
[111]. Increased expression of ClC-K1 was associated with decreased NKCC2 expression 
[111]. In the medullary thick ascending limb, the nephron segment that is specialized in 
NaCl reabsorption, ClC-K2 (-Kb) is expressed on the basolateral membrane where it 
mediates chloride efflux [112, 113]. These channels have been identified in the inner ear 
as well, where they localize to the basolateral membrane of marginal cells of the cochlea 
[114]. ClC-Ka/Kb channels mediated chloride recycling across the basolateral membrane 
of strial cells to provide a counterion pathway for the Na,K-ATPase [114].  
There is one report identifying both ClC-Ka and Kb in human lung. Mummery 
and workers identified, in Calu-3 cells, a chloride conductance that is regulated by both 
pH and extracellular Ca2+ as has been previously described for ClC-K channels in 
heterologous systems [115]. RT-PCR and western blotting confirmed the presence of 
mRNA encoding ClC-K channels and the β-subunit barttin, as well as protein for both 
human ClC-K isoforms and barttin. It is important to note that barttin has been shown to 
colocalize with ClC-K channels in all native tissues in which it is found [105, 106], 
further supporting the notion that this subunit is absolutely essential for normal 
endogenous ClC-K channel function.  
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Mutations in the genes encoding ClC-K channels, as well as the barttin subunit, 
are associated with the genetic disorder Bartter’s syndrome. Bartter’s syndrome is 
characterized by either a severe reduction or complete loss of salt absorption in the thick 
ascending limb of Henle’s loop [116, 117]. This results in salt wasting, hypokalemic 
metabolic alkalosis, and possibly low blood pressure [116, 118]. There are five types of 
Bartter’s syndrome, all of which are autosomal recessive disorders [116]. Of the five 
types of Bartter’s syndrome, two are associated with mutations encoding either ClC-Kb 
(type III Bartter’s syndrome) [119, 120], or barttin (type IV Bartter’s syndrome) [121, 
122]. The mutations associated with type III Bartter’s syndrome are associated with large 
deletions, as well as nonsense and missense mutations of the ClC-Kb gene [116, 119, 
120]. Mutations in ClC-Kb drastically reduced salt absorption in the thick ascending limb 
of Henle’s loop, although there have been no biophysical studies of known ClC-Kb 
polymorphisms to show whether there are severe alterations in chloride conduction 
properties, or altered interactions with barttin [120]. Interestingly, there are no mutations 
in ClC-Ka associated with Bartter’s syndrome.  
Bartter’s syndrome type IV, stemming from mutations in the gene encoding 
barttin, BSND, is a more severe clinical disorder than Bartter’s type III. This disease 
manifests in renal failure and sensorineural deafness [121, 122]. It has been well 
established that barttin is essential for the correct function of ClC-K channels in all ClC-
K expressing cell types in which they have been studied [105]. Mutations in barttin, 
therefore, would affect channel function in all cell types. Hayama and coworkers showed 
that mutations in barttin drastically reduced surface expression of ClC-K2 [122], while 
Waldegger and colleagues showed decreased current density from ClC-K1 when co-
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expressed with a barttin subunit bearing single point mutations that are sufficient to 
induce Bartter’s syndrome type IV [106]. The lack of ClC-K1 surface expression 
resulting form mutant barttin results in impaired Cl- transport throughout the thin and 
thick ascending limbs of Henle’s loop, which leads to complete renal failure. In the inner 
ear, these channels act to mediate Cl- exit through the basolateral membrane of strial 
cells, to reduce Cl- accumulation in the cytoplasm as a result of import through NKCC1 
[114, 123]. Under normal conditions this Cl- recycling allows transport of K+ into the 
cytoplasm, which is then exported out of the apical membrane via KCNQ1/KCNE1 K+ 
channels, leading to a high [K+]ext, which is necessary for the depolarization of sensory 
hair cells. Reduction of ClC-K channel surface expression via barttin mutations indirectly 
reduces the [K+]ext, and prevents depolarization of hair cells, causing deafness [53, 114].  
As discussed earlier, the T481S mutation in ClC-Kb yields channels that both 
express at the cell surface and function in the absence of the accessory protein barttin 
[108]. Jeck and coworkers identified this mutation in ~20% of patients in a study 
incorporating 200 people [108]. This gain-of-function mutation would theoretically lead 
to alterations in salt-handling in the nephron, and has been shown to contribute to 
elevated blood pressure in Dahl rats, which serve as a model system for salt-sensitive 
hypertension. In addition to possible effects on blood pressure, Frey and colleagues 
showed that this mutation also lowered hearing threshold, and may serve a protective role 
against hearing loss [123].  
Interestingly, there are few physiological consequences manifesting only from 
mutations of the gene encoding ClC-K1 (-Ka). The only real effects of lack of ClC-K1 
are revealed in data from knockout animals. As expected from the localization of this 
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channel in the thin ascending limb of Henle’s loop, knockout of ClC-K1 led to 
nephrogenic diabetes insipidus (NDI), a disorder characterized by the production of a 
large amount of dilute urine [124]. Loss of ClC-K1 led to a 50% reduction of the sodium 
and chloride content of the inner medulla, as well as a reduction in urea accumulation. 
This finding suggests a novel mechanism for NDI, as most cases result from loss-of-
function mutations either in the vasopressin V2 receptor, or the aquaporin AQP-2 channel 
[124].  
Like other ClC channels, the importance of ClC-K channels is demonstrated from 
pathophysiology associated with these channels. Correctly assembled ClC-K/barttin 
complexes are necessary for proper kidney function and hearing. Despite a large amount 
of data describing the physiological role of these channels, many of their biophysical 
characteristics need more study. The lack of a consensus regarding the single channel 
behavior of ClC-K channels needs to be addressed, as does the oligomeric structure of 
these channels.  
 
1.2 Properties and physiology of ClC exchangers 
 As discussed above, several members of the ClC protein family function as 
voltage-dependent chloride channels. However, it has recently come to light that many of 
these proteins mediate Cl-/H+ exchange rather than voltage-dependent anion channel 
activity. Unlike their channel counterparts, the exchanger subtypes are generally found on 
intracellular membranes. In mammals it is generally accepted that ClC-3,-4, -5, -6, and -7 
are exchangers. Like ClC channels, however, the canonical exchanger is not mammalian, 
but instead is a bacterial ClC protein, ClC-ec1. In this section, the biophysics of these 
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proteins will be discussed, as will the physiological contributions of each protein (Table 
2)
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Table 2: Properties of ClC Cl-/H+ exchangers. Members of the ClC protein family that act as chloride/proton exchangers are listed 
with basic biophysical propterites, expression patterns, physiological roles, and accociated pathophysiology.  
 
Table 2: Properties of ClC Cl-/H+ exchangers 
 
 Function Expression Physiological Role Pathophysiology and 
Knockout 
 
  Tissue Cellular Localization    
ClC-3 Cl-/H+ Exchanger Ubiquitous 
High expression in brain 
Synaptic Vesicles Endosomal acidification Hippocampal degeneragtion 
(KO) 
 
       
       
ClC-4 Cl-/H+ Exchanger Brain, Skeletal Muscle, 
Liver, Kidney 
Endosomal membrane Endosomal 
Acidification 
  
       
       
ClC-5 Cl-/H+ Exchanger Kidney, Brain, Liver, 
Lung, Intestine 
Endosomes of epithelial 
cells 
Plasma membrane 
Endosomal 
Acidification 
Endocytosis 
Dent’s Disease  
       
       
ClC-6 Cl-/H+ Exchanger Lung, Instestine, 
Pancreas, Brain, Skeletal 
muscle 
Lysomsomal Membrane Lysosomal acidification   
       
       
ClC-7 Cl-/H+ Exchanger Ubiquitous Lysosomal membrane Lysosomal Acidification 
Bone resorption 
Neuronal Ceroid 
lipofuscinosis (KO), 
Osteopetrosis 
 
       
ClC-ec1 Cl-/H+ Exchanger Bacterial Bacterial inner membrane Acid resistance   
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1.2.1 Prokaryotic ClC proteins 
 BLAST homology searches have identified many prokaryotic ClC proteins; some 
species contain as many as two ClC genes, while others have none. Maduke and 
coworkers purified and reconstituted a ClC protein, called EriC or ClC-ec1, from E. coli 
[125]. This protein was classified as a ClC family member based on primary sequence 
homology with other ClC members; therefore Maduke and colleagues postulated that this 
protein should function as a chloride channel. Indeed, 36Cl- flux assays demonstrated that 
vesicles containing ClC-ec1 were capable of conducting chloride against an 
electrochemical gradient, and that these proteins maintain the selectivity sequence 
observed for other ClC proteins: Cl- > Br- > I- [125]. Technical difficulties in obtaining 
very pure samples prevented reconstitution of ClC-ec1 into lipid bilayers; thus 
electrophysiological recording was not possible. Gluteraldehyde crosslinking experiments 
showed that ClC-ec1 exists as a homodimer, which was further confirmed by showing 
that no crosslinking occurred under reducing conditions [125]. Thus, it appeared that the 
ClC protein purified from E. coli was a chloride channel with similar selectivity and 
oligomeric structure as it mammalian counterparts. 
 In 2004, Accardi and Miller came to the dramatic conclusion that the bacterial 
ClC protein ClC-ec1 was, in fact, not a chloride channel as originally thought, but a Cl-
/H+ exchanger. The studies by Miller and coworkers, taking advantage of crystallization-
quality ClC-ec1, were the first to demonstrate ClC-ec1 currents from ClC-ec1 
reconstituted into planar lipid bilayers [126, 127]. Accardi and colleagues showed that 
ClC-ec1 currents were Cl- selective, as had been suggested by uptake assays, and that the 
unitary conductance was just 0.2 pS [127]. These currents were also linear, and showed 
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no voltage-dependent gating. The seminal finding, however, was that upon imposition of 
a Cl- gradient, the shift in reversal potential was sub-nernstein, suggesting that ClC-ec1 is 
not perfectly selective for chloride [126]. Removal of all possible conductive cations had 
no effect on the shift of the reversal potential, suggesting that ClC-ec1 was permeable to 
protons [126]. Indeed, under symmetrical ionic conditions, imposition of a pH gradient 
shifted the reversal potential in a manner consistent with a Cl-/H+ exchanger, not an ion 
channel [126]. Calculation of the exchange stoichiometry showed that ClC-ec1 mediates 
transport of 2 Cl- ions for every H+. This stoichiometry is less strict when substitute 
anions were introduced; H+ cotransport was reduced when Cl- was substituted by 
polyatomic anions such as NO3- and SCN- [128]. Interestingly, mutation of the conserved 
glutamate residue that is thought to be the major determinant for fast gating of voltage-
dependent ClC channels, yielded ClC-ec1 proteins that are nearly perfectly Cl- selective, 
and insensitive to changes in pH [126, 127]. Other work has shown that mutations near 
the central binding site may also uncouple Cl- transport from H+ transport [129-131].  
 Upon the revelation that bacterial ClC proteins mediated Cl-/H+ exchange, 
researchers began to ask if the transport of these ions utilized the same permeation 
pathway, or if they were separate. Accardi and colleagues undertook a mutational study 
to identify the molecular determinants of transport. Sequence alignments have shown that 
the equivalent of the ClC-ec1 residue E148 is conserved in nearly all ClC proteins, the 
exception being ClC-K channels [14]. Mutation of this residue, which acts as an 
extracellular proton transfer group and is important to Cl- transport, leads to 
constitutively active proteins [14, 92]. Accardi and coworkers also identified another 
glutamate residue on the intracellular side of the channel, E203, that is conserved in all 
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ClC proteins believed to act as transporters, but is mutated to valine in all ClC channels. 
Mutation of this residue in ClC-ec1 to E203Q gave channels that conduct Cl-, but in a 
manner that is not coupled to H+ movement [132]. Additionally, this glutamate residue is 
not located near the predicted chloride permeation pathway. These data suggest that there 
are separate ion permeation pathways toward the intracellular side of the protein, one for 
Cl- and one for H+, which merge near E148 [132]. It is important to note that bacterial 
ClC proteins do not seem to have the slow gating processes associated with ClC 
channels. Instead, crosslinking experiments performed by Nguitragool and Miller 
suggested conformational changes during transport that are similar those thought to occur 
during fast gating of ClC channels [133].  
 The functional role that bacterial ClC proteins play is not very well understood. 
Prokaryotes possess a number of ion channels that bear significant homology to human 
ion channels, but it is likely that the physiological roles of these proteins are very 
different in these systems. Iyer and coworkers suggested that E. coli ClC proteins are 
involved in extreme acid resistance [134]. Knockout of the genes encoding the two E. 
coli ClC proteins severely reduced bacterial survival when challenged with extremely 
low pH [134]. The extreme acid resistance mechanism involves electrogenic transport of 
glutamate into the bacterial cell. ClC-ec1 acts as an electrical shunt to facilitate Cl- efflux 
to prevent inner membrane hyperpolarization. The ClC proteins may be ideally suited to 
this play this role. Cl- uptake experiments show that ClC-ec1 becomes maximally 
activated at extremely low pH [126, 134].  
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1.2.2 ClC-3 
1.2.2.1 Biophysical characteristics of ClC-3 
 ClC-3 was first identified from rat brain in 1994 by Sasaki and colleagues [135], 
while the gene encoding human ClC-3 was identified in 1995 by Borsani and coworkers 
via a homology screening approach using the cDNA for ClC-4 (CLCN4) as a template 
[136]. This approach identified a gene with 73% similarity with CLCN4, suggesting that 
this gene encodes a similar, yet distinct protein [136]. This gene, CLCN3, encodes a 760 
amino acid protein, sharing only 20-30% identity to ClC proteins in the channel branch; 
however, it is nearly 80% identical to ClC-4. As shown in Figure 1, the split between 
ClC-0 and ClC-3 was an ancient one, and as we will discuss, this is reflected in vast 
functional differences between the ClC-0 subgroup, and the ClC-3 subgroup. Murine 
ClC-3, also identified using the same approach, only differs from human ClC-3 by two 
amino acids [136]. RT-PCR was performed on samples from many different tissues, and 
ClC-3 was identified nearly ubiquitously, but was highly expressed in the brain [136], 
suggestive of an important role in neurophysiology. A splice variant of ClC-3, ClC-3B, 
was identified by Ogura and colleagues. The C-terminus of this variant contains an extra 
48 amino acids which contains a PDZ domain that likely participates in protein/protein 
interactions [137].  
 The biophysical properties of ClC-3 have been very difficult to characterize. 
Expression of this protein in heterologous systems often leads to currents that are 
indistinguishable from background currents; thus, much of the characterization of this 
channel is not clear. ClC-3 is likely a Cl-/H+ exchanger, much like bacterial ClC proteins, 
and other ClC proteins belonging to this branch (Fig. 1). However, massive 
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overexpression has allowed some characterization of currents mediated by ClC-3 [138-
141]. In virtually all cell systems, ClC-3 is reported to mediate depolarization-induced, 
very strongly outwardly rectifying currents [140, 141]. There is some disagreement 
regarding the ion selectivity of ClC-3, however. All ClC channels, as well as the bacterial 
ClC protein ClC-ec1, show the conductivity sequence of Cl- > Br- > I-. Studies from the 
Weinman lab show a canonical halide selectivity sequence when ClC-3 is expressed in 
CHO-K1 cells [140, 141]. Duan and coworkers, on the other hand, reported a selectivity 
sequence of I- >Cl- that is switched to Cl- > I- when asparagine 579 was mutated to lysine. 
Duan and colleagues also suggested that ClC-3 encodes the protein responsible for 
swelling-induced currents observed in cardiac cells. Work from the Weinman lab 
suggested that the endogenous swelling activated currents in CHO cells show a 
selectivity sequence of I- > Cl-. Interestingly, mutation of the conserved gating glutamate, 
E224, resulted in a constitutively active protein [141]. Due to the fact that work from the 
Weinman lab characterizing ion selectivity is more consistent with data from other ClC 
channels and exchangers, it is generally regarded as more reliable, although it is possible 
that differences in the expression system, and possible differences in ClC-3 isoforms, 
may explain the differences observed for halide selectivity.  
 Interestingly, Huang and coworkers reported that ClC-3 is activated by 
calcium/calmodulin-dependent protein kinase II (CaMKII). Transfection of human ClC-3 
cDNA into tsA-201 cells induced a current that was not active under basal conditions, but 
was greatly stimulated by CaMKII. Characterization of this CaMKII induced current 
showed a strongly outwardly rectifying, depolarization-dependent current with an ion 
selectivity sequence of I- > Cl- [142]. The selectivity of CaMKII-dependent ClC-3 
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currents could be switched to Cl- > I- by mutation of glycine 280 to glutamate, suggesting 
that ClC-3, not an unidentified endogenous channel, was indeed activated by CaMKII, 
and that ion selectivity of wild-type ClC-3 was I- > Cl-, at least under some conditions 
[142, 143].  
 Due to the difficulties associated with heterologous expression of this protein, 
characterization of Cl- and pH dependence has not yet been performed to any large 
degree. Matsuda and coworkers have shown that currents mediated by the ClC-3 short 
isoform were reduced upon lowering [Cl-]ext, and acidification of extracellular pH [144]. 
As observed for ClC-ec1, the shift in reversal potential upon changes in [Cl-] were sub-
nernstein, suggesting that ClC-3 mediated Cl-/H+ exchange [144]. The E224A mutation 
abolished pH-dependent regulation of these currents, inducing a nearly perfectly anion 
selective current [144, 145].  
Additionally, like ClC-K channels, description of single channel currents 
mediated by the ClC-3 is not well established, with no consensus regarding gating 
behavior or single channel conductance. Kawasaki and coworkers reported that ClC-3 
single channel currents showed two open conductance levels, like previously 
characterized ClC channels, but that the conductance levels were not equidistant and the 
unitary conductance was very large [138]. Duan and colleagues reported that ClC-3 
single channel currents exhibited only one open conductance level with a unitary 
conductance of ~ 40 pS [139]. The most reliable single channel data for ClC-3 were 
obtained by Wang and coworkers, who showed that CaMKII activated ClC-3 currents 
displayed two equidistant open conductance levels, with a unitary conductance of just 3 
pS, which is more consistent with the turnover rate of a very fast transporter [146]. 
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Characterization of any gating transitions for ClC-3 has not been performed to date, so it 
is currently unknown whether ClC-3 contains both fast and slow gating processes. 
However, inspection of the single channel currents obtained by Wang and colleagues, 
leads to the suggestion that both gating processes may be present, as both fast transitions 
between conductance levels and long closed durations between bursts are present, 
although these transitions were not quantitatively analyzed [146]. This would suggest that 
gating mechanisms associated with mammalian ClC transporters are more complicated 
than their prokaryotic counterparts.  
 
1.2.2.2 Physiological role of ClC-3 and associated pathophysiology 
 As stated above, ClC-3 is nearly ubiquitously expressed, and the primary 
functional role of this protein is to mediate Cl-/H+ exchange. While all ClC channel 
subtypes are localized to the plasma membrane, ClC-3 seems to be primarily localized to 
intracellular membranes, but may also rarely reach the plasma membrane [75, 141, 145, 
147-149]. A dileucine motif in the N-terminus is involved in cellular localization; 
mutation of this motif to alanine leads to plasma membrane expression [150]. Much of 
the characterization of ClC-3 has come from knockout animals; there is no known human 
disorder associated with mutations in the gene encoding ClC-3, although very interesting 
phenotypes occur as a result of complete knockout of this protein, including the complete 
loss of the hippocampus [147].  
 The role of ClC-3 in neuronal tissue is the most well understood, and well 
accepted. Kawasaki and coworkers found that ClC-3 is abundant in the hippocampus, the 
olfactory bulb, and in the Purkinje cells of the cerebellum, where it initially was proposed 
 53
to act as a Ca2+-dependent Cl- channel [138]. Stobrawa and colleagues confirmed ClC-3 
protein expression in the brain, and found that ClC-3 localized to synaptic vesicles, as 
well as other intracellular membranes; ClC-3 colocalized with a number of intracellular 
markers in both neuronal and non-neuronal tissue [147]. In ClC-3 knockout animals, 
acidification of synaptic vesicles via a V-type H+-ATPase proceeded more slowly, 
suggesting that ClC-3 may provide the parallel Cl- conductance needed for the H+-
ATPase to efficiently acidify synaptic vesicles. Additionally, localization of ClC-3 to 
small synaptic vesicles, as well as overall expression level, was impaired in mice lacking 
the adaptor protein AP-3 [151]. The interaction between AP-3 and ClC-3 could also be 
disrupted pharmacologically using drugs targeting AP-3, suggesting lack of ClC-3 in 
synaptic vesicles was due to disruption of a necessary ClC-3 trafficking complex [151]. 
Interestingly, knockout of ClC-3 led to severe hippocampal and retinal degeneration, 
although the mechanism underlying this degeneration is still not known [147].  
 In addition to altered ClC-3 localization and hippocampal degeneration in 
knockout animals, Dickerson and colleagues showed that ClC-3 KO animals displayed 
altered GABAergic signaling during hippocampal degeneration. They showed that during 
degeneration, there was a progressive loss of GABA producing cells in the dentate gyrus 
[152]. However, this was accompanied by an increase in GABAA receptor density, 
causing altered inhibitory neurotransmission [152]. Dickerson and coworkers suggested 
that this may be a compensatory mechanism in response to chronic excitatory 
stimulation, or reduced inhibitory input, but these possibilities have not been investigated 
further. The role of ClC-3 in modulating synaptic transmission was further invested by 
Wang and coworkers in a study showing that ClC-3 modulated excitatory 
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neurotransmission in immature neurons. Knockout of ClC-3 reduced NMDA-induced 
excitability by reducing mEPSP decay time. Quantal size is also reduced in knockout 
animals, confirming the presence of ClC-3 on synaptic vesicles [146]. Wang and 
colleagues suggested that Ca2+ influx through NMDA receptors leads to the activation of 
ClC-3 via CaMKII; ClC-3 activation subsequently leads to membrane depolarization and 
increased excitability [146]. Enhanced excitability upon ClC-3 activation is abolished 
once expression of the KCC2 K+/Cl- co-transporter is upregulated during neuronal 
development, which reduces [Cl-]int from 40 to 5 mM as neurons mature [146]. The 
mechanism by which ClC-3 activation induces membrane depolarization is not known, 
and may involve indirect effects on other channels in the membrane, as ClC-3 activation 
would lead to Cl- influx, and thus hyperpolarization. Yoshikawa and coworkers suggested 
that the elevated pH of endosomes associated with ClC-3 deficiency may result in the 
neurological disorder neuronal ceroid lipofuscinosis (NCL), a disorder causing numerous 
neurological symptoms including seizures and impaired learning, and resulting in a 
vegetative state and death [153]. However, analysis of naturally-occurring animal models 
for late-onset NCL showed no mutations of CLCN3, even though several polymorphisms 
in ClC-3 were identified [154]. 
 ClC-3 has been proposed to be one of the main chloride channels involved in cell-
volume regulation in cardiac tissue. Britton and colleagues showed that ClC-3 is widely 
expressed in cardiac tissue, with both sarcolemmal and intracellular localization [75]. 
This work showed that expression of ClC-3 in NIH/3T3 cells resulted in novel swelling-
activated currents [75]. Native swelling activated currents in cardiac tissue could be 
inhibited by ClC-3 specific antibodies [155]. Therefore, work from the Hume lab has 
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suggested that ClC-3 provides the native volume-activated chloride currents in cardiac 
cells, and may by involved in regulatory volume decrease [156, 157]. However, work by 
Stobrawa and coworkers, and well as by Wang and coworkers, showed that swelling 
activated currents in neuronal tissue and cardiomyocytes were not altered in ClC-3 
knockout mice [146, 147]. Work by Arreola and colleagues also suggests that the 
swelling activated current observed in salivary acinar cells were not mediated by ClC-3, 
as they also are unchanged in knockout animals [148]. Thus, it is likely that ClC-3 is not 
involved in cell volume regulation, and those cell-volume regulated currents observed in 
the studies by Hume and coworkers were those of native currents upregulated upon 
expression of non-native proteins and were inhibited by non-specific effects of the ClC-3 
antibody.  
 Work from a number of labs has suggested that the primary role of ClC-3 may be 
acidification of intracellular compartments including synaptic vesicles [147], endosomes 
[145, 149, 158], and lysosomes [141]. All evidence suggests that ClC-3 provides a charge 
shunt to offset the positive membrane potential created by H+ pump activity. ClC-3 has 
also been implicated in host defense. Mice lacking ClC-3 showed reduced NADPH 
oxidase activity, imparied phagocytosis, and a decrease in reactive oxygen species (ROS) 
production [159]. Also Miller and coworkers showed that ClC-3 is necessary for 
activation of NF-κB [160]. The role that ClC-3 plays in cardiac tissue requires further 
characterization. Despite this gap in knowledge, it is quite clear that ClC-3 plays a critical 
role in cellular physiology.  
 
1.2.3 ClC-4 
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1.2.3.1 Biophysical characteristics of ClC-4 
 ClC-4 was identified in 1995 by van Slegtenhorst and coworkers [161]. Human 
ClC-4 is a 760 amino acid protein that is found predominantly in brain, skeletal muscle, 
liver, and kidney, and belongs to the same branch of ClC proteins as ClC-3 and ClC-5 
(Fig. 1). Like most members of this particular branch of ClC proteins, biophysical 
characterization has lagged far behind that of the ClC channel subtypes. Unlike ClC-3, 
however, expression of ClC-4 in heterologous systems yields reliable surface expression, 
although this protein most likely localizes to intracellular membranes in vivo [162]. 
Expression of ClC-4 in Xenopus oocytes gave rise to strongly outwardly-rectifying 
voltage-dependent currents [162]. Upon membrane depolarization, channels activated 
very rapidly, with virtually no current induced by membrane hyperpolarization [162]. 
Characterization of ion selectivity showed that ClC-4 was similar to other ClC proteins, 
with a conductance sequence of NO3- > Cl- >Br- > I- [162]. When expressed in Xenopus 
oocytes, changes in extracellular pH had no major effect on ClC-4 mediated currents until 
pH was lowered to 5.5, which reduced macroscopic currents. Mutation of the conserved 
gating glutamate residue in ClC-4 to alanine, E224A, drastically altered macroscopic 
currents. Consistent with the consequences of mutation of this residue in other ClC 
channels or transporters, E224A-ClC-4 currents were voltage-independent, with no time-
dependence for activation at any potential, consistent with a constitutively active protein 
[162]. 
 Characterization of ClC-4 at the single channel level has been very elusive, 
despite plasma membrane expression of this protein in heterologous systems. Vanoye and 
George showed that ClC-4 mediated a strongly outwardly rectifying channel at the single 
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channel level with a slope conductance of ~3 pS [163]. Interestingly, this study also 
showed that ClC-4 currents were sustained by ATP, with rundown of channel activity 
being accelerated by the non-hydrolyzable ATP analogue AMP-PNP, as well as GTP, 
although this was not shown on the single channel level [163]. Hebeisen and colleagues, 
on the other hand, suggested that the single channel amplitude of ClC-4 was just 0.1 pA 
at +140 mV, as measured by noise analysis, much smaller than the 3 pS conductance 
suggested by Vanoye and George [164]. The discrepancy between these measurements is 
unclear, although Hebeisen and colleagues suggested that the difference may lie in the 
recording method; noise analysis was performed on currents from whole-cell recording, 
while the Vanoye study utilized excised inside out patches.  
 It is now clear that ClC-4, like other members of this branch of ClC proteins, 
mediates Cl-/H+ exchange, as has been convincingly shown by two separate studies. 
Picollo and Pusch showed that ClC-4 mediated significant proton transport by measuring 
changes in extracellular pH very close the plasma membrane of Xenopus oocytes. This 
proton transport could be abolished by removing chloride from the bath solution, 
suggesting that chloride transport was required for proton transport [165]. Additionally, 
bona fide ClC channels such as ClC-0 and ClC-2 showed no changes in extracellular pH 
upon channel activation [165]. Scheel and coworkers corroborated this conclusion by 
showing that intracellular pH alkalinizes upon ClC-4 activation [166]. This study 
additionally showed that H+ transport depended on membrane voltage, as no proton 
transport was present upon membrane hyperpolarization. As state above, mutation of the 
gating glutamate, E224, produces constitutively active proteins. Zdebik and coworkers 
showed that the E224A mutation also abolished H+ transport. Mutation of the equivalent 
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of the internal H+ binding site identified for ClC-ec1, E281, abolished both Cl- and H+ 
transport; Cl- transport could be restored with the additional E224A mutation [167]. This 
is consistent with the idea that Cl- binding is dependent upon H+ binding when the gating 
glutamate is still in place.  
 
1.2.3.2 Physiological role of ClC-4 and associated pathophysiology 
 As stated above, ClC-4 is expressed in the brain, skeletal muscle, liver, and 
kidney. The role that this protein plays in these tissues in not well understood, however. 
No disease phenotype is associated with mutations in the gene encoding ClC-4. Suzuki 
and coworkers showed, by immunofluorescence, that ClC-4 strongly colocalized with 
both ClC-3 and ClC-5 on intracellular membranes of HEK-293 cells [168]. Homo-
oligomers of ClC-4 were abundantly detected by co-immunoprecipitation, but Suzuki and 
coworkers also showed that hetero-oligomers between ClC-3, -4, or -5 subunits could 
also be formed [168]. The functional consequences of ClC hetero-oligomerization are not 
understood, but may include important effects on pH dependence of activity, voltage-
dependence of activation, or possibly localization to the plasma membrane versus 
intracellular membranes.  
 Confocal microscopy showed that ClC-4 is expressed endogenously on 
endosomal membranes of cultured epithelial cells [169]. Mohammad-Panah and 
coworkers showed that disruption of endogenous ClC-4 by transfection of antisense ClC-
4 cDNA impaired endosomal acidification, suggesting that this protein is necessary for 
correct endosomal acidification, similar to the role ClC-3 plays in synaptic vesicles [169]. 
Interestingly, confocal microscopy showed that ClC-4 colocalized with CFTR in the 
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brush border of the epithelial cells lining intestinal crypts [170]. This finding led 
Mohammad-Parah and colleagues to postulate the ClC-4 may cycle between the plasma 
membrane, where it aids in Cl- secretion, and intracellular membranes, where it is 
involved in endosomal acidification [53, 169, 170]. 
 As stated above, there are no diseases associated with known mutations of ClC-4. 
This has severely hampered defining the role that this protein may play in physiological 
processes. Indeed, many of the properties of this protein need to be confirmed in vivo, 
such as the potential hetero-oligomerization, as well as the role it may play in chloride 
secretion at the plasma membrane. ClC-4 is very likely to be involved in endosomal 
acidification, but it is not known if ClC-4 plays this role in all cell types in which it is 
expressed. Also, while the basic biophysical properties of transport may be known for 
ClC-4, the stoichiometry of Cl-/H+ exchange still needs to be rigorously established. 
Additionally, the effects of potential hetero-oligomerization on the transport properties 
need to be addressed.  
 
1.2.4 ClC-5 
1.2.4.1 Biophysical characteristics of ClC-5 
 The final member of this branch of ClC proteins, ClC-5, is the most extensively 
studied of the ClC transporters. ClC-5 was cloned from human kidney in 1994 by Fisher 
and colleagues [171, 172]. This 746 amino acid protein is encoded by a 2,238 bp 
transcript, and is >70% identical to both ClC-3 and ClC-4 (Fig. 1) [172]. While ClC-5 is 
clearly expressed in the kidney, transcripts encoding this protein also have been identified 
in brain, liver, and lung, although abundance in lung is very low [173]. Like both ClC-3 
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and ClC-4, it is likely that ClC-5 acts as a Cl-/H+ exchanger; the evidence for this will be 
discussed below [166]. Despite this, ClC-5, much like ClC-4, is readily expressed on the 
plasma membrane in heterologous systems [162, 173, 174]. Currents mediated by ClC-5 
were strongly outwardly rectifying, eliciting current only when membrane potentials 
were more depolarizing than +20 mV [173]. Steinmeyer and colleagues showed that ClC-
5, like other ClC proteins, had a conductance sequence of Cl- >Br- >I- [173]. Two groups 
have shown that ClC-5 is modestly controlled by changes in extracellular pH; currents 
are reduced as extracellular pH becomes more acidic [162, 165]. 
 Like other ClC proteins, mutation of the ClC-5 gating glutamate to alanine, in this 
case E211A, drastically altered macroscopic behavior. E211A-ClC-5 proteins were 
constitutively active, with no outward rectification; in fact, currents were slightly 
inwardly rectifying [162]. Activation of WT ClC-5 shows very little time-dependence. 
Freidrich and coworkers identified several mutations which slow channel activation, 
which initially led to the hypothesis that ClC-5 was an ion channel [162]. However, it is 
now generally accepted that ClC-5 works as a Cl-/H+ exchanger. Picollo and Pusch 
showed that activation of ClC-5, like ClC-4, acidified the extracellular pH very close to 
the plasma membrane, consistent with H+ efflux driven by Cl- influx. The decrease of 
extracellular pH was accompanied by alkalinization of intracellular pH [165]. As stated 
above, macroscopic ClC-5 currents are inhibited by acidification of extracellular pH. The 
pH dependence of ClC-5 current was eliminated by the E211A mutation. This mutation 
also eliminated Cl-/H+ coupling, as activation of E211A-ClC-5 by membrane 
depolarization was no longer accompanied by changes in intracellular pH [167]. Like 
ClC-4, mutation of the inner glutamate residue, E268, abolished both Cl- and H+ transport 
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[167]. Cl- transport could be restored by additional mutation of the gating glutamate 
(E211). This suggests that in the WT protein, Cl- transport is only possible when H+ are 
bound near the intracellular glutamate. Like ClC-4 however, the stoichiometry of 
transport still needs to be determined.  
Two groups have shown that the cytoplasmic domains of ClC-5 are capable of 
binding adenosine nucleotides [175, 176]. The structural basis of this binding will be 
discussed in section 1.4, although significant functional consequences of ATP binding to 
the cytosolic domains also have been shown for ClC-1 [44]. Interestingly, the cytosolic 
domains are nonselective for adenosine nucleotide, with ATP, ADP, and AMP all 
binding with a Kd ~90 μM. While no functional effect on Cl-/H+ counter-transport have 
been shown for binding of ATP, mutation of residues critical for binding nucleotide, 
specifically Y617A, did not alter pH dependence or voltage dependence of activation 
[175]. Thus, the functional role of nucleotide binding still needs to be determined.  
 To date, no single channel data for ClC-5 have been obtained. However, noise 
analysis of ClC-5 currents suggested that the unitary conductance was just 0.5 pS, 
consistent with a transport mechanism, rather than uncoupled diffusion of ions through a 
pore [167]. Interestingly, Zdebik and colleagues proposed that ClC-5 exhibited both 
silent and transporting states similar to the gating processes observed for ClC channels 
[167]. 
 
1.2.4.2 Physiological role of ClC-5 and associated pathophysiology 
 Of the ClC proteins belonging to this branch, ClC-5 is the only protein linked to a 
human disease. Mutations in ClC-5 are linked to the rare hereditary kidney disorder 
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Dent’s disease, corresponding to the high expression of ClC-5 in the kidney [177-179]. 
Dent’s disease is a devastating disorder associated with low-molecular weight 
proteinuria, hypercalciuria, nephrocalcinosis, kidney stones, and renal failure, and can 
often be fatal [173, 180, 181]. Due to the fact that mutations in ClC-5 are a primary cause 
of this disease, much effort has been devoted to the characterization of this protein. In 
addition to high expression of ClC-5 in the kidney, it is also expressed in brain, liver, and 
lung [173]. As stated above, ClC-5 acts as Cl-/H+ exchanger [165, 167]. Gunther and 
coworkers showed that ClC-5 was expressed primarily on endosomes, and colocalized 
with the H+-ATPase, suggesting that ClC-5 may provide an electrical shunt to allow 
proton accumulation associated with endosomal acidification [182]. Vandewalle and 
colleagues also identified ClC-5 in the small intestine, and found that it colocalizes with 
endosomal markers, which is suggestive of ClC-5 playing a similar role in acidification 
of endosomes in the small intestine [183]. When studied in a heterologous expression 
system, ClC-3, -4, and -5 colocalize in endosomes, suggesting that these three proteins 
may play similar roles [168]. In fact, it has been proposed that they may form hetero-
oligomers, although the functional consequences of this type of interaction have not been 
determined [168]. It is possible that this is an artifact of overexpression, and that native 
cells they are present at different stages of the endocytic pathway. 
 One of the main symptoms of Dent’s disease is low molecular weight proteinuria, 
stemming from defective reabsorption of low molecular weight proteins in proximal 
tubular cells, where ClC-5 is normally very highly expressed [184, 185]. Altered 
endosomal acidification by mutations in the gene encoding ClC-5 could lead to impaired 
endocytosis of low molecular weight proteins by preventing proper endosome 
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maturation. Piwon and colleagues showed that knockout of ClC-5 led to strongly reduced 
endocytosis at the proximal tubular apical membrane [180]. Disruption of the gene 
encoding ClC-5 led to severely impaired receptor-mediated endocytosis, fluid-phase 
endocytosis, and endosome recycling [180, 181]. This study also showed that endosomes 
acidified at a slower rate, suggesting that endocytosis is reduced due to impaired 
endosomal acidification [181]. This may be, in part, due to decreased trafficking of ClC-5 
to endocytic vesicles, as observed from ClC-5 knockout mice, as well as mutations in the 
CBS2 domain[186, 187] 
 Endosomal acidification may not be the primary role of ClC-5, however. It has 
been suggested that primary endocytic vesicles are not acidified [188]. In support of this, 
endosomal acidification also was observed to proceed in ClC-5 knockout mice, consistent 
with the presence of alternate conductances in the endosome that may participate in 
acidification. Additionally, Hara-Chikuma and coworkers showed that acidification is 
only modestly impaired in early endosomes from proximal tubular cells [189]. Both 
acidification and chloride accumulation could be completely eliminated by non-specific 
chloride channel inhibitors in both wild-type and ClC-5 knockout cells [189]. In normal 
kidney, low molecular weight proteins (< 70 kDa) are reabsorbed by endocytosis via the 
multiligand tandem receptors megalin and cubilin at the brush border of proximal tubular 
cells. The megalin/cubilin complex is the main albumin receptor in the proximal tubule, 
making it essential for albumin endocytosis [184]. Christensen and coworkers showed 
that in ClC-5 knockout mice, expression of the megalin/cubilin complex at the plasma 
membrane was drastically reduced, greatly reducing albumin uptake [184]. Also, data 
from knockout mice showed that the V-type H+-ATPase in proximal tubular cells is 
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mislocalized to the basolateral membrane [190]. This suggests that ClC-5 may participate 
in the trafficking of cell surface receptors that are intimately involved in endocytosis of 
low molecular weight proteins [184, 190]. 
 The reorganization of proteins receptors involved in uptake of low molecular 
weight proteins provided indirect evidence that ClC-5 may be directly involved in the 
endocytic process [191]. This is further supported by immunofluorescence data showing 
that a small amount of ClC-5 localized not only to apical vesicles just below the brush 
border membrane, but also at the brush border membrane itself [182, 184]. Hryciw and 
colleagues showed, both by yeast two-hybrid screening and GST-pulldown assays, that 
the C-terminus of ClC-5 interacted with the actin depolymerizing protein cofilin [192]. 
Phosphorylation of cofilin, which abolishes the interaction of cofilin with actin, greatly 
reduced albumin endocytosis [192]. Thus, ClC-5 directly interacts with the endocytic 
machinery for albumin uptake, and is directly involved in the localization of the albumin 
receptor megalin/cubilin complex. Interestingly, a recent study from the Poronnik lab 
showed that the PDZ domain in the C-terminus of ClC-5 interacted with the PDZ 
scaffolding protein NHERF2 in opossum kidney cells. siRNA directed against NHERF2 
greatly reduced albumin endocytosis [193]. Taken together, these data suggest ClC-5 is 
necessary for the formation of macromolecular complexes involved in endocytosis of low 
molecular weight proteins such as albumin, and that disruption of this complex by 
removal of ClC-5 leads to the low-molecular weight proteinuria associated with Dent’s 
Disease.  
 ClC-5 also has been implicated in calcium transport. Other well known symptoms 
of Dent’s Disease are hypercalciuria, nephrocalcinosis, and kidney stones, all of which 
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stem from altered calcium transport in the kidney [172, 179, 194, 195]. Knockout mice 
developed by the Guggino lab showed the typical hypercalciuria associated with Dent’s 
Disease, as well as kidney stone formation, and in some cases spinal deformity [196]. 
The mechanism of altered calcium transport in knock-out mice is currently unclear. It has 
been suggested that ClC-5 may be directly involved in endocytosis of calcium 
microcrystals [195]. If these microcrystals are not endocytosed, they provide a nucleation 
point for the formation of larger crystals, and eventually kidney stones [195]. To support 
this hypothesis, Carr and colleagues have shown that disruption of ClC-5 by transfection 
of collecting duct cells with antisense ClC-5 cDNA dramatically altered localization of 
annexin A2 [197]. Annexin A2 is a crystal binding molecule in renal epithelial cells, 
which colocalized with caveolin-1, and is directly involved in both binding and 
endocytosis of calcium microcrystals [197]. Disruption of ClC-5 greatly increased the 
surface expression of annexin A2. Given that ClC-5 is clearly involved with endocytosis, 
increased surface expression of annexin A2 likely stems from decreased endocytosis. 
Thus, disruption of annexin A2 endocytosis would severely reduce calcium microcrystal 
endocytosis, providing nucleation points for the formation of larger crystals, resulting in 
kidney stones. 
 ClC-5 has been extensively studied, with the physiological role in the kidney 
being very well defined. It has become clear that ClC-5 plays a complicated role in 
endocytosis, being involved not only in endosomal acidification, but also serves as an 
essential member of macromolecular complexes involved in endocytosis. However, there 
is still work to be done in order to define the role that ClC-5 may play in other tissues. It 
has been shown recently that ClC-5 is expressed in retinal pigment epithelial cells [198, 
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199]. Additionally, Edmonds and colleagues have identified ClC-5 in the apical 
membrane of airway epithelial cells [200]. It is not currently known if ClC-5 plays a 
similar role in these tissues as it does in the kidney. While it now is accepted that ClC-5 
acts as a Cl-/H+ exchanger, it would be interesting to know more detailed biophysical 
characteristics of ClC-5 activity. The implication that ClC-5 transitions between silent 
periods and active periods may be very important in understanding the evolution of ClC 
channel behavior, which display similar quiescent and active periods.  
 
1.2.5 ClC-6 
1.2.5.1 Biophysical and physiological properties of ClC-6 
 The final branch of mammalian ClC proteins is composed of ClC-6 and ClC-7, 
which were cloned simultaneously (Fig. 1). ClC-6 was first identified from expressed 
sequence tags (ESTs) in 1997 by Brandt and Jentsch using the TBlastN algorithm, and 
was directly isolated from a human brain cDNA library using specific oligonucleotides 
[201]. The ClC-6 protein is comprised of 869 amino acids, with a molecular mass of 97 
kDa. While this protein showed significant homology to ClC-7 (~45%), ClC-6 showed 
only distant homology to the ClC-3 branch (~29%), and even less to the channel branch 
(~23%) [201]. Northern blot analysis showed that ClC-6 mRNA was present in a broad 
range of tissues, including brain, heart, skeletal muscle, lung, liver, pancreas, and kidney 
[202]. Interestingly, Nilius and coworkers identified three alternatively spliced ClC-6 
isoforms, which are named ClC-6b, -6c, -6d [203]. All of these isoforms form truncated 
proteins, with none of them being longer than 353 amino acids (ClC-6c). Even though 
RT-PCR analysis revealed that mRNA encoding ClC-6c is present solely in the kidney, 
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the functional role of this truncated protein is not known, and the presence of ClC-6c 
protein has yet to be verified in any tissue. Despite broad expression of full-length ClC-6 
mRNA, Jentsch and coworkers were only able to identify ClC-6 protein in the nervous 
system, suggesting a role in neurobiology [201]. 
 Biophysical characterization of ClC-6 has so far eluded researchers. Injection of 
cRNA encoding ClC-6 into Xenopus oocytes failed to elicit currents that were discernable 
from endogenous channels. ClC-6 currents also have not been detected in mammalian 
cells transfected with ClC-6 DNA [204]. In fact, confocal imaging of COS and CHO cells 
expressing ClC-6 showed that ClC-6 resided on intracellular membranes [205]. ClC-6 
colocalized with the SERCA2b Ca2+ pump in the endoplasmic reticulum [205]. 
Evolutionarily, ClC-6 is more closely related to ClC transporters than to ClC channels 
(Fig. 1). ClC-6 contains a cytoplasmic glutamate residue that is conserved among ClC 
exchangers; thus, it is likely that ClC-6 acts as a Cl-/H+ exchanger on intracellular 
membranes, however, this has not been conclusively proven.  
 The physiological role of ClC-6 has not been well defined as yet. As stated above, 
ClC-6 mRNA is very broadly expressed; however, the protein is only found in nervous 
system [201, 202], with abundant expression in dorsal root ganglia. Overexpression of 
ClC-6 leads to both ER and early/recycling endosome localization [206]. In these 
heterologous systems, ClC-6 copurified in detergent resistant membrane fractions, i.e. 
lipid rafts. However, in a cell line that endogenously expresses ClC-6, the human 
neuroblastoma cell line SH-SY5Y, ClC-6 colocalized with LAMP-1, a late 
endosome/lysosomal marker [206]. ClC-6 knockout mice developed by Jentsch and 
coworkers showed signs of the lysosomal storage disease NCL, similar to knockout of 
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ClC-3. Disruption of ClC-6 led to enlargement of proximal axons as a result of 
accumulation of material in the lysosome [207]. These mice displayed neurological 
symptoms similar to NCL, including reduced sensitivity to pain and modest behavioral 
changes that included an increase in the acoustic startle response and a decrease in 
exploratory activity [207]. Interestingly, lysosomal pH is not altered in ClC-6 knockout 
mice, suggesting that ClC-6 may not be directly involved in lysosomal acidification 
[207]. Sontheimer and colleagues proposed that ClC-6 may participate in regulatory 
volume decrease of glioma cells, although they also named ClC-2, -3, -5, and -7 as 
candidate proteins [208].  
 ClC-6 is the least understood of all the ClC proteins. Both the biophysical 
characteristics and the physiological role of this protein still need to be further elucidated. 
Mutations in the gene encoding ClC-6 have been associated with human NCL, although 
these mutations are rare [207]. Uchida and coworkers suggested that ClC-6 forms homo-
oligomers, but this has not been rigorously tested [168]. ClC-6 is classified as a Cl-/H+ 
exchanger largely based on data from multiple sequence alignments. The lack of surface 
expression of ClC-6 has been a major hurtle for the biophysical characterization of this 
protein. It is possible that ClC-6 associates an accessory protein similar to the association 
of barttin and Ostm1 with ClC-K and ClC-7 respectively. In short, there is still much 
work to be done in order to understand even the most basic characteristics of ClC-6.  
 
1.2.6 ClC-7 
1.2.6.1 Biophysical properties of ClC-7 
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 Cloned at the same time as ClC-6, ClC-7 is the final mammalian member of the 
ClC protein family. The gene encoding this protein was identified by homology screening 
using primers based on the DNA sequence of ClC-6. ClC-7 is an 803 amino acid, 89 kDa 
protein [201, 209]. Like ClC-6, ClC-7 showed very little homology to other ClC 
exchangers, or the ClC channels. ClC-7 is also very broadly expressed, with mRNA 
being found in pancreas, kidney, skeletal muscle, brain, liver, and lung [201]. As will be 
discussed further below, ClC-7 is also associated with an accessory protein, Ostm1, and 
plays a critical function in bone-resorbing osteoclasts. 
 Biophysical characterization of ClC-7 proteins has been very difficult until just 
recently. Brant and Jentsch found that injection of ClC-7 cRNA into Xenopus oocytes 
yielded no functional channel [201]. However, Nawrath and colleagues suggested that 
ClC-7 mediated acid-activated Cl- current in oocytes. Acidification of bath pH to 5.0 
induced large outwardly rectifying Cl- currents that were not present in mock-injected 
cells [210]. Furthermore, western blot analysis of ClC-7 injected oocytes showed that 
ClC-7 protein was present, although there was no attempt made to separate plasma 
membrane fractions from intracellular membranes [210]. Multiple sequence alignments 
created by Miller and coworkers showed that ClC-7 contains the interior glutamate 
residue common to all ClC exchangers [132], leading to the conclusion that ClC-7 is 
most likely also an exchanger. Concentrative uptake experiments performed by Mindell 
and coworkers showed that ClC-7 did indeed mediate Cl-/H+ exchange. Chloride 
transport could be altered by changing both the [Cl-], as well as the pH gradient. Similar 
to other ClC proteins, ClC-7 had a selectivity sequence of Cl- >Br- >I- [211]. This is the 
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first experimental evidence that ClC proteins of this branch of ClCs act as Cl-/H+ 
exchangers.  
 
1.2.6.2 Physiological role of ClC-7 and associated pathophysiology 
 Like ClC-6, mRNA encoding ClC-7 was present in a very wide variety of tissues, 
as noted above. However, it has been shown by several groups that ClC-7 plays a vital 
role in osteoclasts [212-216]. Most ClC exchangers are expressed primarily on 
intracellular membranes, where they participate in acidification of endosomal 
compartments. Consistent with this, Jentsch and colleagues have shown that ClC-7 was 
primarily expressed in late endosomes and lysosomes; immunofluorescence studies 
showed that ClC-7 nearly completely overlapped with the lysosomal marker LAMP-1 
[212]. There was modest expression in both the trans-Golgi network and the endoplasmic 
reticulum [212]. ClC-7 knockout mice develop severe osteopetrosis, a disorder that is 
associated with increased bone density. In wild type mice, ClC-7 was highly expressed in 
embryonic osteoclasts at the ruffled membrane [212]. Under normal conditions, the 
ruffled border functions much like late endosomes, with late endosomal markers such as 
the V-type H+-ATPase and LAMP-2 also being present at the ruffled membrane. 
Osteoclasts attach to bone, form the ruffled membrane, then secrete acid to degrade the 
bone [53, 212]. In ClC-7 knockout mice, osteoclast development is not impaired; 
however, they fail to properly secrete acid, and thus do not degrade bone [212]. In 
addition to the development of an osteopetrosis phenotype in knockout mice, several 
polymorphisms have been identified in patients with autosomal dominant osteopetrosis 
type II [213, 214, 217].  
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 In addition to osteopetrosis, ClC-7 knockout mice develop a severe lysosomal 
storage disorder with massive accumulation of materials in lysosomes of neurons [218]. 
Jentsch and coworkers showed that after correction of ClC-7 expression in osteoclasts to 
prevent osteopetrosis, the lysosomal disorder led to severe neurological defects including 
hypomotility and loss of motor control [214]. Mindell and coworkers recently have 
shown that ClC-7 provides the main chloride permeation pathway in the lysosome, 
mediating Cl-/H+ exchange [211]. In contrast to the study by Jentsch and coworkers, 
Mindell and colleagues found that knockdown of ClC-7 expression by siRNA treatment 
severely reduced the ability of lysosomes to acidify in vivo [211]. This suggests that ClC-
7 does indeed play a critical role in lysosomal acidification, as well as acid secretion at 
the ruffled membrane. 
 Interestingly, Fuhrmann and coworkers showed that ClC-7 associated with Ostm1 
[219], a 172 amino acid intregral membrane protein that contains a single transmembrane 
domain. Vacher and colleagues identified Ostm1 as the gene defective in grey lethal 
mice, which show severe osteopetrosis [220-222]. ClC-7 could be pulled down with 
Ostm1, and vice versa [219], suggesting that Ostm1 acts as a true β-subunit for ClC-7. In 
fact, it has been shown that ClC-7 is required for Ostm1 localization to the lysosome, 
while Ostm1 is not required for ClC-7 to reach that compartment. In ClC-7 knockout 
mice, Ostm1 expression is greatly reduced, while in grey lethal mice ClC-7 protein 
expression was severely reduced [219]. This suggests that the ClC-7/Ostm1 complex is 
necessary for normal lysosomal function. The mechanism by which ClC-7 protein 
expression becomes unstable in the absence of Ostm1 is not known, and is an interesting 
dilemma considering that Ostm1 is not required for ClC-7 trafficking. Fuhrmann and 
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colleagues suggested that Ostm1 may play a protect ClC-7 from degradation. ClC-7 is the 
only ClC protein that is not glycosylated, which is a novel feature for a lysosomal 
protein, most of which are normally highly glycosylated to protect against lysosomal 
enzymes. Ostm1 is a highly glycosylated protein that may therefore shield ClC-7 from 
degradation when the proteins properly interact [219]. In grey lethal mice that lack 
Ostm1, ClC-7 protein may be abnormally degraded in the lysosome, leading to decreased 
lysosomal acidification, as well as reduced osteoclast function, leading to lysosomal 
storage disease and osteopetrosis.  
 ClC-7 has a very well defined role in lysosomal function, where it participates in 
acidification of the lysosome, and is also critically involved in proper osteoclast function. 
Interestingly, ClC-7 knockout mice are also blind, due to rapid degeneration of the retina. 
Further investigation is required to define the role that ClC-7 plays in physiology of the 
eye. The nearly ubiquitous expression of ClC-7 suggests that this protein may play a 
similar role in all tissues in which it is expressed, although this may not be the case. 
Further investigation is warranted to determine if ClC-7 plays a common role in all cell 
types, or may have divergent roles in other cells.  
 
1.3 Other ClC proteins 
 As outlined above, there are 9 mammalian ClC proteins, but quite a lot of research 
has been devoted to non-mammalian members of the ClC family. Both the canonical 
channel (ClC-0) and exchanger (ClC-ec1) are non-mammalian members of this family. 
Indeed, members of this large family of proteins are present in all phylogenetic domains 
and have provided insights into ClC protein function. ClC proteins from C. elegans, for 
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example, have been very useful for analyzing structural elements of the ClC protein 
family [223-228]. As can be seen from Figure 1, ClC family members from this organism 
include voltage-dependent channels, while at least two of the six C. elegans isoforms are 
predicted to function as exchangers, although transporter function has not been tested for 
these proteins. Interestingly, no plant ClC protein has been shown to be a true voltage-
dependent channel. All Arabadopsis ClC proteins exist within a branch that only contains 
exchangers [229, 230]. In fact, at least one of these proteins, AtClCA, has been recently 
shown to be a NO3-/H+ exchanger, not a Cl-/H+ exchanger [231]. While we will not go 
into detail about the functional properties of ClC proteins in non-mammalian systems, it 
is clear that this diverse group of proteins plays a vital role in many biological systems 
ranging from prokaryotes and plants to higher animals.  
 
1.4 ClC Protein Structure 
 Among ion channels and exchangers, the structure of ClC family proteins is 
unique. Prior to the cloning of ClC-0, studies performed on the voltage-dependent 
chloride conductance from Torpedo electroplax suggested that the functional unit of this 
protein contained two chloride conductance pathways [3, 12, 232]. After the cloning of 
ClC-0, the functional oligomeric structure of this protein was indeed shown to be 
homodimeric, with each protopore possessing a chloride conduction pathway [232]. 
Single channel analysis, as well as hydropathy analysis, of other ClC channels, including 
ClC-1, -2, and -3 showed that this structure is most likely conserved between all family 
members [7, 25, 60, 136]. This quaternary structure is rare among transport proteins. In 
addition, the membrane topology of a ClC protein is a very complicated one. Hydropathy 
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analysis predicted that each mammalian ClC protein adopted a relatively conserved 
topology containing 13 helices [7, 25, 60]. Experiments from the Jentsch lab, utilizing a 
combination of in vitro glycosylation scanning and protease protection, predicted that at 
least 10 of these helices traverse the membrane, and that both the N- and C-termini are 
cytoplasmic [233]. Low resolution electron microscopy by Grigorieff and colleagues 
showed a dimeric structure for ClC-ec1, revealing a two-fold axis of symmetry from a 
top-down view of the protein and two water filled cavities off the axis of symmetry [234]. 
From this top down view the shape of the protein was roughly diamond shaped, with 
dimensions measuring approximately 100 Å in length, and 50 Å wide [234]. This 
structure, however, was not of sufficient resolution to accurately determine the number of 
transmembrane helices, or other structural features.  
 The questions remaining from these low resolution structure predictions were put 
to rest when, in 2002, the lab of Roderick MacKinnon successfully determined the high 
resolution crystal structures of two bacterial ClC proteins, from S. typhimurium and E. 
coli [14]. The high resolution structures showed that both of the bacterial ClC proteins 
formed homodimeric functional units, with both the N- and C-termini of each monomer 
being cytosolic (Fig. 4C). However, these structures also revealed that the membrane 
topology was much more complicated than originally proposed; each subunit was 
composed of 18 helices, 17 of which lay within the membrane (Fig. 4B) [14]. This basic 
structure of the membrane domain is thought to be conserved throughout the ClC protein 
family. Engh and Maduke tested the accuracy of a ClC-0 homology model, based on the 
bacterial crstyal structures, using cysteine accessibility studies, and found that the 
predictions of residue accessibility based on the model were relatively correct [235]. 
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Additionally, MS/MS analysis of the ClC-2 membrane spanning domains revealed that 
the membrane boundaries predicted by the bacterial structures were correct [236]. Thus, 
for the membrane spanning domains, the bacterial crystal structures provide an excellent 
template for studies of other ClC proteins.  
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Figure 4: ClC protein structure. (A) Membrane topology of a voltage-dependent K+ 
channel. These channels are composed of four identical subunits, with each subunit 
containing six transmembrane helices. The voltage sensor is mainly contributed by a high 
density of positive charges in the 4th transmembrane domain, while the pore resides 
between the 5th and 6th transmembrane helices. (B). Membrane topology of a ClC protein. 
Each ClC protein is composed of two identical subunits, each composed of 18 helical 
domains. Unlike voltage-dependent K+ channels, no region of localized charge governs 
the voltage-dependent gating observed for ClC channels. (C) Crystal structure of the S. 
Typhimurium ClC protein shown from the side (left) and top down (right). Note that 
there is no clear ion permeation pathway as would be expected for an ion channel, 
consistent with data showing that this protein is a transporter (D). Crystal structure of the 
C-terminal domain of ClC-0 (left). The right panel shows an overlay of the C-terminal 
domains of ClC-0, -K, and -5. All these domains adopt a similar fold, and may be 
important in ClC channel slow gating. 
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Chloride ions bound within the structure confirmed the presence of two separate 
chloride permeation pathways, one completely contained within each subunit [14], quite 
unlike that of well characterized cation channels whose single, central permeation 
pathways are composed of contributions from each subunit (in the case of K+ channels) 
or domain ( for Ca2+ and Na+ channels) [16]. Also, it has been well established by the 
MacKinnon lab that for at least K+ channels, cations are coordinated by partial negative 
charges contributed by backbone atoms of the residues forming the selectivity filter [237, 
238]. For ClC proteins however, this does not seem to be the case. Like cation channels, 
ClC proteins contain multiple ion binding sites, as revealed by the high resolution 
structures; however, for ClC channels, Cl- ions, at least at the central binding site, are 
coordinated by the side chains of residues from multiple membrane helices: S107 (helix 
D), Y445 (helix R), and main chain amide nitrogen atoms at the end of helix N [14, 239]. 
However, long range interactions may also play an important role in ion coordination; 
Faraldo-Gomez and Roux showed via free energy calculations that K149, which is 
completely buried within the protein, acted to stabilize chloride binding, presumably by 
local hydrogen bonding as well as long range interactions [240].  
 Despite the fact that it has recently come to light that the bacterial proteins are not 
voltage-dependent channels, but Cl-/H+ antiporters, the structures have revealed some 
important features of gating of ClC channel proteins [126, 127]. As stated previously, 
there is no localized region of charged residues similar to the S4 helix of KV channels that 
might provide a molecular basis for voltage-dependent gating (Fig. 4); instead, Cl- itself 
provides the charge underlying the voltage-dependence of channel fast-gating, thereby 
coupling permeation and fast-gating [11]. This feature is very nicely explained by the 
 78
crystal structure, which revealed three chloride binding sites. The most external binding 
site, Sext, may be occupied either by chloride, or the side chain of the conserved glutamate 
residue E148, which may be the primary molecular determinant for fast gating [239]. 
When E148 occupies Sext, the permeation pathway is blocked, and Cl-, therefore, cannot 
conduct. MacKinnon and colleagues suggested that Cl- ions compete with E148 for the 
occupation of this site, imparting the [Cl-]ext dependence of gating observed for many of 
these channels [239, 241]. Voltage-dependence of gating is imparted by a voltage-
dependent Cl- binding step, at least for ClC-0 [9, 11, 17]. Mutation of this glutamate 
residue in every ClC thus far tested has led to channels that completely lack a fast-gating 
processes; single channel records of E166A-ClC-0, for example, only rarely show 
transitions between two distinct open states, residing mainly in a conductance level in 
open level two, i.e. both pore are conducting [239]. In fact, analysis of a structure of E. 
coli ClC bearing the E148Q mutation showed that all three ion binding sites were 
simultaneously occupied by Cl-, consistent with the notion that removal of this glutamate 
abolishes fast gating [239]. Further evidence for the importance of this glutamate residues 
comes from the fact that this residue is conserved in all but two ClC subtypes, the ClC-K 
channels [53, 103]. As stated above, introduction of a glutamate residue at the correct 
position in ClC-K channels gave channels that showed both voltage- and time-dependent 
activation [103]. Q10 calculations of fast gating suggested that the conformational 
changes associated with fast gating were likely very small; the Q10 for fast gating of ClC-
0 was ~1.4, and ~4 for ClC-1 and -2 [15, 37, 67]. Local structural rearrangement of E148, 
or the equivalent residue, would be consistent with the prediction that fast gating only 
involves small conformational changes [239]. Inhibitor studies which will be described in 
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section 1.5, suggest that the conformational change associated with fast gating may 
involve more than just the rearrangement of the single glutamate residue, but are likely 
still only local rearrangements [242].  
 The crystal structures have been less helpful in identifying features of these 
proteins that may contribute to slow gating. This is likely due, in part, to the fact that the 
bacterial proteins are not ion channels. For ClC-0, the Q10 for slow-gating was ~40, 
suggesting a very large conformational change [15]. From the crystal structure it is 
impossible to determine which regions of the protein may move during the slow gating 
process. One critical difference between bacterial and mammalian ClC proteins is the 
presence of large intracellular domains in the mammalian ClCs. As outlined above, 
mutations in these cytosolic domains, in particular the CBS domains, may have drastic 
effects on slow-gating, suggesting that these regions may be directly involved in the 
gating process [23, 69]. Zheng and coworkers confirmed a large rearrangement of the 
cytosolic domains of ClC-0 during gating using spectroscopic microscopy. Using FRET, 
they observed an ~23 Å movement of the C-terminus; this movement was abolished in 
the presence of Zn2+, which promotes closure of the slow gate, as well as by the C212S 
mutation [243]. Mutagenesis studies of ClC-1, performed by Roberts and coworkers, 
showed that several residues at the dimer interface may be involved in slow gating, 
including C277, which is conserved across all ClCs and may participate in inhibition by 
Zn2+ [39]. Since slow gating is proposed to regulate both pores simultaneously, 
involvement of the dimer interface is likely crucial, although structural rearrangements of 
the dimer interface have not been shown. 
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 As stated above, the intracellular C-terminal domains of mammalian ClC proteins 
may be critically involved in channel gating or regulation. Each C-terminal domain 
contains two CBS domains, which have been shown to interact with each other within a 
subunit, but also with the C-terminal domain of the other subunit present in the functional 
ClC protein [175, 244]. The crystal structures of the C-terminal domains of three ClC 
proteins have now been solved: ClC-0, ClC-Ka, and ClC-5 (Fig 4E, F). The C-terminal 
domains of these proteins all adopt similar folds, which can be seen in the structural 
alignment shown in Figure 4F. While the crystal structure of the ClC-0 C-terminal 
domain did not show intersubunit dimerization of the C-terminal domains, Markovic and 
Dutzler did observe dimerization of the ClC-Ka C-terminal domains [244]. 
Ultracentrifugation studies of the soluble C-terminal domains suggested that intersubunit 
dimerization also occured for ClC-0, even though this was not captured in the crystal 
structure [245, 246]. Thus, intersubunit dimerization may be a common feature for 
mammalian ClC proteins, although the functional role is not yet known.  
The crystal structure of the ClC-5 CBS domains showed that ATP was 
coordinated at the CBS1/CBS2 interface [175]. However, this does not seem to be a 
common feature of ClC proteins, as neither ClC-0 nor ClC-K have been shown to bind 
nucleotides. ClC-1 and ClC-2 have shown changes in activity based on ATP 
concentration, but it has not been conclusively proven that ATP binds directly to the CBS 
domains of these channels [44, 46, 47]. The interaction interface of the CBS domains is 
smaller than that of other CBS domain containing proteins, being only ~1500 Å2, and 
Dutzler and colleagues suggest that this may be due, in part, to conformational changes 
that occur within the protein during gating, although this has not been conclusively 
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shown [175, 244]. Interestingly, mutations in the CBS domains of the C. elegans ClC 
protein equivalent to ClC-2 altered accessibility of extracellular residues to MTSET, 
suggesting that the C-terminal domains may interact directly with the intracellular face of 
the channel, and induce allosteric changes in protein structure that may significantly 
influence ion conduction and gating [224].  
 Over the past few years, structure/function studies of ClC proteins have been 
greatly aided by the availability of the bacterial crystal structures. The structural basis for 
fast-gating is now well understood, and the bacterial structures provide an excellent 
template for the eukaryotic ClC protein membrane regions. Molecular dynamics 
simulations aimed at dissecting ion conduction through ClC proteins suggests that that 
the permeation pathway may be similar for ClC channels, although these simulations 
have all been based on the structure of the bacterial ClC transporters [247, 248]. 
However, the structural basis of slow gating is still lagging far behind that of fast gating. 
Although it is known that a large structural rearrangement must occur during this process, 
the conservation of those rearrangements between ClC proteins needs to be determined. It 
is likely that the conformational changes during slow gating of ClC-1 and ClC-2 are 
much smaller than that for ClC-0, given that the Q10 value for this process is much 
smaller for these channels. Additionally, the interaction between the cytosolic domains 
and the membrane domains needs to be further characterized. Detailed analysis of this 
region may not be possible until the crystal structure of a full eukarotic ClC protein is 
obtained. However, pharmacological characterization of ClC proteins using common Cl- 
channel inhibitors has provided some insights into ion conduction and gating, as will be 
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discussed below. This process, however, will be greatly aided by the discovery of high 
affinity inhibitors.  
 
1.5 ClC Protein Pharmacology 
 Pharmacological characterization of ClC proteins has been performed generally 
using only a few types of molecules: heavy metal ions such Zn2+ or Cd2+, clofibric acid 
derivatives, disulfonic stilbenes, and arylaminobenzoates. This limited number of 
inhibitors has been used to characterize only a small percentage of ClC family proteins; 
the majority of pharmacological characterization has been performed on ClC-0, -1, and -
K. We will discuss the insights into ClC channel structure and function that have been 
gained through the use of these inhibitors, as well as the advantages and disadvantages of 
these molecules.  
 
1.5.1 Divalent Heavy Metals 
 Some of the most useful inhibitors of voltage-gated cation channels have been 
peptide toxins isolated from animal venoms such as spiders, scorpion, and cone snails 
[249]. There are hundreds of these toxins that are known to inhibit cation channels. 
During the search for a peptide inhibitor of ClC-0 voltage-gated chloride channels, Chen 
discovered that spider venom contained a component capable of inhibiting ClC-0; 
however, this inhibitory activity was retained when channels were exposed to venom that 
had been previously burned, thereby destroying all peptide components [21]. Activity of 
the venom was subsequently attributed to the presence of divalent heavy metal cations 
that are present in venoms of many poisonous animals. Screening individual ions showed 
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that Zn2+, Cd2+, and Ni2+ could inhibit ClC-0 mediated currents, while Co2+ and Mn2+ 
could not [21]. Investigation into the mechanism of inhibition by these metals showed 
that they had no appreciable effect on the fast-gating process, but significantly increased 
the forward rate of channel inactivation due to closure of the slow gate, likely stabilizing 
a channel conformation in which the slow gate is closed [21]. The affinity of ClC-0 for 
Zn2+ is ~1 - 3 μM, which is among the highest affinity interactions for an inhibitor of ClC 
channels [21]. These transition metals are also known to inhibit other members of the 
ClC family, including ClC-1 and ClC-2 [250, 251], albeit with greatly reduced affinity (> 
50 μM).  
 Investigation of the inhibitory mechanism of transition metals led to 
characterization of one of the molecular determinants of slow gating. Zn2+ and Cd2+ can 
be coordinated by both histidine and cysteine residues [22]. Chen reasoned that because 
Zn2+ acted to facilitate the closure of the slow gate, the binding site of this metal should 
be in a region that strongly contributes to the slow gating process. Site-directed 
mutagenesis of many cysteine residues showed that C212 of ClC-0 provided the binding 
site for these transition metals. Mutation of this residue not only severly impaired the 
ability of Zn2+ to inhibit ClC-0 channels, but also completely removed the slow gating 
process, yielding channels that were nearly constitutively open [22]. Sequence analysis 
revealed that this residue is conserved in both ClC-1 and ClC-2. Indeed, mutation of this 
equivalent residue in ClC-1 and ClC-2 significantly reduced the inhibitory effect of Zn2+ 
on these channels [67, 68, 251]. Additionally, mutation of this cysteine residue in both 
ClC-1 and ClC-2 reduced the contribution of slow gating to channel activation and 
deactivation, consistent with the notion that this particular residue is important for slow 
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gating of ClC channel-type proteins. Inhibition of ClC-1 by these transition metals, 
however, was irreversible, and Duffield and colleagues suggested that they may interact 
with a very low probability state of the slow-gate. They showed that the V321A mutation, 
which reduced open probablilty of the slow gate, greatly increased inhibition by zinc 
[252]. So while the overall effect of zinc on gating of ClC-1 may be qualitatively similar 
its effect on ClC-0, the exact mechanism may not be the same, and needs to be further 
investigated. Interesting, Osteen and Mindell recently found that the Cl-/H+ exchanger 
ClC-4 is also inhibited by zinc. This is particululary interesting due to the fact that this 
transporter does not have the equivalent of a slow-gate, and in this case, zinc is 
coordinated by a group of histadine residues that are absent in the ClC channels [253]. 
This suggests fundamentally different gating mechanisms regulate the ClC channels and 
transporters.  
 
1.5.2 Clofibric acid derivatives 
 Of all available ClC channel inhibitors, the inhibitory effects of clofibric acid 
derived class of ClC inhibitors against their respective targets are the most well 
characterized. The basic structure of one such molecule is shown in Figure 5. Much of 
the work using these molecules has been devoted to characterizing ClC-0, ClC-1, and 
ClC-K. The main clofibric acid derivatives used to inhibit ClC channels are 2-(4-
chlorophenoxy) propionic acid (CPP), 2-(p-chlorophenoxy) butyric acid (CPB), and p-
chlorophenoxy acetic acid (CPA), which display complicated mechanisms of action, 
although they all act exclusively from the intracellular side of ClC-0 and -1 [242, 254, 
255]. The effect of clofibric acid derivatives was first identified by Conte-Camerino and 
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coworkers, who found that clofibrate drastically reduced GCl in skeletal muscle by 
directly inhibiting the channel later identified as ClC-1 [256]. Further investigation 
showed that inhibition of ClC-1 mediated currents by these molecules greatly depended 
on the specific enantiomer used, as most of these molecules are chiral. Specifically, S-
CPP and S-CPB were able to reduce GCl in intact muscle with KDs of 14 and 16 μM 
respectively, while the R-enantiomers had almost no effect [256]. Testing CPP directly 
on ClC-1 mediated currents in Xenopus oocytes showed that inhibition was very 
complicated, depending not only on the CPP enantiomer as previously described, but was 
also strongly voltage-dependent [257]. By studying the inhibition of steady-state ClC-1 
currents by S-CPP, Conte-Camerino and colleagues measured a KD of 40 μM at -80 mV, 
while KD increased as membrane potentials became more positive. In contrast to the 
effect of S-CPP, R-CPP had no effect on ClC-1 currents at concentrations up to 1 mM 
[257]. Interestingly, while the binding site of CPP is likely in the ClC-1 pore, Roberts and 
colleagues showed that CPP actually inhibits channel gating; channels deactivate more 
rapidly at hyperpolarizing potentials, and CPP induces a shift in the V1/2 of activation to 
more depolarizing potentials [258]. It is likely that CPP alters the fast gating process; the 
mutation C277S, which strongly reduces slow gate closures, does not alter the inhibitory 
effect of CPB, suggesting that clofibric acid derivatives have no effect on the slow gating 
process [40]. Also, other mutations that alter slow gating in ClC-1, F307S and A313T, 
also do not alter the inhibitory effect of CPP [259]. A mutational study undertaken by 
Pusch and colleagues probed the binding site of the clofibric acid derivative CPA, and the 
structurally unrelated molecule 9-anthracene carboxylic acid (9-AC) [260]. This worked 
suggested that these drugs share a binding site near the central Cl- binding site, although 
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the orientation of these drugs in the pore is not known. Interestingly, while CPP is 
capable of inhibiting ClC-1 at low μM concentrations, this molecule inhibits ClC-0 and 
ClC-2 with KDs > 1mM, suggesting that the binding sites within the pores of ClC-0 and -
2 are different from that of ClC-1 [257]. Although this molecule is classified as a gating 
modifier, it is possible that the operation of the fast gate is only indirectly affected, as 
occlusion of the ClC pore would likely also alter channel opening and closing due to the 
strong link between permeation and gating of these channels.  
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Figure 5: Organic molecule ClC inhibitors. These molecules have been shown to inhibit 
ClC proteins. The two-dimensional (top) and three dimensional (bottom) stuctures of 
DPC (A), 9-AC (B), DIDS (C), NPPB (D), and CPP (E) are shown. The * represents the 
carbon about which chain substitutions are made to create other members of the clofirbic 
acid family.  
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A number of CPP derivatives have been shown to inhibit ClC-K channels. While 
CPP itself does not inhibit ClC-K well (KD > 1mM), addition of a benzene ring to the 
methyl group (3-phenyl-CPP) increased affinity to the 150 μM range [261]. Like the 
activity of CPP on ClC-1, CPP derivatives inhibited ClC-K1, and –Ka, in a voltage-
dependent manner, being more potent at depolarizing membrane potentials. The 
potencies of these drugs were altered by changes in Cl- concentration, with increased 
inhibitory activity at lower external chloride concentrations. Consistent with this, 
mutation of the extracellular residue N68 to aspartic acid reduced the affinity of 3-
phenyl-CPP for ClC-Ka by more than 5-fold [262]. Additionally, introduction of this 
asparagine residue into the correct position in ClC-Kb resulted in sensitivity to 3-phenyl-
CPP [262]. Thus, CPP analogues may prove useful in probing the pore structure of ClC-
K channels, which are ion channels, but do not display voltage-dependent gating.  
 Recently, clofibric acid derivatives have been very useful in examining the 
conformational changes associated with fast gating. Similar to the effects of clofibric acid 
derivatives on ClC-1, these compounds inhibit ClC-0 strictly from the intracellular side. 
Interestingly, these molecules bind to the pore of ClC-0 in a strongly state dependent 
manner, preferentially binding to the closed state with ~20 fold higher affinity over the 
open state [242]. Consistent with a binding site within the pore, the C212S mutation, 
which eliminates slow gating, does not affect binding of CPB. Lowering internal chloride 
concentration increased the on-rate of the drug, suggesting that CPP derivatives may 
compete with Cl- for occupation of the binding site [254]. However, this may be too 
simplistic, as removal of the gating glutamate by introducing point mutations at E166 
increased the potency of CPA by > 200 fold, but did not eliminate the state-dependence 
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observed in WT channels [255]. Interestingly, lowering the intracellular chloride 
concentration had only modest effects on CPA binding to E166A-ClC-0 channels; 
affinity was increased by only ~3 fold at very depolarizing potentials. While the E166A 
mutation seemed to affect both open and closed channel inhibition, mutation of other 
residues near the intracellular mouth of the pore affected either only closed channel 
inhibition (T481S), or open channel inhibition (S123T, Y512A, K519Q) [242]. Based on 
the crystal structure, it was originally suggested by MacKinnon and colleagues that fast 
gating relied solely on the rearrangement of the E166 residue of ClC-0. While state 
dependent binding of CPP analogues may be explained by competition between the 
inhibitor and Cl- ions within the pore, crystal structures have shown that all chloride 
binding sites are maximally occupied in both the open and closed states [239, 263]. 
Additionally, the ability of mutations to affect either closed channel inhibition or open 
channel inhibition suggests a more significant conformational change within the pore 
than just the rearrangement of a singular glutamate residue during opening and closing of 
the fast-gate. The possibility of larger conformational changes during fast gating needs to 
be further addressed, as this is likely to impact not only the current views on channel 
gating, but on the transport cycle of ClC exchangers as well.  
 
1.5.3 Disulfonic stilbenes 
 Unlike heavy metal inhibitors such as zinc, and the clofibric acid derivatives, 
there has not been a great deal of characterization into the mechanism of inhibition of 
ClC proteins by disulfonic stilbenes. One such molecule, DIDS, has been shown to 
inhibit ClC-0 with affinity in the μM range, and was key in characterization of ClC-0, as 
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susceptibility of the cloned ClC-0 channel was the same as the endogenous voltage-
dependent chloride conductance found in Torpedo electroplax [1, 3, 7]. DIDS is also 
capable of inhibiting ClC-Ka with an affinity in the 100 μM range [262]. Interesting, 
Maduke and coworkers showed that a pentameric hydrolysis product of DIDS could 
inhibit ClC-Ka with a K1/2 of just 0.5 μM [264]. These molecules are presumed to inhibit 
channel activity by an open channel pore block mechanism; however, this has not been 
rigorously tested. Similar to CPP, DIDS is thought to occupy an extracellular binding 
pocket near the pore based on site-directed mutagenesis within the extracellular vestibule 
[262]. Interestingly, Hiraoka and colleagues showed that ClC-2 is completely insensitive 
to this class of molecule, showing no change in activity to DIDS, DNDS, and SITS at 
concentrations up to 10 mM [71]. Matulef and Maduke showed that the prokaryotic ClC 
transporter, ClC-ec1, can be inhibited by DIDS only when it is is applied to the 
intracellular face of the transporter. The Y445C mutation could potentiate transport when 
modified by MTSET only when MTSET was added to the intracellular face of the 
channel. This potentiation could be inhibited by preincubation with DIDS [265]. While 
there is not a great deal of mechanistic information associated with disulfonic stilbenes, 
these molecules have been useful for the basic characterization of some ClC proteins. 
However, the use of these molecules is quite limited; not only do they inhibit ClC 
proteins with very low affinity, they are incredibly non-specific, not only inhibiting some 
ClC proteins, but also CFTR and ClCa, two structurally unrelated chloride channels [266, 
267].  
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1.5.4 Arylaminobenzoates 
 Much like the disulfonic stilbenes, arylaminobenzoates are Cl- channel inhibitors 
characterized by both very low affinity, and lack of specificity. Molecules such as DPC 
and NPPB are capable of inhibiting currents elicited from ClC-0 and ClC-2 from the 
extracellular face, with affinity for ClC-2 being ~ 1 mM [53, 71]. These molecules also 
inhibit CFTR channels with low affinity. The most interesting effects of 
arylaminobenzoates are the differential effects of niflumic acid (NFA) and flufenamic 
acid (FFA) on ClC-K channels. Pusch and colleagues showed that while FFA mediated 
only an inhibitory effect on ClC-Ka, NFA showed biphasic behavior, able to potentiate 
ClC-Ka currents at low concentrations, and inhibit current at high concentrations [268, 
269]. Interestingly, Pusch and colleagues also showed that NFA only inhibited the ClC-
Ka rat homolog, ClC-K1 [269]. The authors suggested the presence of multiple NFA 
binding sites which related to the differential effects of the drug. Furthermore, changes in 
extracellular chloride concentration did not alter the effects of NFA, suggesting that these 
binding sites are not located deep within the pore. Conte-Camerino and colleagues 
suggested that the differential effects of FFA and NFA are due the different 
conformational states that these molecules can adopt; NFA exists in a planar state, while 
FFA does not [268, 270]. Consistent with this idea, Conte-Camerino and colleagues 
showed that synthetic organic molecules that adopt a planar conformation similar to that 
of NFA were also capable of potentiating ClC-Ka currents [270], while non-planar 
molecules could only inhibit ClC-Ka channels. While the exact mechanism by which 
NFA or other planar molecules can potentiate ClC-Ka currents, they can potentially be 
used as lead compounds to treat Bartter’s syndrome resulting from decreased ClC-K 
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conductance [270]. NFA is also capable of inhibiting ClC-1 by interacting with the 
cytoplasmic side of the channel with an affinity of ~42 nM, although the exact binding 
site has not been identified [271]. The effect of these molecules on other ClC proteins has 
not been thoroughly addressed.  
 With the exception of heavy metal inhibitors and the clofibric acid derivatives, 
ClC protein pharmacology is a largely undeveloped field with very few specific 
compounds, and no high affinity molecules. Additionally, very little single channel work 
has been done to further elucidate the mechanisms of inhibition by disulfonic stilbenes 
and arylaminobenzoates. Finally, while these molecules have been used with limited 
success to address both pore structure and conformational changes associated with 
channel gating, the pharmacological characterization of large scale rearrangements of 
ClC proteins and analysis of the structural differences between ClC family member 
subtypes requires new tools. These types of questions have been investigated for cation 
channels using peptide toxins isolated from animal venom. To date, however, no peptide 
toxin has been isolated that is capable of inhibiting a ClC protein.  
 
1.6 Peptide toxins from venomous animals 
 The venoms from various poisonous animals have provided some of the most 
useful pharmacological tools in the form of small peptide toxins that bind to ion channels, 
altering their activity [249]. Thousands of these types of molecules have been isolated 
from the venoms of scorpions, spiders, cone snails, and snakes, some of which are shown 
in Figure 6. Peptide toxins have been especially useful for the study of cation channels 
including KV, CaV, NaV, and TRP channels, as well as KCa and pentameric AChRs [272-
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276]. While these toxins primarily inhibit channel activity, there are some instances 
where channel activity is potentiated by toxin binding. Interestingly, while there are 
hundreds of these inhibitors that are known to affect cation channel activity, there is only 
one that exerts an effect on a chloride channel of known molecular identity. We will 
briefly discuss the benefits that these toxins have provided for detailed structure/function 
analysis of their targets, as well as the lack of these important tools for anion channel 
research.  
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Figure 6: Ion channel peptide toxin inhibitors. Classic peptide toxins isolated from 
scorpion venom, snake venom, and cone snail venom. Three dimensional structures for 
Charybdotoxin (A), Georgia anion toxin 1 (B), Conotoxin MVIIA (C), Hanatoxin (D), 
and LqhIII (E) are shown in cartoon representation. These molecules represent classes of 
molecules which inhibit K+, Na+, or Ca2+ channels. GaTx1 is the only toxin which 
inhibits a Cl- channels. 9-AC (E) is shown on the same scale for size comparison.  
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1.6.1 Peptide toxins active against cation channels 
 Peptide toxins exert their effects primarily by one of two distinct mechanisms; 
they may either occlude the permeation pathway, or alter channel gating by changing the 
energy barrier required for channel activation or deactivation. Most peptide toxins bind to 
their targets with both high affinity, and high specificity. For example, the cone snail 
toxin ω-conotoxin MVIIA, which inhibits neuronal CaV2.2 channels by blocking the 
channel pore, binds with an affinity of ~10 pM when measured in rat brain synaptosomal 
preparations [277], but has little effect on any other Ca2+ channel. Indeed, most peptide 
inhibitors show a binding affinity in the nanomolar range [249]. A few examples of both 
toxin specificity and affinity are shown in Table 3. Another important feature of these 
toxins is their relatively large interaction surface area, as compared to small organic 
molecules which inhibit channels (Table 3). The larger overall surface area generally 
leads to a very large interaction interface, the advantages of which we will discuss below.  
 96
 
Table 3: Selected inhibitors of ion channels. Listed are several peptide toxin inhibitors 
active at various cation and anion channels. Also shown are several organic inhibitors of 
chloride channels, many of which are not selective.  
 
Table 3: Selected inhibitors of ion channel activity 
 Molecular Weight Surface Area 
(Å2) 
Target Affinity 
Toxins:      
 Charybdotoxin 4.3 kDa 4212.2 KCa  
Kv1.3 
2.1 nM 
227 nM 
 
       
 Hanatoxin 4.1 kDa 3942.6 Kv1.2 42 nM  
       
 ω−Conotoxin-MVIIA 3.3 kDa 2589.6 Cav2.2 0.7 nM  
       
 LqhIII 7.0 kDa 7123.9 Nav1.2 
Nav1.7 
342 nM 
13.6 nM 
 
       
 GaTx1 3.7 kDa 3728.4 CFTR 25 nM  
       
Organic Compounds:      
 CPP 200.6 Da 212.1 ClC-1 
ClC-K 
14 μM 
150 μM 
 
       
 DPC 213.2 Da 231.6 CFTR 
ClC-0 
ClC-2 
237 μM 
~ 50 μM 
> 1 mM 
 
       
 DIDS 454.5 Da 377.8 CFTR 
ClC-0 
240 μM 
~ 20 μM 
 
       
 NPPB 300.3 Da 330.9 CFTR 
ClC-2 
35 μM 
500 μM 
 
       
 9-AC 222.2 Da 223.3 ClC-1 
ClC-2 
13 μM 
> 1 mM 
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As stated above, many peptide toxins inhibit channel activity by physically 
occluding the channel pore with a 1:1 stoichiometry. Two of the most important pore 
blocking toxins are charybdotoxin (ChTx), which inhibits some KV and KCa channels 
with nanomolar affinity [278, 279], and agitoxin2 (AgTx2) [280], which also binds to KV 
channels. Prior to the crystallization of the KcsA bacterial K+ channel, both ChTx and 
AgTx2 were used to probe the spatial localization of many residues that contribute to the 
outer pore vestibule of K+ channels [278, 280, 281]. Using a process known a 
thermodynamic mutant cycle analysis (TMCA), MacKinnon and coworkers were able to 
probe the toxin binding interface between AgTx2 and KV channels [280]. TMCA takes 
advantage of the high affinity, large surface area interaction between the toxin and the 
channel, and may be used to locate residues on the toxin and channel that interact with 
each other. Mutations are introduced individually into the toxin or the channel; if the 
residue that is mutated is important for binding, a change in affinity is observed. Next, the 
mutant toxin is tested for activity against the mutant channel. If the mutated residues are 
interacting, then the effect on binding affinity measured by testing the mutant toxin 
against the mutant channel will be greater than the effect of either mutation alone . Using 
this technique MacKinnon and coworkers were able to identify the residues on both 
AgTx2 and the Shaker K+ channel that likely form the interaction interface between the 
two proteins, identifying several residues in the outer vestibule and selectivity filter that 
were involved in toxin binding [282, 283]. The results were confirmed with the 
elucidation of the KcsA structure, which showed that the residues predicted to interact 
with these toxins were major contributors to the outer mouth of the K+ channel pore 
[237]. This pore architecture has since been shown to be conserved in other K+ channels, 
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including both bacterial and mammalian voltage-gated K+ channels, and is likely 
conserved in voltage-gated Na+ and Ca2+ channels [284, 285].  
 Other peptide toxins inhibit channel activity by altering channel gating by 
changing the energy required for channel activation or deactivation. Toxins that modify 
channel gating do not bind near the channel pore, but near the channel gating domain, 
specifically the voltage sensors for voltage-gated cation channels [249, 274]. For voltage-
gated cation channels, the voltage sensor is primarily composed of S3 and S4 helices, as 
shown in Figure 4A. For voltage-gated K+ channels, four identical subunits comprise the 
functional channel; therefore, up to four toxins may be bound to the channel, as 
demonstrated for the spider toxin hanatoxin (Htx) [286]. Other voltage-gated cation 
channels are not composed of identical subunits, but are one protein composed of four 
similar, yet not identical domains. Thus, toxins which modify gating of these channels 
may only have one binding site, such as the toxin LqhIII, which binds to a short region 
between the S3 and S4 helix in domain IV of the human NaV1.2 channel, and drastically 
slows channel inactivation [287]. The binding site at the linker between the S3 and S4 
helix seems to be a conserved feature, as other gating modifier toxins such as ω-
grammatoxin-SIA, hanatoxin, and VsTx1 all seem to bind at homologous locations [249, 
273, 274, 288]. Despite the fact that the binding sites of these toxins are small compared 
to that of pore blocking toxins, their usefulness is not diminished. Gating modifier toxins 
have provided critical insights into the structure of the voltage sensor of voltage-gated K+ 
channels [274]. The structure of the bacterial voltage-gated K+ channel KvAP showed a 
very peculiar and controversial arrangement of the voltage sensor; the S3 and S4 helices 
were arranged in a manner that suggested that they moved together during gating, and 
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was deemed the paddle model [284]. This contradicted much experimental data 
suggesting that only the S4 helix moved during channel gating. Swartz and colleagues 
have used hanatoxin to show that the S3-S4 voltage sensor is a portable motif by creating 
chimeric proteins bearing the S3-S4 helix of Kv2.1 that are both voltage-gated, and 
sensitive to hanatoxin [289, 290]. In fact, hanatoxin sensitivity may be transferred to the 
newly identified family of proton channels, and voltage-dependent phosphatases, which 
contain a voltage-sensing domain similar to KV channels, but lack a pore domain [290]. 
Thus, the S3-S4 structural domain seems to be an important feature for channel activity, 
although conformational changes associated with voltage-dependent gating have not been 
addressed using hanatoxin. Interestingly, MacKinnon and coworkers have shown that 
peptide toxins from spider venoms, such as hanatoxin and VsTx1, actually partition into 
the lipid, and reach their binding site by lateral diffusion across the membrane [291]. 
Other structure/function studies using the scorpion toxin Ts1, which modifies gating of 
NaV1.4, showed that locking the S4 voltage sensor of one domain influences the position 
of the S4 helices in the other domains of the voltage sensor [292]. Ts1 binds NaV1.4 with 
a 1:1 stoichiometry, which suggests that gating of the NaV1.4 channel is a cooperative 
process [292]. Finally, peptide toxin activators of TRPV channels have been recently 
identified [293]. Although they have not yet been used to rigorously characterize TRP 
channel activity, these toxins appear to lower the barrier for activation. 
 Peptide toxins active against cation channels have been extremely useful 
molecules. It is likely that subtle differences in primary sequence of both toxins and 
channels underlie both the affinity and specificity that these toxins display. It is likely 
that these toxins will continue to play a very important role in structure/function studies, 
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although they also provide very important physiological tools; they can be used to silence 
background channels in native cells, and are becoming sources of peptidomimetic drugs 
used to treat chronic pain.  
 
1.6.2 Peptide toxins active against anion channels 
 While there are hundreds of peptide toxins available for cation channel research, 
there is almost a complete lack of these tools available for the study of anion channels. 
Debin and colleagues identified a component of Leiurus quinquestriatus venom, named 
chlorotoxin (ClTx), which inhibited a chloride conductance expressed in rat colonic 
epithelial cells and glial cells [294, 295]. However, the molecular identity of the channel 
that underlies this chloride conductance has never been identified; ClTx does not inhibit 
voltage-activated, cAMP-dependent, or Ca2+-dependent chloride channels [296]. 
Sontheimmer and colleagues have shown that ClTx inhibits matrix metalloproteinase II, 
not a chloride channel [297].  
 The only peptide toxin found to inhibit a chloride channel of known molecular 
identity is GaTx1, which inhibits CFTR only from the intracellular side of the membrane. 
GaTx1, like other peptide toxins, inhibits CFTR with low nanomolar affinity, but in a 
strongly state dependent manner [295, 298, 299]. As described above, CFTR activity 
requires phosphorylation by PKA, as well as binding and hydrolysis of ATP at the 
nucleotide binding domains [298]. McCarty and coworkers showed that inhibition of 
CFTR channels by GaTx1 is greatly dependent upon channel open probability; GaTx1 
inhibits channels with low PO with greater efficacy than channels with high PO. While 
this can be linked to alterations of [ATP], they showed that this was not directly due to 
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competition for ATP binding, as channels bearing mutations that greatly increase PO were 
also inhibited poorly by GaTx1 [298, 299]. Analysis of single channel records showed 
that GaTx1 induced very long closed durations, silencing channels for tens of seconds to 
minutes. Thus, GaTx1 binds preferentially to the closed state of the channel, and modifies 
channel gating by stabilizing the closed state. This will be a very useful tool to study 
ATP-dependent gating of CFTR channels, providing a tool to assess conformational 
changes between closed and open states, as well as potentially identify sites within CFTR 
that are important for translating conformational changes within the nucleotide binding 
domains to the pore domain.  
 While CFTR is a very important chloride channel, there are many other chloride 
channels that lack quality inhibitors that can be used to study their activity. Included in 
this category are the channels in the ClC protein family, which, as described above, are 
critically involved in cell physiology. The need for these molecular tools is highlighted 
both by the lack of specific, high affinity inhibitors, and by the need for pharmacological 
tools that can aid in the characterization of channel gating and permeation. 
 
1.7 Goal of the work presented in this dissertation 
 The goal of the work described in this dissertation was to: 1) determine if venom 
from the scorpion Leiurus quinquestriatus hebraeus contained a peptide component 
capable of inhibiting ClC-0, -1, or -2, and perform initial characterization of the 
inhibitory activity of venom, and 2) isolate the active component and characterize the 
inhibitory activity of the identified toxin. 
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PART 1 
 
 
INHIBITION OF CLC-2 CHLORIDE CHANNELS BY A PEPTIDE COMPONENT OR 
COMPONENTS OF SCORPION VENOM
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CHAPTER 2 
 
 
 
INTRODUCTION 
 
 
 
The phylogenetically ubiquitous Cl- channel proteins within the ClC family are 
responsible for a multitude of physiological functions in organisms as varied as 
mammals, elasmobranchs, yeast, and green plants [28, 300]. Represented by nine 
mammalian variants, ClC proteins show widespread differential tissue distribution and 
provide regulatory control over numerous cellular functions ranging from the electrical 
excitability of skeletal muscles and neurons [29], to volume regulation of epithelial cells 
[28]. ClC channels are voltage-gated, and in some cases pH- or swelling-activated, as in 
ClC-2 [62, 301]. Mutations within these channels have been linked to such heritable 
human diseases as myotonia (ClC-1) [26], Dent’s disease (ClC-5) [194], and Bartter’s 
syndrome (ClC-Ka) [119]. ClC proteins such as ClC-2, ClC-5, and ClC-Kb are expressed 
in the kidney, where they play an important role in Cl- transport in the ascending limbs of 
the loop of Henle, as well as the collecting duct [302]. Knockout mutants suggest that 
ClC-3 has a role in the formation of the hippocampus [147], and mutations in ClC-2 may 
be responsible for certain forms of generalized epilepsy [92], although this has not been 
conclusively proven. ClC-2 is also proposed to play a role in cystic fibrosis (CF).  
CF is the most common lethal, autosomal recessive disease among Caucasians, 
and is caused by a defect in the Cystic Fibrosis Transmembrane conductance Regulator  
(CFTR). Both ClC-2 and CFTR are localized to epithelial cells in the lung and intestine 
[28, 76, 79, 80, 99, 303]. While CFTR is clearly localized to the apical membranes of 
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these epithelia, there is disagreement concerning the membrane localization of ClC-2. 
Contradictory studies have shown it localized to either the basolateral membrane [80, 81], 
or the apical membrane [76, 80, 304]. It has been proposed that ClC-2 may be a candidate 
channel for ameliorating the CF phenotype; it is possible that ClC-2 can provide the 
necessary Cl- conductance at the apical membrane that is lacking when CFTR is 
defective. It also has been proposed, however, that disruption of ClC-2 can increase 
survivorship in CF patients [76, 99]. These contradictory studies make understanding 
ClC-2 very important, so that the role of ClC-2 in CF or treatment for CF can be better 
assessed.  
Given the relative importance of ClCs, it is surprising that the fine structure and 
the underlying gating mechanisms of mammalian members of the ClC family remain 
unknown. In-depth structural analysis of membrane proteins is slow due to difficulty in 
successful formation of crystals for study. The recently solved structures of two bacterial 
ClC channel homologues have provided a roadmap for determination of pore structure of 
mammalian ClCs [14], but many questions remain unanswered. Despite considerable 
homology between bacterial and mammalian ClCs, the large cytoplasmic domains 
present in mammalian ClCs may have significant influence on both the function of those 
channels and their structure in comparison to the bacterial ClCs. A second problem is that 
crystal structures only capture a snapshot of molecular structure and may not describe the 
dynamic features of the gating process. ClC channels exhibit a fast gating process, which 
controls access to one of the two protopores, and a slow gating process, which controls 
access to both pores simultaneously. Although the ClC crystal structure provides some 
hints about residues involved in fast gating, it confers little other information about the 
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overall control of channel gating. Experiments utilizing structural probes in combination 
with site-directed mutagenesis are still necessary for the study of permeation and gating 
in ClC channels. Channel blockers such as DIDS and DNDS show little effect [71]; CPB 
and CPP have been used with some success in examining the gating processes of ClC-0 
and ClC-1 [254, 257, 259], but they bind with relatively low affinity (K1/2 ~ 15 μM). DPC 
and NPPB (K1/2 ~ 1 mM) have been shown to be effective pore blockers of these 
channels, albeit with low affinity [71]. Heavy metal ions such as Zn2+ have been used in 
gating studies of ClC-0 [21]. However, high affinity probes of ClC channels have yet to 
be discovered. In order for detailed studies of ClC channel structure and dynamics to 
beperformed, new tools are needed which can address these issues.  
Peptide toxins have been very useful for studying pore structure and gating 
mechanisms of voltage-gated cation channels [281, 289, 305]. They usually exhibit high 
affinity interactions and can act as either pore blockers or gating modifiers. These types 
of tools are lacking for chloride channel research. Recently, a component of scorpion 
venom has been shown to inhibit CFTR [295]. However, there are no known peptide 
inhibitors for the ClC family. Chlorotoxin (ClTx), a peptide toxin from the venom of 
Leiurus quinquestriatus quinquestriatus, has been shown to inhibit Cl- current in channels 
reconstituted from rat intestinal cell membranes, although the molecular identity of this 
channel is not known [294, 306]. Studies have shown, however, that ClTx does not 
inhibit volume-regulated, calcium-activated, or cAMP- activated Cl- channels from the 
extracellular side [296], or CFTR from the intracellular side [295]. Preliminary studies 
have shown that chlorotoxin has no inhibitory effect on ClC channels.  
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In this study, we asked whether scorpion venom contains a peptide component (or 
components) that may be an inhibitor of ClC Cl- channels. The identification of a peptide 
inhibitor for ClC channels will provide an excellent tool for studying the structure and 
gating mechanisms of these complex proteins. We investigated the effects of partially-
fractionated venom from the scorpion L. quinquestriatus hebraeus (Lqh) on the 
permeation and gating characteristics of ClC-0, ClC-1 and ClC-2. We show that one or 
more peptide components of venom interact in a voltage-dependent manner with ClC-2 
from the extracellular side of the channel to inhibit Cl- currents, while currents from ClC-
0 and ClC-1 were not affected. Further, our data suggest that this peptide inhibitor acts as 
a gating modifier of ClC-2 channels. 
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CHAPTER 3 
 
 
 
MATERIALS AND METHODS 
 
 
 
3.1 Oocyte and cRNA Preparation 
Xenopus oocytes were isolated as previously described [307] and incubated at 
18oC in a modified Liebovitz’s L-15 medium (pH 7.5) with a cocktail of antibiotics 
(gentamicin, penicillin, streptomycin) and HEPES. For electrophysiological recording, 
cRNA was prepared for Torpedo ClC-0 and human ClC-1 using constructs in the pTLN 
vector, kindly donated by T. Jentsch (Institut für Molekulare Neuropathobiologie, 
Hamburg, Germany), and for rabbit ClC-2 using a construct in pSportI [71], donated by 
H.C. Hartzell (Emory University, Atlanta, GA). For two-electrode voltage clamp, oocytes 
were injected with 2.5 to 25 ng of either ClC-0, ClC-1, or ClC-2 cRNA, and data were 
collected 2-5 days after injection. For macropatch recordings 100 ng ClC-2 cRNA were 
injected per oocyte. All recordings were performed at room temperature.  
 
3.2 Preparation of Venom, Chlorotoxin, DPC, and NPPB 
Dried whole venom (Latoxan, France; or Sigma Chemical Co., Chicago, IL) was 
prepared at a stock concentration of 2 mg/mL in the appropriate bath solution (see 
below). The mucous portion of the venom was removed by processing the venom with 
four strokes in a Potter-Elvehjem tissue grinder, followed by centrifugation at 6000 × g 
for 30 minutes to pellet the mucous component. The supernatant was passed through a 10 
kDa molecular weight cut-off filter (Millipore Corp; Bedford, MA) by centrifugation at 
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2000 × g for 40 minutes. The resulting partially fractionated venom “Lqh pf-venom” was 
then distributed into 1 mL aliquots and stored at -80oC. Native chlorotoxin (Latoxan, 
isolated from Lqh venom), was prepared in the appropriate bath solution at a 
concentration of 1.2 μM, and used immediately. 
Trypsinization was performed by incubating Lqh pf-venom solution with 
0.0028% trypsin (Sigma, from porcine pancreas) overnight at room temperature. The 
solution was then boiled for 1 hour to deactivate the trypsin, and stored at -80oC. For 
control experiments, undiluted Lqh pf-venom was boiled for 1 hour and allowed to cool 
before use. Boiled venom, with and without trypsinization, was then diluted to 0.1 
mg/mL in recording solution.  
DPC (Sigma) was dissolved directly in bath solution at a concentration of 1 mM, 
and stored at 4oC. NPPB (Sigma) was dissolved in DMSO to a stock concentration of 100 
mM and stored at 4oC. Stock NPPB was diluted to 100 μM in bath solution for 
experiments and used immediately. The final concentration of DMSO in experimental 
solutions was no greater than 0.1%, which had no apparent effect on ClC-2 currents.  
 
3.3 Two-Electrode Voltage Clamp Recordings 
Standard two-electrode voltage clamp (TEVC) techniques were used to study 
whole cell currents. Currents were acquired using a GeneClamp 500B amplifier and 
pClamp software (Version 8.4; Axon Instruments, Union City, CA) at a corner frequency 
of 500 Hz. Electrodes were pulled from borosilicate glass (Sutter Instruments; Novato, 
CA) for a resistance that ranged from 0.3-1.3 MΩ when filled with 3 M KCl. Bath 
solution for whole cell experiments (ND96) was nominally Ca2+ free and contained (in 
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mM): 96 NaCl, 2 KCl, 1 MgCl2, 1 BaCl2 and 5 HEPES. For experiments with ClC-2, 
solutions also contained 20 mM mannitol to limit swelling-activated currents. For 
selectivity experiments, NaCl was replaced with the Na+ salt of each of the anions 
studied, with 4 mM Cl- remaining in the bath solution. Substitutions were always made in 
the same order (Br-, I-, aspartate) and bracketed with data for Cl- (ND96 solution) before 
and after each substitute ion solution. Relative permeability (PX/PCl) and relative 
conductance (GX/GCl) for each substitute anion were calculated as previously shown 
using the average data for the bracketed exposure to Cl- [307]. Relative conductance was 
calculated as IErev +25 mV (X-)/ IErev + 25 mV (Cl-), where IErev +25 mV denotes the current at 25 mV 
more depolarizing than the reversal potential. Slope conductance for Cl- used was the 
average of the Cl- recordings bracketing the recordings with the substitute anion. This 
procedure allowed the comparison of several ions in each experiment while controlling 
for changes in cell conditions. All solutions were adjusted with NaOH to pH 7.5. All 
experiments were performed using an agar bridge, and corrected for changes in junction 
potentials measured using a flowing KCl electrode [307]. 
 
3.4 Macropatch Recordings 
Outside-out macropatches were used to assess the activity of trypsinized venom 
on ClC-2. The oocyte was placed in hypertonic stripping solution to allow the cell to 
shrink, and then the vitelline membrane was manually removed. Macropatch pipettes 
with resistances of 1-5 MΩ were pulled from borosilicate glass, fire-polished, and filled 
with solution containing (in mM): 150 NMDG-Cl, 5 MgCl2, 10 TES and 2 Tris·EGTA 
(pH 7.4). Extracellular bath solution contained (in mM): 150 NMDG-Cl, 5 MgCl2 and 10 
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TES (pH 7.4). Experiments were performed on patches with seal resistance >100 GΩ. 
Inside-out macropatches were used to test the effect of boiled venom on ClC-2. Pipettes 
were backfilled with 0.1 mg/mL boiled venom in extracellular solution; the tip of the 
pipette was filled with extracellular solution lacking venom. Recordings were made every 
five minutes while venom diffused to the tip until current reached steady-state. Data were 
acquired using an Axopatch 200B amplifier (Axon) operated by pClamp software. Data 
were filtered at 500 Hz, and acquired at 1 kHz.  
 
3.5 Voltage Protocols 
To determine the specificity of the venom for the different plasma membrane ClC 
channels, we individually tested ClC-0, ClC-1 and ClC-2 using step protocols with 13 
test pulses for ClC-0, and 12 test pulses for ClC-1 and -2 (Fig. 7 top). For ClC-0, 
membrane potential was held at -140 mV for 5 seconds to activate the slow gate, and 
stepped to +60 mV for 150 ms to activate the fast gate. Voltage was then stepped to 
potentials ranging from -160 to +80 mV in 20 mV increments with a pulse duration of 
300 ms, followed by a tail pulse to -100 mV for 100 ms. For ClC-1, VM was held at -30 
mV, and stepped to potentials ranging from -160 to +60 mV in 20 mV steps of 160 ms 
duration, with a tail pulse at -120 mV for 40 ms. The ClC-2 12-pulse voltage protocol 
used for initial experiments held VM at -30 mV, and then stepped to potentials ranging 
from -160 to +60 mV in 20 mV steps, with a pulse duration of 3 s, and a tail pulse at +40 
mV for 100 or 500 ms. The interpulse duration was 30 s for ClC-0, 15 s for ClC-1, and 45 
s for ClC-2.  
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Voltage- and concentration-dependence of inhibition of ClC-2 were examined 
using a 5-pulse protocol stepping from -160 mV to +60 mV in +55 mV increments. The 
Lqh pf-venom was applied at concentrations ranging from 0.01 mg/mL to 0.3 mg/mL for 
5 minutes prior to testing (concentrations of Lqh pf-venom hereafter are expressed as 
equivalent to the stated concentration of whole, unprocessed venom). Concentration-
dependence was assessed by comparing maximal inhibition of quasi-steady-state currents 
at -160 mV or peak tail currents to pre-venom records for each concentration. Voltage-
dependence was determined by comparing the I-V relationship for quasi-steady-state 
currents or peak tail currents to pre-venom records. For selectivity experiments cells were 
voltage clamped at -30 mV, stepped to -160 mV for 6 sec (to fully activate the channels) 
and rapidly ramped from -160 to +80 mV over a 50 ms period.  
We compared the macroscopic kinetics between control cells and venom-treated 
cells using a single voltage pulse protocol of extended duration. VM was held at -160 mV 
for 6 seconds, then stepped to +40 mV for 1.2 seconds. Time constants (τ) were 
calculated by fitting the quasi-steady-state activation currents and the tail currents to the 
sum of two exponential functions, using pClamp software.  
Voltage protocols for ClC-2 in outside-out macropatches were similar to those for 
TEVC, with a holding membrane potential of -30 mV. One pulse of 1.5 s duration at VM 
= -160 mV with a tail pulse +40 mV for 250 ms was used.  
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3.6 Data analysis 
Data were analyzed using pClamp and SigmaPlot 7.0 (Jandel Scientific; San 
Raphael, CA). The percent inhibition was determined from the quasi-steady-state 
activation currents at the end of the pulse to VM = -160 mV (after subtracting 
instantaneous currents) and the peak tail currents as: 
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −=
I
II
c
vcInhibition *100%  
where IC and IV are the control currents and currents in the presence of venom, 
respectively. Values for percent inhibition given in the text, therefore, specifically reflect 
inhibition of quasi-steady-state currents at -160 mV, or tail currents at +40 mV. 
 
3.7 Statistics 
Results are expressed as mean + S.E.M. for n observations. Comparisons are by 
Student’s t-test, with differences considered significant when p < 0.05. All statistical 
analysis was performed using SigmaStat 2.03 (Jandel Scientific; San Rafael, CA).  
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CHAPTER 4 
 
 
 
RESULTS 
 
 
 
4.1 Venom Selectively Inhibits ClC-2 
It is well known that peptide toxins from venomous animals contain peptide 
inhibitors active against ion channels. None, however, have been shown to be active 
against members of the ClC voltage-gated chloride channel family. It was hypothesized 
that the peptide Chlorotoxin (ClTx), from the venom of the scorpion Leiurus 
quinquestriatus hebraeus, inhibited a chloride conductance. The molecular target of this 
toxin was later shown to be matrix metalloproteinase 2, not a chloride channel, although a 
chloride channel target may still exist [297]. However, due to the fact that this particular 
venom has been a rich source of peptide toxins active against cation channels, and it was 
thought to contain at least one peptide toxin active against a chloride channel, we 
screened this venom for activity against ClC channels. The effect of partially-fractionated 
scorpion venom (Lqh pf-venom) on ClC-0, human ClC-1, and rabbit ClC-2 expressed in 
Xenopus oocytes was examined using standard TEVC techniques (Fig. 7). While ClC-2 
showed considerable inhibition both of the quasi-steady-state activation currents at 
hyperpolarizing potentials (58.0 + 5.9% inhibition at 0.1 mg/mL and VM = -160 mV, n = 
16), and of the instantaneous tail currents (62.0 + 6.7% inhibition), neither ClC-0 or ClC-
1 showed significant reduction in currents despite using up to two-fold higher 
concentrations than used for ClC-2 (20-fold higher than the apparent IC50 for ClC-2). 
Native, purified chlorotoxin showed no inhibition of ClC-2 Cl- currents (6.3 + 7.6% at 
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1.2 μM, n = 2). These data indicate that a component (or components) of scorpion venom 
other than chlorotoxin selectively inhibited ClC-2, suggesting that the active toxin, once 
isolated, would potentially be a powerful tool for exploring structural aspects of this 
particular channel.  
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Figure 7: Effects of scorpion venom on macroscopic ClC currents. Upper panels are the 
TEVC voltage protocols, center panels are representative currents in the absence of 
venom and the lower panels show representative currents from the same oocytes in the 
presence of venom for (A) ClC-0 (0.2 mg/mL pf-venom), (B) ClC-1 (0.2 mg/mL pf-
venom), and (C) ClC-2 (0.1 mg/mL pf-venom).  Note that inhibition occurred only for 
ClC-2 with maximum inhibition ~50% in this example.  The dashed line indicates the 
zero-current level for all traces. 
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One potential problem with studying ClC-2 channels expressed in Xenopus 
oocytes arises from the fact that currents from endogenous oocyte channels may resemble 
currents from ClC-2 [308, 309], as endogenous channels are also activated by prolonged 
pulses to hyperpolarizing potentials. Because activity of these endogenous channels may 
be enhanced when the cells are injected with large volumes of cRNA, it was important to 
determine whether the currents we identified as ClC-2 actually arose from ClC-2 
channels. To address this problem, we periodically tested batches of ClC-2 cRNA-
injected oocytes for permeability and conductance sequences by replacing Cl- with Br-, I- 
or aspartate. One distinguishing feature of these two channel types is that the endogenous 
channels show a selectivity sequence of I- > Cl- while all ClCs have the selectivity 
sequence of Cl- > Br- > I- for both permeability and conductance [28]. Selectivity was 
testing using ramp protocols described in the Materials and Methods. Each substitute 
anion was bracketed by recordings with normal Cl- containing solution, to account for 
any rundown that may occur during the course of the experiment. The results of 
selectivity experiments (Table 4) showed that the currents elicited in ClC-2 injected 
oocytes had a permeability sequence of Cl- > Br- > I- > aspartate, and a conductivity 
sequence of Cl- > Br- > aspartate > I-, which is consistent with ClC channel currents [28]. 
Representative I/V plots are shown in Figure 8. 
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Figure 8: Ion selectivity of ClC-2. The current-voltage relationship was obtained by 
comparing depolarizing ramps from -160 to +80 mV. Representative currents from one 
oocyte, in the presence of Cl-, Br-, I-, and aspartate, are shown.  A shift in reversal 
potential to more positive membrane potentials indicates the substitute ion is less 
permeable than chlrodide. Thus, for ClC-2, the permeability sequence is Cl- > Br- > I- > 
aspartate.  
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Table 4: Anion selectivity of ClC-2 currents in oocytes. Reversal potential, relative 
permeability, and relative conductance for Cl-, Br-, I-, and aspartate as obtained from 
experiment shown in Figure 8. (*) indicates p < 0.05 compared to Cl- 
  
Table 4: Anion Selectivity of ClC-2 currents in oocytes 
 Erev(mV) PX/PCl GX/GCl 
Cl- -36.8 + 2.52 1.0 1.0 
Br- -30.0 + 2.21* 0.76 + 0.004* 0.85 + 0.02* 
I- -12.9 + 2.78* 0.37 + 0.02* 0.27 + 0.03* 
Aspartate 9.14 + 3.62* 0.15 + 0.01* 0.35 + 0.02* 
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4.2 Inhibition by Venom is Reversible  
Many very high affinity peptide toxins show relatively slow kinetics for both the 
on-rate of the toxin, as well as the off-rate, showing return to baseline currents over many 
minutes. Also, it is important to demonstrate that venom activity is reversible upon return 
to non-venom containing recording solution in order to rule out possible non-specific 
effects. Therefore, to determine if inhibition of ClC-2 by venom is reversible, we 
measured the amount of inhibition over the duration of an experiment, including during 
exposure to venom and subsequent washout. Time series of currents at VM = -160 mV in 
one-minute intervals during exposure to 0.1 mg/mL Lqh pf-venom (n = 3), and 
subsequent washout, show the progression of inhibition to be relatively slow and 
completely reversible (Fig. 9). Maximum inhibition occurred after ~5 minutes of 
exposure, though the majority of inhibition occurred within the first two minutes, which 
is the period during which the solution in the recording chamber should be entirely 
exchanged. Activity returned to pre-venom values after ~10 minutes of washout. 
However, in some cases washout took considerably longer than 10 minutes, implying that 
the off-rate of the venom is slow, consistent with other peptide inhibitors.  
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Figure 9: Inhibition of ClC-2 by venom. Time series for the inhibitory effect of venom 
(0.1 mg/mL, n = 3) on ClC-2 currents using a single pulse voltage protocol (fractional 
activation currents at VM = -160 mV) taken at one-minute intervals.  Venom flow was 
initiated at t = 0 and continued for 6 minutes.  Maximum inhibition occurred at ~5 
minutes of exposure. Inhibition was reversible within ~ 10 minutes. 
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4.3 The Inhibitory Component (or Components) is a Peptide  
Many of the most potent and selective inhibitors of voltage-gated channels are 
peptide toxins isolated from animal venom [249]. Peptide components of a wide variety 
of venoms have provided useful tools in the study of cation channels to determine aspects 
of both pore structure and gating processes [280, 286, 310]. We tested the hypothesis that 
the active component(s) of scorpion venom is a peptide by incubating Lqh pf-venom with 
the protease trypsin to digest any proteins within the venom, and then boiling the mixture 
to inactivate the enzyme. However, when applied to whole oocytes under TEVC, the 
trypsinized venom produced significant leak current. It is possible that the trypsinization 
process released bound calcium ions, which in turn activated calcium-activated chloride 
channels, although the addition of chelating agents such as EGTA into our solutions did 
not resolve this problem. In contrast, outside-out macropatches from oocytes expressing 
ClC-2 remained stable during exposure both to Lqh pf-venom and trypsinized Lqh pf-
venom. Macropatch currents showed no significant inhibition by 0.1 mg/mL trypsinized 
Lqh pf-venom (Fig. 10B,E), while strong inhibition was observed in response to 
untreated Lqh pf-venom (Fig. 10B,C). As a control we asked whether boiled 
untrypsinized Lqh pf-venom inhibited ClC-2 currents using TEVC. Boiled Lqh pf-venom 
at 0.1 mg/mL inhibited ClC-2 quasi-steady-state currents in TEVC experiments to the 
same degree as unboiled Lqh pf-venom at the same concentration (62.0 + 4.38% 
inhibition, n = 3; Fig. 10B). Boiled venom also inhibited ClC-2 in inside-out 
macropatches in experiments where the pipette solution contained 0.1 mg/mL boiled 
venom (36.9% inhibition; see Methods), as shown in Figure 10D. Macropatch currents 
elicited by a pulse to VM = -160 mV were allowed to stabilize as the boiled venom 
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solution diffused to the patch, and currents showed no change over 20 minutes after 
maximal inhibition by boiled venom was reached. The difference in degree of inhibition 
between TEVC and macropatch recordings could be attributed to the differing 
cytoplasmic chloride concentrations. These data suggest that the lack of inhibition with 
trypsinized venom is due to the peptide being degraded by trypsin, and not denaturation 
by boiling. Since heat stability is a common feature of peptide toxins, which usually have 
multiple intrapeptide disulfide bridges [311], this supports the hypothesis that the active 
component(s) is a heat stable peptide.  
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Figure 10: Trypsinization destroys activity of pf-venom. (A) Voltage protocol for 
excised,  outside-out macropatch recordings. (B) Normalized current remaining for 
currents at VM = -160 mV for control, trypsinized venom (105.7  + 10.0%, p = 0.31, n = 
5), and pf-venom (68.5 + 6.2%, p < 0.015, n = 3) in outside-out macropatches, as well as 
pf-venom (42.0 + 4.9%, p < 0.001, n = 16) and boiled pf-venom (38.0 + 4.38%, p = 
0.006, n = 3) for TEVC recordings.  Venom concentration was 0.1 mg/mL for all of these 
experiments. (*) indicates p < 0.05.  (C) Macropatch currents at VM = -160 mV in the 
absence (black trace) and presence (red trace) of untreated pf-venom. (D)  Inside-out 
macropatch current at VM = -160 mV in the absence (black trace) and presence (red 
trace) of boiled pf-venom that was backfilled in the patch pipette. (E) Macropatch current 
at VM = -160 mV in the absence (black trace) and presence (red trace) of trypsinized pf-
venom.  The dashed line indicates the zero-current level for all traces. 
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4.4 Inhibition is Concentration-Dependent 
Peptide toxins typically inhibit their targets with very high affinity, usually in the 
nanomolar range [249, 312, 313], which makes them valuable tools for in depth studies 
of channel structure and gating processes [280, 286, 310]. Inhibition of ClC-2 currents by 
scorpion venom was clearly concentration-dependent, for both the quasi-steady-state 
current (Fig. 11A), and the tail current (Fig. 11B). The dose-response curve for inhibition 
of quasi-steady-state current at VM = -160 mV for each Lqh pf-venom concentration (Fig. 
11C) was fit to a three parameter Hill equation (r2 = 0.91; p = 0.08). The data show clear 
concentration-dependent inhibition up to 0.1 mg/mL with saturation occurring at 
concentrations above 0.1 mg/mL. The apparent IC50 was 0.01 mg/mL, and the Hill 
coefficient was 0.97. This likely represents a high affinity interaction between the active 
component(s) and ClC-2, because it is not likely that the active component is present at 
very high abundance in the venom mixture, which may contain hundreds of individual 
components.  
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Figure 11: Voltage- and dose-dependence of inhibition of ClC-2 by venom. Voltage 
dependence of the (A) quasi-steady-state activation currents and (B) tail currents of ClC-
2 at zero (filled circles), 0.01 (open circles), 0.03 (filled triangles),  0.1 (open triangles), 
and 0.3 (filled squares) mg/mL pf-venom using a 5 pulse voltage protocol. (C) 
Concentration dependence of inhibition at VM = -160 mV. All concentrations include 3-
16 replicates.  The line was fit to the mean at each concentration using a three parameter 
Hill equation. 
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4.5 Venom Shifts Apparent Voltage-Dependence of Activation  
The mechanism of inhibition may be assessed by analyzing the effects of Lqh pf-
venom on the voltage dependence of activation of ClC-2. ClC-2 currents display a high 
degree of inward rectification due to poor activation at potentials more depolarizing than 
-30 mV. This form of current-voltage relationship is seen for both quasi-steady-state 
currents and tail currents at +40 mV. Peptide inhibitors may inhibit channels by either 
blocking channel conductance through the pore by physically occluding the pore, or by 
alter channel gating, such that the energy required for channel activation is higher; thus a 
stronger stimulus is required to achieve channel activation. These mechanisms of 
inhibition would therefore have different effects on the relationship between channel 
activation and voltage. Pore blockers would lower the maximum current, leaving the 
voltage-dependence of activation unchanged, while gating modifiers would shift the 
voltage-dependence of activation. In the presence of venom the apparent voltage-
dependence of activation for quasi-steady state currents is shifted to more 
hyperpolarizing potentials (Fig. 12A). This may be caused by voltage dependent 
occlusion of the pore. However, this relationship was also seen for tail currents elicited 
when the voltage was stepped to +40 mV (Fig. 12B). The voltage-dependence of 
activation for tail currents may be converted to a PO/V curve if maximal conductance is 
assumed to have a PO ~1. In the case of ClC-2, the PO/V curve does not saturate within 
the voltage range applied; however, maximal PO may be estimated, and the V1/2 can be 
calculated from the fit. A shift in the V1/2 for channel activation in the presence of venom 
would imply that the active component of venom acts as a gating modifier. Analysis of 
voltage-dependence of activation from tail currents of multiple experiments reveals that 
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venom does indeed shift the V1/2 of channel activation from 126 + 2 mV to 176 + 20 mV 
(Fig. 13), suggesting that the active component of venom acts as a gating modifier.  
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Figure 12: Effect of venom on ClC-2 macroscopic currents. Voltage dependent 
inhibition by pf-venom (0.1 mg/mL) of the (A) quasi-steady-state and (B) tail currents of 
ClC-2 in a representative experiment using the 12-pulse protocol described in Figure 7.   
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Figure 13: Venom shifts the ClC-2 activation curve. The PO/V curve of ClC-2 that the 
half-maximal activation voltage is shifted to the left in the presence of 0.1 mg/mL. PO 
was normalized to current at VM = -160 mV in the absence of venom. Each point 
represents measurements from 8 experiments. 
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4.6 Voltage-Dependence of Inhibition 
We examined the voltage-dependence of inhibition of quasi-steady-state currents 
with voltage step protocols, as well as inhibition of tail currents at +40 mV (Fig. 14). 
Inhibition of quasi-steady-state current showed significant voltage dependence. There 
was increasing inhibition of quasi-steady-state currents as the membrane potential 
became more depolarizing (Fig. 14A left). Comparison of current remaining at -160 mV 
to that at -60 mV showed a significant difference (p = 0.03, n = 8). Plotting I/Io for tail 
currents, however, showed no voltage dependence when comparing tail current remaining 
following steps to -160 mV versus that following steps to -60 mV (p = 0.34). This is 
likely due to small contaminating currents at positive membrane potentials that are due to 
activation of endogenous channels in the oocyte. 
To further clarify the mechanism of inhibition, we compared inhibition of ClC-2 
by Lqh pf-venom with inhibition by small organic molecules known to be pore blockers 
of a variety of Cl- channels. Inhibition by DPC was voltage-dependent (Fig 14B); 
however, as the I/Io plot indicates, inhibition decreased with more depolarizing potentials 
throughout the voltage protocol. Inhibition by NPPB followed the same trend as 
inhibition by DPC for both activation and tail currents (Fig. 14C). Indeed, both DPC and 
NPPB led to an increase in current at weakly hyperpolarizing potentials. These results 
were unlike the results for Lqh pf-venom, suggesting that venom inhibits ClC-2 channels 
via a mechanism different from that underlying inhibition by DPC or NPPB. 
 131
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Comparison of inhibition of ClC-2 by venom and known pore blockers.  
Effect of (A) pf-venom (0.1 mg/mL, n = 8), (B) DPC (1 mM, n = 6), and (C) NPPB (100 
μM, n = 4) on normalized ClC-2 activation currents (left panels) and tail currents (right 
panels). (*) indicates statistical difference between current remaining at VM = -60 mV 
compared to current remaining at VM = -160 mV.  
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4.7 Kinetics of ClC-2 Gating 
Another way to assess the mechanism of inhibition is to examine effects of the 
inhibitor on the kinetics of either channel activation of deactivation. Open channel pore 
blockers should have no effect on the kinetics of either channel activation, or 
deactivation, because they simply reduce the number of channels that are able to conduct. 
Due to the fact that open channel blockers may bind or unbind at any time, no effect on 
channel kinetics should be observed. Gating modifiers, on the other hand, may alter 
channel activation kinetics or deactivation kinetics due to the fact that they intrinsically 
alter either the opening rate or the closing rate of the channel. This may be reflected as a 
change in the macroscopic kinetics of activation or deactivation. Using this approach to 
determine if an inhibitor is a gating modifier may be difficult, because a state-dependent 
pore blocker that can only bind in the closed state will also appear to slow channel 
activation. Channel kinetics were examined by using a prolonged voltage step protocol to 
obtain values for the time constant of activation (τactivation) at VM = -160 mV, as well as 
the time constant for deactivation (τdeactivation) from the tail pulse at VM = +40 mV (Fig. 
15). Both of these relaxations were fit best by the sum of two exponential functions. In 
the presence of venom, inhibition of ClC-2 was exhibited as an increase (2.50 + 0.35 
fold, n = 7, p= 0.008, at 0.03 mg/mL venom) in the time constant for the fast component 
of τactivation (Fig. 15C). At a higher concentration, both time constants of activation were 
significantly affected. The slow component showed a 1.92 + 0.18 fold increase (n = 11, p 
< 0.001), while the fast component showed a 2.89 + 0.49 fold increase (n = 11, p < 0.001) 
(Fig. 15C). There was no change in the time constants of deactivation for ClC-2 when 
exposed to venom at a concentration of 0.1 mg/mL (data not shown). This indicates that 
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the activation of the channel is significantly slowed in the presence of venom, which is 
consistent with the action of a gating modifier. There were no significant changes in 
fractional area contributed by each time constant for activation (Fig. 15D) or deactivation 
(data not shown) in the presence of 0.03 or 0.1 mg/mL venom. This suggests that fast and 
slow gating may be highly coupled in ClC-2, as one would expect that the contribution of 
one time constant would change if it were affected more than the other. This coupling of 
fast and slow gating in ClC-2 has been described previously by Zuniga [67], and more 
recently by de Santiago et al. [68]. 
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Figure 15: Venom alters channel activation kinetics. Effect of pf-venom (0.03 mg/mL 
and 0.1 mg/mL) on the activation kinetics of ClC-2. (A) Extended TEVC voltage 
protocol. The step potential was held for six seconds; tail potential was held for 1.2 
seconds. (B) Representative TEVC recording, at VM = -160 mV, before pf-venom (black 
trace) and with 0.1 mg/mL pf-venom (red trace). Data were fit with a second-order 
exponential and the time constants (τ) were normalized to values before pf-venom.  The 
dashed line indicates zero-current level. (C) Effect of pf-venom on the long (τ1, filled 
bars) and short (τ2, open bars) time constants for activation. Values above the dashed line 
represent increased time constants while values below represent a decrease.  The 
fractional contributions to the fit from τ1 and τ2 for channel activation are shown in panel 
(D).  Pre-venom results are represented by the black bars, while results with pf-venom 
are represented by the gray bars.  Statistical analysis was performed on non-transformed 
data. (*) indicates p < 0.05. 
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4.8 State Dependence 
Inhibition appears to be independent of the activation state of the channel. By 
plotting the degree of relative inhibition over time during the three-second activation 
pulse, we found no significant change in the percent decrease in the current (Fig. 16). In 
order for a state-dependent pore-blocker to appear to slow channel activation kinetics, it 
must unbind during channel activation. This would appear as more inhibition at the 
beginning of the voltage pulse, with reduced inhibition at the end. The degree of 
inhibition did not change significantly over the duration of the pulse. However, even 
though the current remaining at the beginning of the pulse is not statistically different 
from the current remaining at the end of the pulse, it does trend toward significance (p = 
0.09, n = 16), hence, the trend suggests more inhibition at the end of the pulse than at the 
beginning. Therefore it is unlikely that the active component acts as a state-dependent 
pore blocker.  
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Figure 16: Inhibition of ClC-2 does not change over the voltage pulse. Fractional current 
remaining is shown for specific time point during a three second voltage pulse to VM = -
160 mV. There is no change in inhibition of ClC-2 currents over the course of the voltage 
pulse (n = 16). 
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4.9 Effect of Venom on Swelling Activated Currents 
It has been shown that ClC-2 channels can be activated in several different ways, 
including pH-dependent activation, swelling activation, and voltage-dependent gating 
[300]. We have shown above that venom acts as a gating modifier by slowing voltage-
dependent activation of ClC-2. We next tested for effects of venom on swelling induced 
activation of ClC channels by swelling oocytes expressing the channel by exposure to 
ND96 with 10 mM mannitol. We observed a 1.25 + 0.05 fold increase in currents as a 
result of swelling ( n = 7, p = 0.01). To test if venom inhibits the induction of swelling 
activated currents, we exposed ClC-2 channels to 0.1 mg/mL Lqh pf-venom in ND96 
with 20 mM mannitol, and then exposed the channels to 0.1 mg/mL Lqh pf-venom in 
ND96 with 10 mM mannitol to induce swelling activated currents. When the channels 
were swollen with 10 mM mannitol in the presence of 0.1 mg/mL Lqh pf-venom, we 
observed a 1.36 + 0.09 fold increase in currents (n = 7, p = 0.007) (Fig. 17A). This is not 
a significant change in the fold increase in currents as a result of swelling (p = 0.33), 
indicating that venom has no effect on the induction of swelling activated currents. This 
trend was maintained with tail currents, where control cells showed a 1.22 + 0.05 fold 
increase (n = 7, p = 0.03), and cells swollen in the presence of venom showed an increase 
of 1.10 + 0.05 fold (n = 7, p = 0.05) (Fig. 17B). When the percent apparent inhibition of 
steady-state currents was compared for venom with 20 mM mannitol, and venom with 10 
mM mannitol, there was a significant decrease in the amount of inhibition observed under 
swelling conditions, compared to control (57.51 + 0.05 % vs. 42.81 + 0.05% p = 0.008) 
(Fig. 17C). Tail currents however, showed no significant change in the amount of 
inhibition observed for Lqh pf-venom with 10 or 20 mM mannitol. The lack of effect on 
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swelling-induced ClC-2 currents suggests that the effect of cell swelling on ClC-2 is not a 
direct gating mechanism, consistent with the suggestion that swelling-induced currents 
only reach steady-state after a period of > 10 minutes.  
 139
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Effect of pf-venom on swelling induced ClC-2 currents.  Data are plotted as 
fold increase of  (A) activation currents and (B) tail currents upon induction of swelling. 
Closed circles represent fold increase in currents upon swelling for individual 
experiments, while open circles are mean  + SEM for control cells. Closed triangles are 
individual experiments for fold increase in current upon swelling in the presence of 0.1 
mg/mL venom, and open triangles are mean + SEM for cells in the presence of venom.  
(C) Percent inhibition of ClC-2 time-dependent activation currents at VM = -160 mV, for 
venom prepared with 20 or 10 mM mannitol. (D) Percent inhibition of ClC-2 tail currents 
at VM = +40 mV, for venom prepared with 20 or 10 mM mannitol. 
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CHAPTER 5 
 
 
 
DISCUSSION 
 
 
 
Peptide toxins have proven to be indispensable tools in studying pore structures 
and gating mechanisms in a variety of voltage-gated channels [249, 280, 312, 314]. In 
this study, we investigated the inhibitory effects of venom isolated from the scorpion L. 
quinquestriatus hebraeus on three plasma membrane members of the ClC family. Of the 
three channels studied, the venom showed a strong inhibitory effect only on ClC-2. This 
suggests that the inhibition is not due to the action of heavy metal ions such as Zn2+ or 
Cd2+, which could be contaminants carried in venom, that are known to inhibit ClC-0 and 
ClC-1, as well as ClC-2 [21]. Thus, unlike the inhibitory effects of other organic 
molecules such as DPC, 9-AC, and members of the clofibric acid family [71, 257], and 
despite the relatively high homology in the primary sequence of the three channels [315], 
the selective nature of the venom suggests that it could not only be a powerful tool for 
understanding the structure of ClC-2 but may also offer insight into the functional 
relevance of the structural differences between various ClC members.  
Our results have shown that a peptide component (or components) of scorpion 
venom inhibits ClC-2. The toxin is slow to bind to the channel, taking approximately five 
minutes to show maximum inhibition, at 0.1 mg/mL equivalent concentration, and is 
relatively tenacious once bound, taking approximately ten minutes to fully restore pre-
venom current levels during washout. In addition, macropatch data have shown that 
trypsinization of the Lqh pf-venom removes the inhibitory effect, strongly suggesting that 
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the active component(s) is a peptide. The possibility remains that multiple components of 
the venom are acting in concert, and that trypsinization of the partially fractionated 
venom disrupts the interaction of the components responsible for inhibition. Experiments 
have shown that native ClTx (Latoxan) does not inhibit ClC-2. Lqh venom contains 
several components that are similar to components of L. quinquestriatus quinquestriatus 
venom, the source of ClTx [316], and given the large number of peptide toxins that have 
been identified, it is possible that the active component(s) of this venom is a peptide that 
has already been characterized. However, it is also possible that the active component is a 
novel peptide. Once the toxin is isolated, sequence analysis will allow for an evaluation 
of evolutionary relationships to other toxins.  
Determining the underlying mechanism of inhibition is complicated, since 
permeation and gating are tightly coupled in ClC family channels [28, 317]. However, 
two lines of evidence suggest that the venom acts as a gating modifier. First, ClC-2 
channel activity is clearly voltage-dependent and venom shifts the voltage-dependence of 
activation to more hyperpolarizing potentials. However, at the test potentials used in this 
study, ClC-2 currents never apparently reach full activation, even at extremely 
hyperpolarizing potentials (e.g., -160 mV) that are barely tolerated by the cell. Hence, 
estimation of maximal Po, and its potential decrement in the presence of venom, is 
difficult [62]. Secondly, inhibition by venom alters channel activation kinetics; this is 
observed as a slowing of both time constants of activation for ClC-2 in the presence of 
venom. This effect also appears to be dose-dependent, with more pronounced effects at 
higher concentrations of venom. This slowing of activation could represent a stabilization 
of the closed state, which is not uncommon for gating modifiers. Gating in ClC channels 
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is complicated, in that there are both fast and slow gating processes, and in that gating 
and permeation are linked, with Cl- acting as both the gating charge and the permeant ion 
[28]. It is possible that the active component(s) has some effect on permeation that is not 
evident in our assays, but these results taken together provide convincing evidence that 
the main effect of the venom is modification of channel gating. Whether the venom acts 
on the fast or slow gate presently is unknown. In ClC-2, it is difficult to separate the fast 
and slow gates at the macroscopic level. It may be that single channel recordings, in 
association with the purified toxin, can differentiate between these possibilities, but the 
low single channel conductance of these channels [62] will make those experiments 
difficult to perform. 
The finding that the active component(s) of venom behaves as a gating modifier 
suggests that it must function to prevent some conformational change that is necessary 
for gating. In voltage-gated K+ channels the S4 region responsible for the detection of 
voltage is linked to the movement of S5 and S6, which are the pore lining helices [237]. 
Binding of voltage-sensing toxin (VSTx) prevents the movement of the S4 region, and 
thus inhibits gating [288]. Although the domain movements associated with gating of 
ClC channel proteins are not known, it is proposed that the movement of a conserved 
glutamate residue that lies within the pore regulates fast gating [66-68, 239]. The 
mechanism underlying the slow gate is still unknown, although the slower kinetics of this 
gate would suggest that large movements of the protein are necessary. Given that the 
ClC-2 activation rates are slowed by venom, it is possible that this peptide is directly 
interacting with one of the gates. The dose response indicates a Hill coefficient of 0.97, 
which would suggest that the toxin is interacting with the channel with a 1:1 
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stoichiometry. This would indicate either an interaction with the single slow gate, or an 
allosteric interaction that may affect all gates. Interaction with the two fast gates would 
provide two binding sites, and possibly give a Hill coefficient significantly different than 
one, assuming binding of the toxin to each of the fast gates is an independent event. It has 
been shown that Cl- can act as the principle gating charge in ClC channels; ClC-2 relies 
on intracellular Cl- to gate the channel [18]. Since the venom works from the extracellular 
side of the channel, venom-induced disruption of intracellular Cl- binding sites through a 
direct interaction is unlikely. 
Purification of a single peptide that inhibits ClC-2 would provide a powerful tool 
in the study of gating for ClC channels. Once the active component or components are 
isolated a functional map of the channel can be made, so that the protein movements 
necessary for gating can be identified. This report provides the basis for the identification 
of a tool that will lead to a better structural understanding of mammalian ClC channels. 
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PART 2 
 
 
 
ISOLATION OF A NOVEL PEPTIDE INHIBITOR OF CLC-2 CHLORIDE 
CHANNELS
 145
CHAPTER 6 
 
 
 
INTRODUCTION 
 
 
 
ClC proteins form a family of voltage-gated Cl- channels and Cl-/H+ exchangers 
that are found in animals, plants, and bacteria [28]. These proteins are expressed on the 
plasma membrane and some intracellular membranes in both excitable and non-excitable 
cells [28, 301]. There are nine mammalian members of the ClC family which perform 
functions as varied as maintenance of membrane potential in neuronal cells (for ClC-2) 
[92], Cl- transport across plasma membranes of epithelial and skeletal muscle cells (ClC-
1, ClC-2, ClC-Ka/b) [28, 318], and participation in lysosomal acidification (ClC-5, ClC-
6) [301]. Defects in the genes encoding ClC proteins are linked to a number of diseases 
including myotonia, epilepsy, Dent’s disease, and Bartter’s syndrome [28, 92, 301, 319]. 
It has recently been suggested that ClC-2 may play a role in constipation-associated 
irritable bowel disease as well as in atherosclerosis [84, 86]. Most ClC channels show 
localized tissue expression; ClC-1 for example is expressed solely in skeletal muscle, 
while ClC-Ka/b is localized to the kidney. ClC-2, on the other hand, is expressed nearly 
ubiquitously, suggesting that this channel plays an important, yet largely undefined, 
physiological role [28, 301].  
 ClC proteins are structurally unrelated to cation channels, with the functional unit 
being a homodimer [12]. In 2002, the crystal structure of a bacterial ClC protein was 
solved, revealing a very complicated membrane topology consisting of 18 α-helical units 
per subunit, some of which fully traverse the membrane, while some do not [14]. 
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Examination of the crystal structure revealed no obvious pore, as is evident in K+ channel 
structures, even though bound Cl- ions were evident [14, 237]. Shortly after the crystal 
structure was solved it was shown that the bacterial ClC protein was actually a Cl-/H+ 
exchanger, and not a channel [126, 127]. Molecular dynamics studies have revealed a 
tortuous transmembrane permeation pathway through the ClC protein [247]. Comparison 
of the amino acid sequence of the S. typhimurium ClC protein with that of the eukaryotic 
ClC channels ClC-0, -1, and -2 revealed only 22%, 16%, and 19% identity overall (data 
not shown). This divergence is largely in the cytoplasmic domains, which are absent in 
bacterial ClC proteins; sequence identity is much higher in the transmembrane domains.  
Gating in ClC proteins is complicated, involving both fast and slow gating 
processes which are thought to involve separate regions of the protein [28]. Fast gating 
controls the opening and closing of both protopores independently; these gates operate on 
the millisecond timescale or faster. Through examination of the crystal structure, and 
subsequent electrophysiological analysis, the fast gating process was revealed to involve 
a conserved glutamate residue deep within each pore [239]. This glutamate residue lies 
near a Cl- binding site and moves slightly to open the pathway in response to changes in 
membrane voltage and subsequent changes in occupancy of that site, thus providing the 
link between permeation and gating observed in ClC channels [237, 318]. In contrast, 
slow gating controls both pores simultaneously, operating on the hundreds of 
milliseconds to seconds timescale. Unlike fast-gating, the regions of the ClC protein 
involved in slow gating are still unknown, despite the availability of the crystal structure. 
It is believed that the dimer interface contributes to slow gating, as well as the long 
cytoplasmic C-terminal domain, an isolated version of which was recently crystallized 
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[23, 38, 39, 69, 243, 245]. However, the conformational changes involved in the fast and 
slow gating processes are still largely unknown. Also, in both ClC-1 and -2, fast and slow 
gating are linked through an undetermined mechanism [33, 68].  
Despite the availability of the bacterial ClC protein crystal structure, our 
understanding of gating mechanisms and structural rearrangements of ClC proteins has 
lagged behind that of their cation channel counterparts. This is due in large part to a lack 
of useful pharmacological agents, such as peptide toxins, that may be used as tools. 
Toxins from venomous animals such as scorpions, snakes, and cone snails have been 
used for a number of years to define the permeation pathways and gating processes of 
cation channels [320]. However, no peptide toxins have been isolated that inhibit a ClC 
channel, and only one toxin has been isolated that inhibits a Cl- channel of known 
molecular identity [298]. We recently showed that the venom from the scorpion L. 
quinquestriatus hebraeus contains a peptide component that inhibits the ClC-2 chloride 
channel [61]. Here, we report the isolation of this peptide toxin, and its initial proteomic 
and pharmacological characterization.  
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CHAPTER 7 
 
 
 
MATERIALS AND METHODS 
 
 
 
7.1 Oocyte and cRNA Preparation 
Xenopus oocytes were isolated as previously described [61] and incubated at 18oC 
in a modified Liebovitz’s L-15 medium (pH 7.5) with a cocktail of antibiotics 
(gentamicin, penicillin, streptomycin) and HEPES. cRNA was prepared from rabbit ClC-
2 using a construct in pSportI, donated by H.C. Hartzell (Emory University, Atlanta, 
GA). For two-electrode voltage clamp experiments (TEVC), oocytes were injected with 
2.5 - 50 ng of cRNA encoding ClC-1, -2, -3, or -4, 0.06 - 1 ng ShB-IR cRNA, 50 - 100 ng 
GABAC-rho subunit cRNA, or 2 - 20 ng cRNA encoding wild type Cystic Fibrosis 
Transmembrane Conductance Regulator (WT-CFTR). For patch recordings, oocytes were 
injected with 0.5 - 2 ng ClC-2 cRNA or Flag cut-Δ-R-CFTR. Data were collected at room 
temperature 2 - 5 days post injection. Methods for animal handling are in accordance 
with the NIH guidelines and the protocol was approved by the Animal Use and Care 
Committee of the Georgia Institute of Technology and Emory University. 
 
7.2 Venom Preparation and Toxin Purification 
Venom from Leiurus quinquestriatus hebraeus was obtained from Latoxan 
(France), and prepared as described [61]. Dried whole venom was prepared at a stock 
concentration of 2 mg/mL in the appropriate bath solution (see below) for 
electrophysiological recording. For toxin purification venom was prepared at a 
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concentration of 5 mg/mL in solution that contained (in mM): 150 NMDG-Cl, 5 MgCl2, 
10 TES, and 10 Tris·EGTA, pH 7.5. Subsequent fractions were resuspended in ND96. All 
venom and fraction concentrations are stated as equivalent to the dried weight of whole 
venom.  
Reversed-phase HPLC was performed on Lqh pf-venom prepared as described 
above. RP-HPLC was performed on a Waters 1525 binary HPLC coupled to a Waters 
2487 dual wavelength absorbance detector, utilizing a Zorbax 300SB-C3 column (4.6 
mm x 250 mm) or Zorbax SB-C18 column (4.6 mm x 250 mm). Lqh pf-venom or venom 
fraction was applied to the column in 500 mL aliquots. Samples were eluted with 
gradients of aqueous acetonitrile. Elution gradients were designed to optimize protein 
separation, and absorbance was monitored at 220 nm. Separations on the C3 column were 
performed using an elution gradient which ramped from 0- 95% acetonitrile over 50 
minutes, with brief periods where the percent acetonitrile was held constant. The protocol 
then ramped back to 0% acetonitrile over 5 minutes and this condition was held constant 
for another 5 minutes. The first round of separations on the C18 column were performed 
using an elution gradient that ramped from 0-25% acetonitrile over 50 minutes, held at 
25% acetonitrile for 5 minutes, and then ramped back to 0% acetonitrile over 5 minutes. 
For final peak collection using the C18 column, the percent acetonitrile was held at 5% 
for 5 minutes, then ramped to 20% over 55 minutes. All collected fractions were dried via 
SpeedVac and were resuspended in volumes of the appropriate bath solution equivalent 
to the total volume of Lqh pf-venom injected onto the column. Resuspended fractions 
were stored at -80oC 
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7.3 Electrophysiology 
Standard TEVC techniques were used to study whole cell ClC-2 currents 
expressed in Xenopus oocytes. Currents were acquired using a GeneClamp 500B 
amplifier and pClamp 8.4 software (Axon Instruments, Union City, CA). Data were 
acquired at 2 kHz and filtered at a corner frequency of 500 Hz. Bath solutions and 
voltage protocols for TEVC experiments with ClC channels were as previously described 
in Chapter 3. Currents were measured in the absence and presence of venom fractions, or 
isolated toxin, with percent inhibition being assessed at the end of the activation pulse. 
For ShB-IR experiments, leak currents were subtracted using a P/4 protocol. GABAC and 
CFTR recordings were performed at a holding potential of VM = -60 mV.  
Inside-out multi-channel and single-channel patch clamp experiments were 
performed as previously described [299]. All data were recorded to DAT tape at 10 kHz 
and were subsequently filtered at 100 Hz and acquired by computer at 500 Hz. For 
inside-out patches in the presence of toxin, the toxin was backfilled into the pipette and 
allowed to diffuse to the surface of the patch. Multi channel patch recordings of Flag cut-
Δ-R-CFTR were performed by application of 0.2 mM ATP or 0.2 mM ATP + 60 nM 
toxin to the intracellular face of patches containing CFTR; currents were recorded at VM 
= -80 mV. Unless otherwise stated, all single channel traces depicted in the figures were 
recorded at VM = -100 mV. For all electrophysiological data shown, the horizontal 
dashed line indicates the zero-current level. 
In order to prevent loss of material, all toxin containing solutions were prepared 
immediately prior to experiments from a 20 μM stock. All solution lines and recording 
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chambers were coated with BSA to prevent loss of material due to sticking to plastic or 
glass.  
 
7.4 Protein Analysis 
The active toxin was analyzed via MALDI-MS at the Georgia Institute of 
Technology Bioanalytical Mass Spectrometry Facility. Edman degradation was 
performed at the Emory University Microchemical and Proteomics Facility. Sequence 
analysis of the natural and modified (reduced and alkylated) peptides was performed 
using Applied Biosystems model Procise-cLC automated protein sequencer (Applied 
Biosystems 491cLC CLC capillary protein sequencing system; Foster City, CA) using the 
manufacturer's cycles with slight modifications. Prior to sequencing, natural and 
modified samples were de-salted and purified via RP-HPLC. 
 
7.5 Homology Modeling 
 The homology model of the GaTx2 toxin was created using the Modeller 8v2 
program, using Neurotoxin P01 as the template structure [321]. The GaTx2 homology 
model was then minimized via a 5 ps, 2500 step simulation with NAMDv2 utilizing the 
charmm22 force field. Prior to minimization, disulfide bridges were patched in order to 
ensure that the disulfide bonds remained intact during energy minimization.  
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7.6 GaTx2 Synthesis 
Methods for peptide synthesis, purification, and folding have been previously 
described [322, #325]. Solid phase synthesis was performed by Fmoc chemistry, using 
the HBTU/HOBT/DIPEA method on an Applied Biosystems 431A synthesizer. 
Oxidative cyclization of the crude linear peptide was performed under equilibrating 
conditions. The cyclized peptide was then purified from the reaction mixture via RP-
HPLC and characterized by MALDI-MS and analytical HPLC. 
 
7.7 Statistics 
Data are expressed as mean + SEM for n obervations. Differences were determined to be 
significant when p< 0.05, using paired and unpaired Student’s t-tests. 
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CHAPTER 8 
 
 
 
RESULTS 
 
 
 
8.1 Isolation of the Active Toxin 
We recently showed that a peptide component of scorpion venom is capable of 
specifically inhibiting the ClC-2 chloride channel [61]. In order to isolate the active 
component of this venom, we used reversed-phase HPLC (RP-HPLC) to separate the 
components of partially-fractionated venom (Lqh pf-venom), which contains only 
components smaller than 10 kDa. We tested each fraction for inhibition of ClC-2 currents 
using two-electrode voltage clamp (TEVC). With initial separation performed using a C3 
column, we observed that the fraction collected from 0 - 10 minutes, Fraction A, retained 
activity similar to Lqh pf-venom (Fig. 18A, 45.7 + 6% inhibition, fraction concentration 
0.1 mg/mL equivalent, n = 3, p = 0.01).  
The brief retention time of the active component on the C3 column suggests that 
the toxin is very hydrophilic.; therefore, further separation of components was not 
feasible using the C3 column. In order to increase the retention time of the active 
component so that it no longer co-eluted with the salt peak, further isolation and 
purification of the active toxin was achieved through two successive rounds of RP-HPLC 
using a C18 column, as summarized in Figure 18B and 18C. The isolated toxin, peak #3, 
eluted at ~5% acetonitrile using this elution gradient, and was sufficient to fully 
recapitulate the activity observed for Lqh pf-venom when diluted to the same equivalent 
concentration (64.2 + 5.3% inhibition at 0.1 mg/mL equivalent, n = 4, p = 0.025). Amino 
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acid analysis performed during protein sequencing (see Fig. 3) revealed that this toxin 
was present at very low abundance, with 0.1 mg/mL venom containing only 10 nM toxin. 
A dose-response curve constructed using native purified toxin showed that the KD at VM 
= -160 mV is only 80 pM, which represents the highest affinity interaction of any ClC 
channel inhibitor identified to date (Fig. 18D).  
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Figure 18: Isolation of the active toxin. (A - C) Left: Representative RP-HPLC 
chromatograms of Lqh pf-venom (A) or active fractions (B, C) The area included in the 
gray boxes, or indicated by an arrow, contains the active fraction or peak. The elution 
gradient is represented by a dashed line. The right panel presents summary data for 
fraction activity. Bars show mean + SEM for 3-10 observations. The inset shows 
representative traces from TEVC experiments in the absence (black trace) or presence 
(red trace) of the active fractions or isolated peak at VM = -160 mV stepped from –30 
mV. (D) Dose-response curve from a single TEVC experiment for inhibition of ClC-2 at 
VM = -160 mV by 0.01, 0.1, 1, or 10 nM native toxin.  
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8.2 Proteomic Characterization of GaTx2 
Peak #3 was then subjected to MALDI-TOF mass spectrometric analysis to 
determine the molecular mass of the intact compound, and to ensure that the collected 
chromatographic peak contained only one component. This analysis revealed that peak #3 
contained one component with an apparent mass of 3.19 kDa (Fig. 19A); a doubly 
charged species of the same component was also apparent. This is within the mass range 
of many short-chain peptide inhibitors isolated from Leiurus quinquestriatus venom.  
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Figure 19: Proteomic characterization of GaTx2. (A) MALDI-MS analysis of peak 3. (B) 
Sequence alignment of GaTx2 with other previously identified, highly related toxins. 
Disulfide bridge connectivity (specifically for GaTx2) is shown below the sequence 
alignment, while the predicted secondary structure for GaTx2 is shown above the 
sequence. (C) Homology model of GaTx2 (middle) shown with the NMR structures of 
Scyllatoxin (left) and Chlorotoxin (right), in three orientations. The top panel shows 
disulfide bridges in bond representation. 
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Initial attempts to determine the primary sequence of the active toxin were 
performed via MS/MS; however no fragmentation of the toxin was observed, even under 
very harsh conditions such as Xenon bombardment, likely due to the presence of multiple 
disulfide bonds. Additionally, attempts to sequence a reduced form of the toxin via 
MS/MS failed because of the very low abundance of the active component. Reduction of 
the active toxin with DTT followed by carboxamidomethylation induced a mass shift 
(3191.6 to 3539.5 kDa), as determined by MALDI-MS, that corresponded to the 
modification of 6 cysteine residues, indicating that the intact protein contained 3 disulfide 
linkages. Due to the difficulties obtaining primary sequence information from MS 
methods, the primary sequence of the toxin was determined via Edman degradation; 
however, only a few residues of the intact toxin could be sequenced using this process. 
Therefore, the reduced/carboxamidomethylated toxin was sequenced using Edman 
degradation and amino acid analysis, providing the complete primary sequence: 
1VSCEDCPDHCSTQKARAKCDNDKCVCEPI29. The identity of the C-terminal 
residue, I29, was determined by amino acid analysis. This sequence was confirmed by 
Edman sequencing of Lys-C protease digested, reduced/carboxamidomethylated toxin. 
We have isolated this toxin from venom on three separate occasions, as confirmed by MS 
analysis of the active fraction from these isolations. Sequence comparisons revealed that 
this primary sequence exactly matches the sequence of Leiuropeptide II (LPII) (Fig. 
19B), a peptide isolated in 1997 from the same scorpion which was not shown to have 
any lethal effects when injected into mouse brain or insects [323]. In fact, LPII was 
proposed to be a potassium channel inhibitor based on cysteine alignment and the 
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presence of a lysine residue at position 18, which is in the same position in the folded 
protein as the critical lysine (Lys27) of charybdotoxin. Lysine 27 is part of a critical 
dyad, with its partner being an aromatic residue located ~6Å away [324]. In LPII, 
however, this aromatic residue is absent. No target for LPII has ever been identified. 
Because this toxin actually inhibits a chloride channel, instead of a K+ channel as 
originally proposed, we have renamed it Georgia anion toxin 2 (GaTx2) to avoid 
confusion. GaTx2 is also very similar in primary sequence to a number of other toxins; 
the most relevant are shown in Figure 19B. Of these toxins, only four have been shown to 
be active against ion channels: neurotoxin P01, which is weakly toxic [325], scyllatoxin, 
which inhibits Ca2+-activated K+ (KCa) channels [326], and maurotoxin and OdK1, both 
of which inhibit KV1.2 [327, 328]. 
Short-chain peptide toxins from scorpion venoms tend to adopt a roughly similar 
tertiary structure, and many of these structures have been solved via NMR or X-ray 
crystallography. The NMR structure of GaTx2 (leiuropeptide II) has been previously 
solved [323]; however, the coordinates are unavailable. Therefore, created a homology 
model of GaTx2 based on the NMR structure of neurotoxin P01 [321], in order to make 
structural comparisons of GaTx2 to other known scorpion toxins (Fig. 19C middle). 
Neurotoxin P01 is 93% identical to GaTx2, providing an excellent template for an 
accurate homology model. This model predicts that GaTx2 is composed of 2 β-strands 
and one α-helix, which are connected via 3 disulfide bonds. The basic fold and disulfide 
connectivity are consistent with the NMR structure of LpII [323]. This basic fold is 
highly conserved among numerous toxins isolated from various scorpion species [275]. 
GaTx2 is noticeably more compact than both scyllatoxin (Fig. 19C left) and chlorotoxin 
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(Fig. 19C right), a toxin isolated from a related scorpion that is thought to inhibit an 
unidentified Cl- channel in rat brain when reconstituted into lipid bilayers [294, 326]. The 
primary and secondary structures of GaTx2 are also very different from GaTx1, a 
recently isolated peptide inhibitor active against the CFTR Cl- channel [298]. GaTx2 is 
~400 Da smaller than GaTx1 and has one fewer disulfide bond. GaTx2 has a calculated 
pI of just 4.51, which accounts for the large negative electrostatic potential that is 
associated with the protein and could possibly explain the lack of activity against cation 
channels.  
 
8.3 Inhibition of ClC-2 by Synthetic GaTx2 
In order to determine if the component that was isolated from venom is truly 
responsible for the observed inhibitory activity, we produced GaTx2 via solid-phase 
chemical synthesis, as has been done for many other peptide inhibitors [322, 329]. The 
folded synthetic toxin shows the same mass as the purified native toxin, indicating that no 
post-translational modifications were associated with the native toxin other than the three 
disulfide bonds (Fig. 20A). Activity of the synthetic form of GaTx2 was tested initially 
via TEVC using the same voltage protocols applied during the isolation of the toxin. 
TEVC experiments showed that synthetic GaTx2 inhibited ClC-2 mediated currents by 
61.41 + 8.02 % at VM = -160 mV (n = 3) (Fig. 20B, C). This activity was almost exactly 
the same as that observed by the native toxin (64.24 + 5.37, n = 4) (Fig. 20C).  
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Figure 20: Inhibition of ClC-2 macroscopic currents by synthetic GaTx2.(A) MALDI-
MS of the folded synthetic GaTx2 matches the mass spectra of the native toxin (B) TEVC 
experiment at VM = -160 mV in the absence (black trace) or presence (red trace) of 10 
nM synthetic GaTx2. (C) Comparison of percent inhibition by native and synthetic 
GaTx2 at the same concentration at VM = -160 mV. The native and synthetic toxins 
inhibit ClC-2 currents to the same degree (Native GaTx2, n = 4; Synthetic GaTx2, n = 3). 
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8.4 Kinetics of Inhibition of ClC-2 by GaTx2 
 In order to gain a better understanding of inhibition of ClC-2 by GaTx2, we 
measured the rate of both onset of, and recovery from inhibition of ClC-2 currents using 
TEVC; solution exchange in these experiments was complete within ~10 seconds. In 
order to allow sufficient channel activation, and maximal deactivation between pulses, 
channels were activated every 15 seconds with a 1 second voltage pulse to VM = -100 
mV, followed by a tail pulse to +40 mV. Evaluation of inhibition of ClC-2 currents by 1 
mM Zn2+, as a control, showed that inhibition occurred very rapidly, with a time constant 
for recovery from inhibition of ~38 seconds (Fig. 21A, C). Time-dependent currents were 
inhibited by ~95% by 1 mM Zn2+, as expected [250]. These experiments were then 
repeated using GaTx2 over a broad concentration range. Data obtained in the presence of 
100 pM GaTx2 show a fast onset of inhibition and a slow recovery from inhibition (Fig. 
21B, D). Using this protocol, we were able to construct a dose-response curve for 
inhibition of ClC-2 time-dependent currents by synthetic GaTx2 at VM = -100 mV. 
Fitting the data with a three-parameter Hill function gave a KD = 22 +10 pM and a Hill 
coefficient of ~1 (Fig. 22A), consistent with the very high affinity interaction observed 
for native GaTx2. Furthermore, we observed that the first order on-rate of GaTx2 
increased as a function of [GaTx2], while the off-rate was independent of toxin 
concentration. The very slow off-rate (KOff = 0.0034 s-1) is consistent with an intimate 
interaction between toxin and channel. The fit of the first order on-rates gave a second 
order rate constant of 43×106 M-1s-1 (Kon) (Fig. 22B). This value is likely an 
underestimate of the true rate constant, which is impacted by the solution exchange time 
and interpulse duration of the voltage protocol. These values are consistent, however, 
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with values that have been reported for other channel/toxin interactions [279]. 
Calculation of the KD from the rate constants, given as Koff/Kon, gave a value of 80 pM.  
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Figure 21: Time-course of inhibition of ClC-2 by synthetic GaTx2. (A) Control 
recording of ClC-2 in the presence of 1 mM Zn2+, a well characterized inhibitor of ClC-2 
channels. Channels were activated every 15 seconds by a 1 second voltage pulse to -100 
mV, followed by a tail pulse to +40 mV. Zn2+ was applied after channel activity had 
stabilized. (B) Experiment in the presence of 100 pM GaTx2 using the protocol just 
described. Note that time-dependent currents were inhibited by ~40%. (C) Summary data 
for five experiments in the presence of 1 mM Zn2+. Time dependent currents were 
inhibited by ~95% very rapidly, and returned to near baseline within 2 minutes. (D) 
Summary data for experiments in the presence of 100 pM GaTx2. Onset of inhibition 
occurred rapidly (n = 5), while recovery from inhibition was very slow (n = 2 for this 
concentration), taking > 7 minutes to return to baseline.  
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Figure 22: GaTx2 inhibits ClC-2 with very high affinity. (A) Dose-response curve for 
inhibition of ClC-2 currents by synthetic GaTx2 at VM = -100 mV. Data were fit with a 
three parameter Hill equation, giving a KD = 22 + 10 pM. Each point represents data from 
3 -5 TEVC experiments. (B). Plot of first order rate constants for the onset of inhibition 
(open squares), and recovery from inhibition (filled circles). The rate of onset of 
inhibition was concentration dependent, with a second order rate constant of 43 × 106 M-
1s-1 (n = 3-5 for each point), obtained from the slope of the line for the fit of the data. 
Recovery from inhibition was concentration independent with a rate of 0.0034 s-1 (n = 2 - 
3 each point; some error bars are smaller than the symbols).  
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8.5 Inhibition of ClC-2 by GaTx2 is voltage dependent 
In order to further characterize the activity of synthetic GaTx2, we recorded from 
inside-out multi-channel patches, where the pipette was backfilled with varying 
concentrations of synthetic toxin. The pipette was backfilled in such a way as to allow 10 
minutes of control recording (at VM = -100 mV or -60 mV), followed by 10 minutes of 
recording in the presence of GaTx2. We then calculated the average window current from 
five separate four-minute windows in both control and experimental conditions. When no 
toxin was backfilled into the pipette, we observed no change in average window current 
over the course of the experiment (Fig. 23A). However, when 2 nM synthetic GaTx2 was 
backfilled into the pipette, average window currents were drastically reduced at the end 
of the experiment (Fig. 23A, B; 80.4 + 2.0% decrease). We repeated these experiments 
with varying concentrations of GaTx2 to obtain a dose-response curve, which provided 
KD = 12 + 5 pM and a Hill coefficient of ~1 at -100 mV using this protocol (Fig. 23B). 
This value is not significantly different from the KD measured using TEVC at the same 
membrane potential. 
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Figure 23: Synthetic GaTx2 inhibits ClC-2 in a voltage-dependent manner.  (A) Multi-
channel inside-out patch recording of ClC-2 at VM = -100 mV in the presence of control 
extracellular solution (top), or 2 nM synthetic GaTx2 (bottom). The record at the left is 
from the beginning of the experiment, while the record at the right is from the end of the 
experiment, after the backfilled toxin had time to diffuse to the patch at the tip of the 
electrode. (B) Dose-response curve for inhibition of ClC-2 currents from multi-channel 
patches by GaTx2 at concentrations of 2 pM, 20 pM, 200 pM, and 2 nM; VM = -100 mV. 
All points contain data from 6 - 17 measurements of window current at each 
concentration. (C) Comparison of inhibition of ClC-2 by 2 pM GaTx2 when currents 
were measured at VM = -60 or -100 mV, in multichannel patches as shown in part A; * 
indicates p <0.001.  
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Our previous experiments with Lqh-pf venom indicated that inhibition of ClC-2 
was voltage-dependent, with improved inhibitory efficacy at less hyperpolarizing 
potentials [61]. The experiment shown in Figure 18D provided a KD of 80 pM at VM = -
160 mV; in contrast, the experiments shown in Figure 23 provided a KD of 12 pM. This 
suggests that the binding affinity of GaTx2 is voltage-dependent. In order to further 
characterize this phenomenon, we compared the degree of inhibition of ClC-2 current by 
2 pM synthetic GaTx2 at VM = -100 and -60 mV using multi-channel patches (Fig. 23C). 
At VM = -100 mV, 2 pM toxin did not inhibit ClC-2 significantly (4.0 + 9.9 % inhibition, 
n = 11 windows); however, at VM = -60 mV, ClC-2 currents were inhibited 41.4 + 4.1 % 
(n = 17 windows) by 2 pM toxin, confirming the notion that inhibition of ClC-2 by 
GaTx2 is voltage-dependent.  
 
8.6 Effect of GaTx2 on Single ClC-2 Channels 
Understanding the mechanism of inhibition of ClC-2 by GaTx2 will be essential 
for using this toxin as a tool to probe ClC channel structure and function. Peptide toxins 
may either inhibit channels by acting as pore blockers, which fully or partially occlude 
the pore, or by acting as gating modifiers, making it more difficult for the channel to open 
[249]. In order to determine if GaTx2 alters the single channel conductance of ClC-2, 
which may bee indicative of pore block, we created all-points amplitude histograms from 
segments of records with only 1-2 open channels, in the absence and presence of GaTx2. 
In the presence of 2 nM GaTx2, the single protopore amplitude at -100 mV was 
unchanged from control (0.25 + 0.01 pA vs. 0.26 + 0.01 pA, n = 3, p = 0.45) (Fig. 24A) 
as measured from the difference between levels O1 and O2 from the amplitude 
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histograms created from 2-minute sections of record in the absence and presence of toxin. 
This suggests that GaTx2 does not induce partial conductances, although this does not 
discount the possibility of inhibition via a pore block mechanism. We next performed 
patch clamp experiments with either one or two channels in the patch and 20 pM GaTx2 
backfilled into the pipette. Measuring channel activity as NPO/N, we observed that 
NPO/N was reduced by 59.5 + 8% (Fig. 24D, n = 2) at –100 mV, which is consistent with 
the reduction of window current observed in multichannel patches for this concentration 
of toxin (Fig. 23B). Some toxins act via a pore block mechanism by inducing long closed 
states within a channel burst [278, 295]. Expanded recordings of bursts (Fig. 24C) show 
that there appear to be no toxin-induced intraburst closures that would be consistent with 
a pore block mechanism.  
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Figure 24: GaTx2 inhibits ClC-2 by slowing channel opening. (A) All-points amplitude 
histograms in the absence (left) and presence (right) of 2 nM GaTx2. (B) Representative 
single channel trace of ClC-2 with and without 20 pM synthetic toxin at VM = -100 mV. 
(C) Expanded single channel trace of a ClC-2 burst in the absence and presence of 20 pM 
GaTx2. (D) Comparison of channel activity (as NPO/N) in the absence and presence of 20 
pM GaTx2. (E) Comparison of latency to opening of the first double-barreled burst after 
stepping from 0 to -100 mV, in the absence and presence of 20 pM GaTx2. 
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Prior experiments with Lqh pf-venom led us to propose that ClC-2 is inhibited by 
this toxin via modification of channel gating; channel activation was slowed in the 
presence of venom [61]. We reasoned that this effect may be apparent as a change in the 
latency to first opening of single ClC-2 channels. In the presence of 20 pM GaTx2, we 
observed a 7.67 + 0.25 fold increase (from 13 + 5 s to 107 + 40 s) (Fig. 24E, n = 2) in the 
latency to first opening upon stepping from VM = 0 to -100 mV, which is consistent with 
a modification of channel gating.  
 
8.7 GaTx2 is not an Open Channel Blocker 
 Thus far, our experiments have suggested that GaTx2 acts to slow channel 
opening via modification of channel gating. To provide further evidence for this 
mechanism, we tested the effect of GaTx2 on channels that had reach steady-state 
activation using outside-out macropatches. We reasoned that if GaTx2 modifies channel 
gating, application of toxin to open channels should not reduce current amplitude, or 
would reduce currents very slowly. If the toxin inhibited via an open channel pore block 
mechanism, then currents should be reduced even if toxin was applied when channels are 
open. To test this, we activated ClC-2 channels with a pulse to -100 mV, and allowed 
current to reach steady-state (Fig. 25). After steady-state had been achieved, usually after 
several minutes, 2 nM GaTx2 was applied for at least 1 minute using a fast perfusion 
system with a solution exchange time constant of ~20 ms [61]. Application of toxin did 
not inhibit open channel currents (1.02 + 0.02 fold change, n = 5, p = 0.15) (Fig. 25A, B), 
although application of toxin before steady state was reached led to substantial inhibition 
(Fig. 25A inset). In contrast, application of 1 mM DPC for 30 seconds to open channels 
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resulted in 44.90 + 3.00 % inhibition (n = 9, p < 0.01) (Fig. 25 B, D). This suggests that 
DPC inhibited ClC-2 channels via an open channel pore block mechanism, while GaTx2 
was not capable of inhibiting open channels. This also suggest that GaTx2 does not alter 
channel fast gating, as slowing of this process should resemble open channel block of 
macroscopic currents. Therefore, it seems likely that GaTx2 inhibits ClC-2 channel 
activation by inhibiting slow gating.  
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Figure 25: GaTx2 cannot inhibit open ClC-2 channels. ClC-2 channels were studied 
using outside-out macrpatches activate by a voltage step to VM = -100 mV. Channel 
activity was allowed to reach steady-state. Patches were then exposed to either 2 nM 
GaTx2 (A), or 1 mM DPC. Summary data shown in (C) and (D) shows that while GaTx2 
is unable to inhibit ClC-2 steady-state currents (n = 5) (C), DPC is able to inhibit very 
well (n = 9) (D). The inset in (A), on the other hand shows that if GaTx2 is applied to 
channels during the activation phase, then currents are inhibited.  
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8.8 Specificity of GaTx2 
Most peptide toxins are usually highly specific for their respective targets, 
although not always perfectly selective. Charybdotoxin (ChTx), for example, is known to 
inhibit both KCa, and KV channels [278, 279]. Although ClC-2 is a very broadly 
expressed Cl- channel, many other Cl- channel types are expressed in excitable and non-
excitable cells. Most inhibitors available for Cl- channels are very non-specific. In order 
to develop GaTx2 into a useful tool, we first needed to determine if GaTx2 is specific for 
ClC-2 or if it is capable of inhibiting other anion-selective channels. We first asked 
whether GaTx2 is capable of inhibiting any other members of the ClC channel family. 
We previously showed that venom had no effect on the skeletal muscle Cl- channel ClC-1 
[61]. To confirm this we asked whether synthetic GaTx2 could inhibit ClC-1. We 
compared currents in the presence of toxin to those after washout of toxin in order to 
account for channel rundown. In the presence of 10 nM GaTx2, tail currents at VM = -120 
mV from pulses to +60 mV were 1.036 + 0.012 fold larger than currents after washout of 
toxin, implying no inhibition of ClC-1 (Fig. 26A). Application of 10 nM GaTx2 to ClC-3 
likewise did not alter currents at VM = +80 mV ( Fig. 26B, 0.90 + 0.05 fold, n = 3, p = 
0.18). GaTx2 also was not capable of inhibiting ClC-4 mediated Cl- transport measure at 
VM = +80 mV (10 nM GaTx2, 0.97 + 0.02 fold, n = 3, p = 0.42) (Fig. 26C), indicating 
that GaTx2 does not inhibit a ClC protein that functions as a transporter. We also know 
from previous experiments that Lqh pf-venom does not inhibit ClC-0 [61]. Thus, GaTx2 
is not capable of inhibiting currents mediated by any other ClC channel on which we 
have tested it. 
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Figure 26: GaTx2 cannot inhibit other ClC proteins. In TEVC experiments, GaTx2 was 
applied to oocytes expressing either ClC-1 (A), ClC-3 (B), or ClC-4 (C). Representative 
currents in the absence and presence of toxin are shown in the top panels, while summary 
data is presented in the bottom panel. GaTx2 was unable to inhibit any other ClC protein. 
n = 3 - 4 for each type.  
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We have recently identified and characterized a peptide inhibitor of currents 
mediated by CFTR chloride channels. CFTR was not inhibited by the venom fraction that 
contains GaTx2 [295]. However, in order to corroborate these results we tested the effect 
of synthetic GaTx2 on CFTR. We first tested GaTx2 on CFTR currents by application of 
toxin to the extracellular face of the channels using TEVC. Channels were activated by 
200 mM IBMX + 25 mM db-cAMP. After steady-state activation was achieved, 20 nM 
GaTx2 was applied for 5 minutes. No change in current was observed during the 
application of toxin (Fig. 27A, 0.95 + 0.02 fold, n = 2), consistent with the notion that 
Lqh pf-venom could not inhibit CFTR currents from the extracellular fact. Due to the fact 
that GaTx1 only inhibited CFTR from the intracellular face [298], we applied 60 nM 
GaTx2 to the intracellular face of the channel using multi-channel patches. For these 
experiments we used Flag-cut ΔR-CFTR, a mutant CFTR lacking the R-domain, 
rendering it independent of phosphorylation by PKA insensitive to dephosphorylation-
mediated rundown. Channels were activated with 0.2 mM ATP, then reactivated with 0.2 
mM ATP + 60 nM GaTx2. No inhibition of channels currents was observed (Fig. 27B, 
0.91 + 0.13 fold, n = 10 windows, p=0.74). Therefore, GaTx2 also is not capable of 
inhibiting CFTR from either the extracellular or intracellular face.  
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Figure 27: GaTx2 cannot inhibit CFTR. (A) TEVC experiment in which WT-CFTR 
channels were activated by a mixture of IBMX and db-cAMP. Channel activity increased 
rapidly, then decayed and settled to steady state level. Channels were then exposed to 20 
nM extracellular GaTx2 for 5 minutes. Summary data presented in the bottom panel show 
that GaTx2 cannot inhibit ClC-2 from the extracellular side (n =2). (B) Inside-out multi-
channel patch recording of Flag-cut-ΔR-CFTR, VM = -80 mV. Channels were activated 
by application to the intracellular face of CFTR either 0.2 mM ATP or 0.2 mM ATP + 60 
nM GaTx2. Window currents for multiple 3-minute windows were analyzed in the 
absence and presence of GaTx2 for multiple patches. Summary data in the bottom panel 
show that GaTx2 cannot inhibit CFTR from the intracellular side (n = 10 windows). 
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We next asked whether GaTx2 is capable of inhibiting currents from ligand-gated 
chloride channels formed by GABAC receptors. GABAC currents were measured by 
TEVC both in the absence and presence of GaTx2 (Fig. 28A). Comparison of current in 
the presence of 10 μM GABA to currents in the presence of 10 μM GABA plus 10 nM 
GaTx2 showed no change (13 + 9.4 % increase, n = 3, p = 0.32). GABA-induced Cl- 
currents also did not significantly increase upon removal of toxin from the bath solution 
(14 + 19% increase, p = 0.74). This suggests that GaTx2 is not capable of inhibiting 
GABAC receptors. 
Xenopus oocytes contain a large number of endogenous calcium-dependent 
chloride channels (ClCa). Application of 10 mM Ca2+ to the face of an excised inside-out 
patch rapidly activates these channels, which rundown over the course of the experiment. 
Therefore, control records and records in the presence of GaTx2 were obtained from 
different patches. In order to access toxin activity, we measured current decay over the 
course of three pulsed exposures to high [Ca2+]; toxin was applied between the 1st and 2nd 
Ca2+ pulses. If GaTx2 inhibited channel currents, we expected to observe a greater degree 
of rundown in toxin-containing patches versus control patches. However, the decay 
between pulses was the same with and without 10 nM GaTx2 (Fig. 28B, 25.67 + 3.65% 
(control, n = 5), vs. 34.11 + 5.26, (+GaTx2, n=6), p = 0.24), suggesting that GaTx2 is not 
capable of inhibiting these channels from the intracellular side. We were unable to test 
the effect of GaTx2 on ClCa when applied to the extracellular face because receptor-
mediated activation of these channels exhibits irreversible desensitization after one 
exposure to receptor ligand (not shown). 
 179
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: GaTx2 does not inhibit other major Cl- channel types. (A) TEVC recording of 
oocytes expressing GABAC channels activated by 10 μM GABA (VM = -60 mV). 
Channels were exposed to 20 nM GaTx2 for 5 minutes then activated by GABA again. 
GaTx2 was then removed, while the oocyte was still exposed to GABA. The bottom 
panel shows that GaTx2 does not inhibit GABAC currents (n = 3), and GABA-activated 
current does not increase when GaTx2 is removed. (B) Inside out macropatch recording 
of endogenous Xenopus Ca2+-dependent Cl- channels, VM = -50 mV. Channels were 
activated by multiple applications of 10 mM Ca2+, and the amount of rundown was 
quantified. Toxin was applied to some patches between the first and second application 
by Ca2+. The degree of rundown between the 1st and 2nd application of Ca2+ did not differ 
between control patches and patches exposed to toxin (control, n = 5; GaTx2, n = 6).  
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Finally, because the toxin bearing the sequence of GaTx2 was originally predicted 
to be a K+ channel inhibitor, we sought to determine if this toxin could inhibit the 
voltage-gated Drosophila Shaker K+ channel B variant with inactivation-removed (ShB-
IR), by exposing oocytes expressing ShB-IR to 20 nM GaTx2, a concentration that 
strongly inhibits ClC-2 currents (Fig. 29A). We observed no inhibition of ShB-IR 
currents, indicating that GaTx2 does not interact with this channel (1.00 + 0.007 fold, n = 
2). We similarly tested the effect of GaTx2 on the mammalian Shaker equivalent KV1.2, 
and observed no change in K+ currents (Fig. 29B, 0.99 + 0.03 fold, n = 4, p=0.55). It is 
possible that GaTx2 may inhibit these channels at a much higher concentration, but it had 
no effect in the concentration range that effectively inhibits ClC-2 mediated currents. 
Thus, we have shown that GaTx2 is a specific ClC-2 inhibitor, being unable to inhibit 
other members of the ClC family, CFTR, GABAC, ClCa, or major voltage-dependent K+ 
channels.  
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Figure 29: GaTx2 does not inhibit voltage-dependent K+ channels. TEVC recording of 
Shaker ShB-IR K+ channels (A), and KV1.2 channels (B). Channels were activated by a 
voltage pulse to 0 mV from a holding potential of VM = 90 mV. Channels were exposed 
to either 20 nM GaTx2 (A), or 10 nM GaTx2 (B). Summary data show that GaTx2 is not 
capable of inhibiting Shaker ShB-IR K+ channels (n = 2), or KV1.2 (n = 4).  
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CHAPTER 9 
 
 
 
DISCUSSION 
 
 
 
We previously showed that Lqh pf-venom contained a peptide component that 
inhibited the ClC-2 chloride channel [61]. Here we describe the successful isolation and 
initial characterization of this toxin, which we have named GaTx2. This toxin is a 3.2 
kDa peptide with three disulfide bonds which hold together a secondary structure 
composed of one α-helix and two β-strands. Although the sequence of GaTx2 has been 
previously described [323], this is the first description of its molecular target. The target 
for this toxin was predicted to be a K+ channel based solely on sequence alignments with 
other known or putative K+ channel toxins. Therefore, this is also the first toxin that has 
been shown to be misclassified, raising the possibility that a number of other toxins 
capable of inhibiting anion-selective channels have already been sequenced.  
The crystal structure of a bacterial ClC protein has been very useful for directing 
experiments aimed at gaining further understanding of the pore structures and fast gating 
mechanisms of ClC channel proteins [239, 242]. Although the crystal structure has not 
been as useful for understanding slow gating, some progress has been made through 
mutagenesis studies [23, 38, 39, 69, 243]. The new crystal structures of the isolated C-
terminal domain from ClC-0 will likely be very helpful in this regard [245]. However, 
many of the conformational changes associated with channel gating are still unknown, 
and are unlikely to be elucidated strictly by studying available structures, which do not 
capture the dynamic nature of these proteins. The GaTx2 toxin will allow the biophysical 
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study of these gating processes in greater detail. GaTx2 inhibits ClC-2 with higher 
affinity than any other available drug and, in fact, is the best inhibitor of any chloride 
channel. The previously best available ClC inhibitor, a pentameric DIDS hydrolysis 
product, inhibits ClC-Ka with a K1/2 of 0.5 μMwhile GaTx1 inhibits CFTR with a KD of 
25 nM at -100 mV [264, 298]. The apparent dissociation constant of GaTx2 for ClC-2 at -
100 mV is ~ 15 pM (Fig. 22A, 23B). Consistent with this high affinity interaction, 
recovery of ClC-2 currents from inhibition is very slow, with a time constant of ~300s. 
Interestingly, inhibition of ClC-2 by GaTx2 seems to be protocol dependent. 
Application of toxin to channels that have reached steady state activation did not reduce 
currents. However, significant inhibition was observed when channels were allowed to 
close in the presence of toxin, as observed for both TEVC recording and inside-out multi-
channel patches. Therefore, GaTx2 does not mediate a simple open channel block 
mechanism such as that seen for some peptide toxins. Inhibition of GaTx2 is also 
voltage-dependent, with stronger inhibition at more physiological membrane potentials. It 
is presently unclear why maximal inhibition is ~60% for TEVC, while 80% inhibition 
can be achieved using patch clamp techniques. It is possible that the differences in 
recording conditions, such as chloride concentrations, may affect the inhibitory activity 
of GaTx2. Details regarding the exact mechanism of inhibition still need to be addressed. 
The voltage-dependence and protocol dependence suggest that the mechanism by which 
GaTx2 inhibits ClC-2 is a complicated one.  
  The physiological role of ClC-2 is still largely undefined. It is thought that ClC-2 
may play a role in vascular smooth muscle cells and may be expressed on the apical 
membrane of epithelial cells along with CFTR, although this is still controversial [99, 
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303]. GaTx2 will be useful in determining the role of ClC-2 in these cells and may aid in 
determining the membrane localization of ClC-2 in specific cell types. Also, mutations in 
ClC-2 have been implicated in epilepsy [92], while under-activity of WT ClC-2 has been 
implicated in constipation-associated inflammatory bowel disease [86]. Therefore, GaTx2 
may serve as a lead compound for peptidomimetic drugs that target ClC-2. 
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CHAPTER 10 
 
 
 
PERSPECTIVES AND FUTURE DIRECTIONS 
 
 
 
10.1 Summary of Presented Work 
The goal of the work presented in this dissertation was to identify and 
characterize a peptide inhibitor targeting a member of the ClC family of voltage-gated 
chloride channels and chloride/proton exchangers. Initial experiments showed that venom 
from the scorpion Leiurus quinquestriatus hebraeus was able to inhibit currents mediated 
by the ClC-2 chloride channel from the extracellular side when expressed in Xenopus 
oocytes. The data presented in Chapters 2 - 9 provide a description of the first peptide 
toxin inhibitor of any ClC protein, specifically ClC-2. As a first step towards isolation of 
the active toxin, we characterized the effect of Lqh pf-venom on ClC-2 mediated Cl- 
currents using a combination of TEVC and macropatch techniques. The active 
component was then isolated using multiple rounds of RP-HPLC with columns of varied 
hydrophobicity. Proteomic characterization of the toxin was then carried out using a 
combination of MALDI mass spectrometry, N-terminal protein sequencing, and amino 
acid analysis. The active toxin, which we named Georgia anion toxin 2 (GaTx2), is 
composed of 29 amino acids, has a molecular mass of 3.2 kDa, and contains three 
disulfide bridges. We have also produced this toxin using solid-phase chemical synthesis. 
Finally, basic pharmacological characterization of the active toxin was performed using a 
combination of TEVC, macropatch, and single channel recording.  
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  ClC proteins are expressed in nearly all cell types, where they are involved in 
maintenance of membrane potential, electrical excitability, endocytosis, and acidification 
of intracellular compartments. While there is a large base of general knowledge regarding 
these proteins, many of the biophysical characteristics for most ClC family members 
remain vague, in large part due to the lack of specific pharmacological tools that can be 
used to study ClC protein structure/function relationships. Peptide toxins isolated from 
animal venoms have provided just such tools for many cation channels. However, there is 
only one peptide toxin available that inhibits a chloride channel of known molecular 
identity; GaTx1 inhibits the CFTR chloride channel [298]. Our initial studies showed that 
Lqh pf-venom contained a peptide component capable of inhibiting ClC-2 mediated Cl- 
currents, but not currents mediated by ClC-0 or ClC-1. Peptide toxins active against 
cation channels inhibit channel activity by two distinct mechanisms; they may physically 
occlude the ion permeation pathway, or they may modifiy channel gating in such a way 
that increases the energy required for channel activation. Our data suggest that ClC-2 
channel activation was shifted to more hyperpolarizing potentials in the presence of 
venom, supporting the hypothesis that the active component may be a gating modifier. 
Consistent with this hypothesis, channel activation kinetics were slowed in the presence 
of venom. While ClC-2 is a voltage-dependent channel, it is also activated by cell 
swelling and extracellular acidification. Interestingly, the active component of venom 
appears to act solely on the voltage-dependent gating mechanism, as swelling activation 
of ClC-2 was unaltered in the presence of venom.  
Isolation of this active component via RP-HPLC led to the purification of a 3.2 
kDa protein, which we have named Georgia anion toxin 2 (GaTx2). A toxin with the 
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same primary sequence was previously isolated in 1997, but no target was identified, and 
no further studies using this toxin have been carried out since the original isolation. In the 
present work, we showed that GaTx2 is a specific inhibitor of ClC-2 chloride channels. 
This toxin cannot inhibit currents other members of the ClC family, CFTR from the 
extracellular or intracellular side, GABAC Cl- channels, Ca2+-dependent chloride 
channels from the intracellular side, or the voltage-dependent K+ channels Shaker and 
KV1.2. GaTx2 inhibited ClC-2 currents with very high affinity (KD ~ 15 pM at -100 mV) 
and, like venom, in a voltage-dependent manner; the toxin inhibited with high affinity at 
more physiological membrane potentials, i.e. higher affinity at -60 mV versus -100 mV. 
Importantly, synthetic GaTx2 was able to inhibit ClC-2 currents in the same manner as 
native GaTx2. This is important because not only does this prove that the toxin isolated 
from venom was the active component, but it also makes future studies using this toxin 
more feasible, as isolation of the toxin from venom is both time consuming and difficult.  
GaTx2 appears to alter channel gating in a manner similar to that of venom; 
channel activation kinetics are slowed in the presence of toxin. Our data suggest that this 
toxin is not a simple open channel blocker because it is unable to inhibit ClC-2 mediated 
currents when applied to channels that have reached steady-state activation with a PO ~1, 
consistent with the notion that this toxin is a gating modifier. A state-dependent pore 
blocker that binds only when the channel is closed would yield similar results; however, 
if GaTx2 inhibited ClC-2 currents via this mechanism then toxin would unbind during the 
course of a voltage pulse. Our data examining the effect of Lqh pf-venom on ClC-2 
currents suggest that the amount of inhibition does not decrease over the course of the 
voltage pulse. The trend actually shows greater inhibition at the end of the pulse than at 
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the beginning, although there is no statistical significance. Thus, it is unlikely that GaTx2 
acts as a state-dependent pore blocker, leaving modification of channel gating the only 
likely mechanism of inhibition.  
 
10.2 Future Directions and Implications 
GaTx2 represents the first peptide toxin inhibitor of ClC channels, and is the 
highest affinity inhibitor of any chloride channel. The experiments described in this 
dissertation have provided a basis for the development of this toxin as a pharmacological 
tool that may be used to study ClC channel structure/function relationships. While this 
toxin represents the first of a new class of peptide inhibitors, it is important to point out 
that this is likely not the only peptide toxin active against ClC proteins. Thousands of 
peptide toxins exist in nature when the components of venoms from other scorpion, 
spider, snake, and cone snail species are taken into account [249]. Although many, but by 
no means all, of these toxins have been purified from these animal venoms, most are 
characterized solely based on sequence alignments and disulfide bridge connectivity, as 
was the case originally for GaTx2 [323]. This simply emphasizes the need for 
experimental confirmation for conclusions based on in silico methods. 
Many future studies utilizing this toxin are possible. One of the first that needs to 
be undertaken is to determine if GaTx2 can inhibit ClC-2 in a cell line which natively 
expresses this channel. Most cell types exhibit several types of chloride currents. While 
ClC-2 RNA has been shown to be nearly ubiquitously expressed via Northern blot 
analysis [60], there is still a question of whether the protein is expressed in all of these 
cells. If GaTx2 is able to inhibit endogenous ClC-2 channel activity, the pattern of 
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functional protein expression may be established. Furthermore, there is still some 
controversy regarding membrane localization of ClC-2 in cells where protein expression 
has been well established [76, 78, 80, 303]. GaTx2 can be used in Ussing chamber 
experiments to establish either apical or basolateral localization for ClC-2 where the issue 
remains unclear. This toxin may also be critical for determination of the physiological 
role of ClC-2, which is still undefined in many cell types. Studies have indicated that 
ClC-2 may be involved in migration of glioblastoma cells, possibly playing a role in 
regulatory volume decrease [330]. Inhibition of endogenous Cl- current using the non-
specific Cl- channel inhibitor NPPB reduced cell migration; this was corroborated by 
similar effects of knock-down of ClC-2 using siRNA [330]. Preliminary studies from our 
lab suggest that GaTx2 can also inhibit migration of U87 glioblastoma cells. An invasion 
assay using transwell inserts showed that when cells were allowed to invade for 20 hours 
in the absence of toxin, a large number of cells were able to migrate through the insert; 
this migration was reduced when the experiment was performed in the presence of 500 
nM GaTx2 (Fig. 30A). Additionally, preliminary experiments examining proliferation of 
Caco-2 cells suggest that proliferation is slowed when grown in the presence of GaTx2. 
Using transepithelial resistance as a measure of cell proliferation, cells were grown either 
in the absence or presence of 4 nM GaTx2. In the absence of toxin cells reached 
confluency quickly both before and after wounding by a high voltage pulse. However, 
when cultured in the presence of toxin both initial growth and wound healing were 
slowed (Fig. 30B). This provides strong evidence that ClC-2 is involved in both 
migration of U87 cells and proliferation of Caco-2 cells, but these studies need to be 
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repeated, and performed in combination with whole-cell recording to examine the GaTx2 
sensitive current to establish that this current is indeed mediated by ClC-2.  
 191
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: GaTx2 alters cell migration and proliferation. (A) Migration assay of U87 
glioblastoma cells that have been allowed to migrate for 20 hours either in the absence 
(left) or presence of 500 nM GaTx2 (right). (B) Wound healing assay examining Caco-2 
cell growth. Cells were allowed to proliferate either in the absence (black trace) or 
presence (red trace) of 4 nM GaTx2. Once a tight epithelium was established, cells were 
wounded by a high voltage pulse, and allowed to proliferate again. Membrane resistance 
is used as a measure of confluency; high resistance indicates a tight epithelium. 
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As outlined in Chapter 1, ClC-2 is believed to be involved in epilepsy, with one 
specific mutation, G715E, shifting the voltage-dependence of ClC-2 activation to more 
depolarizing potentials, leading to overexcitability of neurons [92]. It has also been 
proposed that ClC-2 is involved in constipation-associated inflammatory bowel disease . 
In the intestine it has been well established that ClC-2 has a basolateral localization, thus 
aiding in chloride efflux and water absorption. Inhibition of basolaterally localized ClC-2 
would prevent excess water reabsorption, and relieve constipation. Finally, ClC-2 is 
expressed in the same lung epithelial cells that express CFTR, the chloride channel 
dysfunctional in cystic fibrosis (CF). It has been postulated that ClC-2 may serve as an 
alternate Cl- pathway in these cells, thereby alleviating the loss of Cl- transport associated 
with cystic fibrosis. Recently, peptide toxins have become very useful as lead compounds 
for pharmaceuticals, including a conotoxin derivative that is used to treat chronic pain 
[331]. It may therefore be possible to use GaTx2 as a lead compound for drugs that can 
be used to treat the diseases associated with altered ClC-2 activity. If GaTx2 can be 
developed in such a way as to promote ClC-2 activation, then this toxin may also serve as 
a platform to develop drugs that activate alternative Cl- transport in patients suffering 
from CF.  
 In addition to the experiments that can be performed to examine the physiological 
role of ClC-2, GaTx2 will most likely be an excellent tool for ClC-2 structure/function 
studies. One of the first steps that must be taken is the identification of the binding site 
for GaTx2. Peptide toxins that bind to cation channels bind their targets in regions that 
are critical for channel function, i.e. the pore domain or voltage sensor, and these toxins 
have been used to dissect both ion permeation and voltage-dependent gating [267, 274, 
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281]. For ClC channels, while it is largely accepted that the available crystal structure 
provides an excellent template for structural studies of ClC proteins from higher 
organisms, there is little doubt that there must be some critical differences between the 
bacterial and eukaryotic proteins. One important discovery was the determination that the 
bacterial ClC protein is a Cl-/H+ exchanger, not an ion channel [126, 127]. This suggests 
that the permeation pathway may be different between the two classes of proteins, and 
also that the gating mechanisms will likely be very different. In fact, the ClC transporter 
ClC-ec1 appears only to have a fast gating mechanism, as determined by Q10 
measurements of the transport rate . While fast gating may be similar for both ClC 
channels and transporters, slow-gating appears to be non-existent in the transporters, and 
is very poorly understood from a structural standpoint for ClC channels . Our data 
suggest that GaTx2 acts as a gating modifier that may alter slow gating of ClC-2. The 
protocol dependent activity of GaTx2 suggests that this toxin is very sensitive to the 
conformation of the channel; therefore, GaTx2 will likely serve to report the structural 
changes that ClC-2 undergoes during voltage-dependent gating. This makes identification 
of the binding site a necessary step. This should first be undertaken by using specific 
mutations of the ClC-2 channel that are known to affect gating, such as deletion of the N-
terminus, and the G715E mutation, as well as the E217A and C256S mutations to 
determine the effect that these mutations have on toxin activity, and to examine which 
gating mechanism is more strongly affected by GaTx2. The effect of GaTx2 on ClC-2 
gating can also be assessed using specific voltage protocols designed to isolate the fast 
and slow gating processes, such as those successfully used by de Santiago and coworkers 
[68]. A third approach that would unambiguously address this question is to 
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quantitatively examine the effect of GaTx2 on ClC-2 single channels, although the very 
slow off-rate of the toxin would make these experiments very difficult. 
Chimeric channels will likely be very useful for the identification of the toxin 
binding site due to the fact that GaTx2 has no effect on currents mediated by ClC-0 or 
ClC-1. Therefore, ClC-0/ClC-2 or ClC-1/ClC-2 chimeras could be used to identify the 
general region to which the toxin binds. Once this region is identified, point mutations 
can be made to identify the specific residues involved in binding. Likewise, the residues 
on GaTx2 that contribute to toxin efficacy must be identified. Due to the fact that WT-
GaTx2 can be successfully synthesized, making mutant GaTx2 is a simple matter of 
replacing a specific residue during the synthesis process. Each mutant toxin can then be 
tested to determine if the introduced mutation alters toxin activity. The residues that 
contribute to toxin activity will likely line one face of the toxin. Once both sides of the 
toxin/channel interaction interface are identified, thermodynamic mutant cycle analysis 
(TMCA) can be used to determine which residues interact with each other. TMCA has 
been very successfully used to map the interaction interface between agitoxin2 and the 
Shaker K+ channel. This process systematically tests combinations of wild type and 
mutant toxins and channels, and provides a measurement for the interaction energy for 
the specific combinations. In this way, the exact orientation of the toxin within the 
binding site can be determined. This will be important to assess why GaTx2 inhibits ClC-
2 channels, but not other ClC proteins. There must be critical differences between the 
ClC members within the binding site. Also, once the binding site is identified, researchers 
can determine what effect mutations of the toxin binding site have on ClC-2 gating, and if 
mutation of analogous residues in other ClC proteins also alters channel gating. It would 
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also be interesting to determine if the GaTx2 binding site can be transferred to other ClC 
proteins, and if this new chimeric protein has altered biophysical characteristics.  
Finally, a detailed study aimed at in depth examination of the inhibitory 
mechanism of GaTx2 needs to be performed. Our data suggest that GaTx2 acts as a 
gating modifier, but these results will only serve as a starting point for more directed 
study. We have shown that inhibition of ClC-2 currents by GaTx2 is voltage dependent, 
but a more detailed analysis is needed to determine if the membrane potential affects 
toxin on-rate or off-rate. It also needs to be determined if GaTx2 activity is affected by 
either intracellular or extracellular chloride concentration. Our data show a maximal 
inhibition of ~60% using TEVC, while ~80% inhibition can be achieved using multi-
channel patches. The most notable difference in the experimental conditions is that of the 
solution composition, with the bath solutions for the patch experiments containing 150 
mM chloride compared to 100 mM for TEVC experiments; the difference is even larger 
when comparing the intracellular chloride concentration, ~30 mM for TEVC versus 150 
mM for patch recording. Thus, it is possible that chloride concentration may play a role 
in the activity of the toxin. If this is the case, however, it will need to be determined if 
this is a direct effect of chloride concentration on toxin binding, or if changing chloride 
concentration simply shifts channel PO such that toxin activity is altered, especially 
considering that permeation and gating are linked in ClC channels [11]. As a gating 
modifier, GaTx2 is sensitive to channel open probability, making it likely that anything 
that changes channel open probability, such as changing chloride concentration, will also 
likely alter toxin activity. The effect of GaTx2 on swelling activation, pH-dependent 
gating, and PKA activation also needs to be investigated.  
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10.3 Closing 
Identification of this toxin is a major step forward for the pharmacology of ClC 
channels. This will open the way for detailed study of ClC structure/function 
relationships using pharmacological tools, and be very useful for physiological study of 
ClC-2. Finally, this toxin has the potential to be a lead compound for the development of 
therapeutics to treat inflammatory bowel disease, epilepsy, and possibly CF. Future work 
utilizing GaTx2 will lead to a deeper understanding of ClC protein biophysics and 
physiology, and this toxin will hopefully only be the first in a new family of peptide toxin 
inhibitors of ClC proteins.  
 197
LITERATURE CITED 
 
 
 
1. White MM & Miller C, A voltage-gated anion channel from the electric organ of 
Torpedo californica. J Biol Chem, 1979. 254: p. 10161-10166. 
 
2. Miller C & White MM, A voltage-dependent chloride conductance channel from 
Torpedo electroplax membrane. Ann N Y Acad Sci, 1980. 341: p. 534-551. 
 
3. Miller C & White MM, Dimeric structure of single chloride channels from 
Torpedo electroplax. Proc Natl Acad Sci U S A, 1984. 81: p. 2772-2775. 
 
4. Hanke W & Miller C, Single chloride channels from Torpedo electroplax. 
Activation by protons. J Gen Physiol, 1983. 82: p. 25-45. 
 
5. Middleton RE, Pheasant DJ, & Miller C, Purification, reconstitution, and subunit 
composition of a voltage-gated chloride channel from Torpedo electroplax. 
Biochemistry, 1994. 33: p. 13189-13198. 
 
6. Catalan M, et al., ClC-2 in guinea pig colon: mRNA, immunolabeling, and 
functional evidence for surface epithelium localization. Am J Physiol Gastrointest 
Liver Physiol, 2002. 283: p. G1004-1013. 
 
7. Jentsch TJ, Steinmeyer K, & Schwarz G, Primary structure of Torpedo marmorata 
chloride channel isolated by expression cloning in Xenopus oocytes. Nature, 
1990. 348: p. 510-514. 
 
8. White MM & Miller C, Probes of the conduction process of a voltage-gated Cl- 
channel from Torpedo electroplax. J Gen Physiol, 1981. 78: p. 1-18. 
 
9. Richard EA & Miller C, Steady-state coupling of ion-channel conformations to a 
transmembrane ion gradient. Science, 1990. 247: p. 1208-1210. 
 
10. Bauer CK, Steinmeyer K, Schwarz JR, & Jentsch TJ, Completely functional 
double-barreled chloride channel expressed from a single Torpedo cDNA. Proc 
Natl Acad Sci U S A, 1991. 88: p. 11052-11056. 
 
11. Pusch M, Ludewig U, Rehfeldt A, & Jentsch TJ, Gating of the voltage-dependent 
chloride channel CIC-0 by the permeant anion. Nature, 1995. 373: p. 527-531. 
 
12. Middleton RE, Pheasant DJ, & Miller C, Homodimeric architecture of a ClC-type 
chloride ion channel. Nature, 1996. 383: p. 337-340. 
 
13. Ludewig U, Pusch M, & Jentsch TJ, Independent gating of single pores in CLC-0 
chloride channels. Biophys J, 1997. 73: p. 789-797. 
 198
 
14. Dutzler R, et al., X-ray structure of a ClC chloride channel at 3.0 Åreveals the 
molecular basis of anion selectivity. Nature, 2002. 415: p. 287-294. 
 
15. Pusch M, Ludewig U, & Jentsch TJ, Temperature dependence of fast and slow 
gating relaxations of ClC-0 chloride channels. J Gen Physiol, 1997. 109: p. 105-
116. 
 
16. Swartz KJ, Towards a structural view of gating in potassium channels. Nat Rev 
Neurosci, 2004. 5: p. 905-916. 
 
17. Chen TY & Miller C, Nonequilibrium gating and voltage dependence of the ClC-
0 Cl- channel. J Gen Physiol, 1996. 108: p. 237-250. 
 
18. Pusch M, Jordt SE, Stein V, & Jentsch TJ, Chloride dependence of 
hyperpolarization-activated chloride channel gates. J Physiol, 1999. 515 ( Pt 2): 
p. 341-353. 
 
19. Chen TY, Chen MF, & Lin CW, Electrostatic control and chloride regulation of 
the fast gating of ClC-0 chloride channels. J Gen Physiol, 2003. 122: p. 641-651. 
 
20. Chen MF & Chen TY, Different fast-gate regulation by external Cl(-) and H(+) of 
the muscle-type ClC chloride channels. J Gen Physiol, 2001. 118: p. 23-32. 
 
21. Chen TY, Extracellular zinc ion inhibits ClC-0 chloride channels by facilitating 
slow gating. J Gen Physiol, 1998. 112: p. 715-726. 
 
22. Lin YW, Lin CW, & Chen TY, Elimination of the slow gating of ClC-0 chloride 
channel by a point mutation. J Gen Physiol, 1999. 114: p. 1-12. 
 
23. Estevez R, et al., Functional and structural conservation of CBS domains from 
CLC chloride channels. J Physiol, 2004. 557: p. 363-378. 
 
24. Li Y, Yu WP, Lin CW, & Chen TY, Oxidation and reduction control of the 
inactivation gating of Torpedo ClC-0 chloride channels. Biophys J, 2005. 88: p. 
3936-3945. 
 
25. Steinmeyer K, Ortland C, & Jentsch TJ, Primary structure and functional 
expression of a developmentally regulated skeletal muscle chloride channel. 
Nature, 1991. 354: p. 301-304. 
 
26. Koch MC, et al., The skeletal muscle chloride channel in dominant and recessive 
human myotonia. Science, 1992. 257: p. 797-800. 
 
27. Gronemeier M, et al., Nonsense and missense mutations in the muscular chloride 
channel gene Clc-1 of myotonic mice. J Biol Chem, 1994. 269: p. 5963-5967. 
 199
 
28. Jentsch TJ, Stein V, Weinreich F, & Zdebik AA, Molecular structure and 
physiological function of chloride channels. Physiol Rev, 2002. 82: p. 503-568. 
 
29. Steinmeyer K, et al., Inactivation of muscle chloride channel by transposon 
insertion in myotonic mice. Nature, 1991. 354: p. 304-308. 
 
30. Pusch M, Steinmeyer K, & Jentsch TJ, Low single channel conductance of the 
major skeletal muscle chloride channel, ClC-1. Biophys J, 1994. 66: p. 149-152. 
 
31. Steinmeyer K, et al., Multimeric structure of ClC-1 chloride channel revealed by 
mutations in dominant myotonia congenita (Thomsen). EMBO J, 1994. 13: p. 
737-743. 
 
32. Fahlke C, Rhodes TH, Desai RR, & George AL, Jr., Pore stoichiometry of a 
voltage-gated chloride channel. Nature, 1998. 394: p. 687-690. 
 
33. Saviane C, Conti F, & Pusch M, The muscle chloride channel ClC-1 has a double-
barreled appearance that is differentially affected in dominant and recessive 
myotonia. J Gen Physiol, 1999. 113: p. 457-468. 
 
34. Fahlke C, et al., Mechanism of voltage-dependent gating in skeletal muscle 
chloride channels. Biophys J, 1996. 71: p. 695-706. 
 
35. Rychkov GY, et al., Concentration and pH dependence of skeletal muscle 
chloride channel ClC-1. J Physiol, 1996. 497 ( Pt 2): p. 423-435. 
 
36. Accardi A & Pusch M, Fast and slow gating relaxations in the muscle chloride 
channel CLC-1. J Gen Physiol, 2000. 116: p. 433-444. 
 
37. Bennetts B, Roberts ML, Bretag AH, & Rychkov GY, Temperature dependence 
of human muscle ClC-1 chloride channel. J Physiol, 2001. 535: p. 83-93. 
 
38. Hebeisen S, et al., The role of the carboxyl terminus in ClC chloride channel 
function. J Biol Chem, 2004. 279: p. 13140-13147. 
 
39. Duffield M, Rychkov G, Bretag A, & Roberts M, Involvement of helices at the 
dimer interface in ClC-1 common gating. J Gen Physiol, 2003. 121: p. 149-161. 
 
40. Accardi A, Ferrera L, & Pusch M, Drastic reduction of the slow gate of human 
muscle chloride channel (ClC-1) by mutation C277S. J Physiol, 2001. 534: p. 
745-752. 
 
41. Pedersen TH, Nielsen OB, Lamb GD, & Stephenson DG, Intracellular acidosis 
enhances the excitability of working muscle. Science, 2004. 305: p. 1144-1147. 
 
 200
42. Palade PT & Barchi RL, Characteristics of the chloride conductance in muscle 
fibers of the rat diaphragm. J Gen Physiol, 1977. 69: p. 325-342. 
 
43. Pedersen TH, de Paoli F, & Nielsen OB, Increased excitability of acidified 
skeletal muscle: role of chloride conductance. J Gen Physiol, 2005. 125: p. 237-
246. 
 
44. Bennetts B, et al., Cytoplasmic ATP-sensing domains regulate gating of skeletal 
muscle ClC-1 chloride channels. J Biol Chem, 2005. 280: p. 32452-32458. 
 
45. Bennetts B, Parker MW, & Cromer BA, Inhibition of skeletal muscle ClC-1 
chloride channels by low intracellular pH and ATP. J Biol Chem, 2007. 282: p. 
32780-32791. 
 
46. Tseng PY, Bennetts B, & Chen TY, Cytoplasmic ATP inhibition of CLC-1 is 
enhanced by low pH. J Gen Physiol, 2007. 130: p. 217-221. 
 
47. Zifarelli G & Pusch M, The muscle chloride channel ClC-1 is not directly 
regulated by intracellular ATP. J Gen Physiol, 2008. 131: p. 109-116. 
 
48. Gurnett CA, Kahl SD, Anderson RD, & Campbell KP, Absence of the skeletal 
muscle sarcolemma chloride channel ClC-1 in myotonic mice. J Biol Chem, 1995. 
270: p. 9035-9038. 
 
49. Papponen H, et al., Regulated sarcolemmal localization of the muscle-specific 
ClC-1 chloride channel. Exp Neurol, 2005. 191: p. 163-173. 
 
50. Pusch M, Myotonia caused by mutations in the muscle chloride channel gene 
CLCN1. Hum Mutat, 2002. 19: p. 423-434. 
 
51. Lipicky RJ & Bryant SH, Sodium, potassium, and chloride fluxes in intercostal 
muscle from normal goats and goats with hereditary myotonia. J Gen Physiol, 
1966. 50: p. 89-111. 
 
52. Bryant SH & Morales-Aguilera A, Chloride conductance in normal and myotonic 
muscle fibres and the action of monocarboxylic aromatic acids. J Physiol, 1971. 
219: p. 367-383. 
 
53. Zifarelli G & Pusch M, CLC chloride channels and transporters: a biophysical and 
physiological perspective. Rev Physiol Biochem Pharmacol, 2007. 158: p. 23-76. 
 
54. Cho DH & Tapscott SJ, Myotonic dystrophy: emerging mechanisms for DM1 and 
DM2. Biochim Biophys Acta, 2007. 1772: p. 195-204. 
 
55. Klocke R, Steinmeyer K, Jentsch TJ, & Jockusch H, Role of innervation, 
excitability, and myogenic factors in the expression of the muscular chloride 
 201
channel ClC-1. A study on normal and myotonic muscle. J Biol Chem, 1994. 269: 
p. 27635-27639. 
 
56. Beck CL, Fahlke C, & George AL, Jr., Molecular basis for decreased muscle 
chloride conductance in the myotonic goat. Proc Natl Acad Sci U S A, 1996. 93: 
p. 11248-11252. 
 
57. Rhodes TH, et al., A missense mutation in canine C1C-1 causes recessive 
myotonia congenita in the dog. FEBS Lett, 1999. 456: p. 54-58. 
 
58. Fahlke C, et al., An aspartic acid residue important for voltage-dependent gating 
of human muscle chloride channels. Neuron, 1995. 15: p. 463-472. 
 
59. Pusch M, Steinmeyer K, Koch MC, & Jentsch TJ, Mutations in dominant human 
myotonia congenita drastically alter the voltage dependence of the CIC-1 chloride 
channel. Neuron, 1995. 15: p. 1455-1463. 
 
60. Thiemann A, Grunder S, Pusch M, & Jentsch TJ, A chloride channel widely 
expressed in epithelial and non-epithelial cells. Nature, 1992. 356: p. 57-60. 
 
61. Thompson CH, et al., Inhibition of ClC-2 chloride channels by a peptide 
component or components of scorpion venom. J Membr Biol, 2005. 208: p. 65-76. 
 
62. Jordt SE & Jentsch TJ, Molecular dissection of gating in the ClC-2 chloride 
channel. EMBO J, 1997. 16: p. 1582-1592. 
 
63. Ramjeesingh M, et al., Quaternary structure of the chloride channel ClC-2. 
Biochemistry, 2000. 39: p. 13838-13847. 
 
64. Nobile M, Pusch M, Rapisarda C, & Ferroni S, Single-channel analysis of a ClC-
2-like chloride conductance in cultured rat cortical astrocytes. FEBS Lett, 2000. 
479: p. 10-14. 
 
65. Weinreich F & Jentsch TJ, Pores formed by single subunits in mixed dimers of 
different CLC chloride channels. J Biol Chem, 2001. 276: p. 2347-2353. 
 
66. Niemeyer MI, et al., A conserved pore-lining glutamate as a voltage- and 
chloride-dependent gate in the ClC-2 chloride channel. J Physiol, 2003. 553: p. 
873-879. 
 
67. Zuniga L, et al., The voltage-dependent ClC-2 chloride channel has a dual gating 
mechanism. J Physiol, 2004. 555: p. 671-682. 
 
68. de Santiago JA, Nehrke K, & Arreola J, Quantitative analysis of the voltage-
dependent gating of mouse parotid ClC-2 chloride channel. J Gen Physiol, 2005. 
126: p. 591-603. 
 202
 
69. Yusef YR, et al., Removal of gating in voltage-dependent ClC-2 chloride channel 
by point mutations affecting the pore and C-terminus CBS-2 domain. J Physiol, 
2006. 572: p. 173-181. 
 
70. Grunder S, Thiemann A, Pusch M, & Jentsch TJ, Regions involved in the opening 
of CIC-2 chloride channel by voltage and cell volume. Nature, 1992. 360: p. 759-
762. 
 
71. Furukawa T, Ogura T, Katayama Y, & Hiraoka M, Characteristics of rabbit ClC-2 
current expressed in Xenopus oocytes and its contribution to volume regulation. 
Am J Physiol, 1998. 274: p. C500-512. 
 
72. Arreola J, Begenisich T, & Melvin JE, Conformation-dependent regulation of 
inward rectifier chloride channel gating by extracellular protons. J Physiol, 2002. 
541: p. 103-112. 
 
73. Hinzpeter A, et al., Membrane cholesterol content modulates ClC-2 gating and 
sensitivity to oxidative stress. J Biol Chem, 2007. 282: p. 2423-2432. 
 
74. Suh BC & Hille B, PIP2 is a necessary cofactor for ion channel function: how and 
why? Annu Rev Biophys, 2008. 37: p. 175-195. 
 
75. Britton FC, et al., Molecular distribution of volume-regulated chloride channels 
(ClC-2 and ClC-3) in cardiac tissues. Am J Physiol Heart Circ Physiol, 2000. 279: 
p. H2225-2233. 
 
76. Gyomorey K, et al., Expression of the chloride channel ClC-2 in the murine small 
intestine epithelium. Am J Physiol Cell Physiol, 2000. 279: p. C1787-1794. 
 
77. Mohammad-Panah R, et al., ClC-2 contributes to native chloride secretion by a 
human intestinal cell line, Caco-2. J Biol Chem, 2001. 276: p. 8306-8313. 
 
78. Blaisdell CJ, et al., pH-regulated chloride secretion in fetal lung epithelia. Am J 
Physiol Lung Cell Mol Physiol, 2000. 278: p. L1248-1255. 
 
79. Cuppoletti J, et al., ClC-2 Cl- channels in human lung epithelia: activation by 
arachidonic acid, amidation, and acid-activated omeprazole. Am J Physiol Cell 
Physiol, 2001. 281: p. C46-54. 
 
80. Lipecka J, et al., Distribution of ClC-2 chloride channel in rat and human 
epithelial tissues. Am J Physiol Cell Physiol, 2002. 282: p. C805-816. 
 
81. Pena-Munzenmayer G, et al., Basolateral localization of native ClC-2 chloride 
channels in absorptive intestinal epithelial cells and basolateral sorting encoded 
by a CBS-2 domain di-leucine motif. J Cell Sci, 2005. 118: p. 4243-4252. 
 203
 
82. Hinzpeter A, et al., Association between Hsp90 and the ClC-2 chloride channel 
upregulates channel function. Am J Physiol Cell Physiol, 2006. 290: p. C45-56. 
 
83. Britton FC, et al., Functional characterization of novel alternatively spliced ClC-2 
chloride channel variants in the heart. J Biol Chem, 2005. 280: p. 25871-25880. 
 
84. Cheng G, Kim MJ, Jia G, & Agrawal DK, Involvement of chloride channels in 
IGF-I-induced proliferation of porcine arterial smooth muscle cells. Cardiovasc 
Res, 2007. 73: p. 198-207. 
 
85. Tewari KP, Malinowska DH, Sherry AM, & Cuppoletti J, PKA and arachidonic 
acid activation of human recombinant ClC-2 chloride channels. Am J Physiol Cell 
Physiol, 2000. 279: p. C40-50. 
 
86. Cuppoletti J, et al., SPI-0211 activates T84 cell chloride transport and 
recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol, 2004. 
287: p. C1173-1183. 
 
87. Smith RL, et al., Differential expression of an inwardly rectifying chloride 
conductance in rat brain neurons: a potential mechanism for cell-specific 
modulation of postsynaptic inhibition. J Neurosci, 1995. 15: p. 4057-4067. 
 
88. Staley K, et al., Alteration of GABAA receptor function following gene transfer of 
the CLC-2 chloride channel. Neuron, 1996. 17: p. 543-551. 
 
89. Bosl MR, et al., Male germ cells and photoreceptors, both dependent on close 
cell-cell interactions, degenerate upon ClC-2 Cl(-) channel disruption. EMBO J, 
2001. 20: p. 1289-1299. 
 
90. Blanz J, et al., Leukoencephalopathy upon disruption of the chloride channel ClC-
2. J Neurosci, 2007. 27: p. 6581-6589. 
 
91. Kajita H, Omori K, & Matsuda H, The chloride channel ClC-2 contributes to the 
inwardly rectifying Cl- conductance in cultured porcine choroid plexus epithelial 
cells. J Physiol, 2000. 523 Pt 2: p. 313-324. 
 
92. Haug K, et al., Mutations in CLCN2 encoding a voltage-gated chloride channel 
are associated with idiopathic generalized epilepsies. Nat Genet, 2003. 33: p. 527-
532. 
 
93. Niemeyer MI, et al., Functional evaluation of human ClC-2 chloride channel 
mutations associated with idiopathic generalized epilepsies. Physiol Genomics, 
2004. 19: p. 74-83. 
 
 204
94. Stogmann E, et al., Mutations in the CLCN2 gene are a rare cause of idiopathic 
generalized epilepsy syndromes. Neurogenetics, 2006. 7: p. 265-268. 
 
95. Everett K, et al., Linkage and mutational analysis of CLCN2 in childhood 
absence epilepsy. Epilepsy Res, 2007. 75: p. 145-153. 
 
96. McCarty NA, Permeation through the CFTR chloride channel. J Exp Biol, 2000. 
203: p. 1947-1962. 
 
97. Ostedgaard LS, et al., Processing and function of CFTR-DeltaF508 are species-
dependent. Proc Natl Acad Sci U S A, 2007. 104: p. 15370-15375. 
 
98. Riordan JR, CFTR function and prospects for therapy. Annu Rev Biochem, 2008. 
77: p. 701-726. 
 
99. Zdebik AA, et al., Additional disruption of the ClC-2 Cl(-) channel does not 
exacerbate the cystic fibrosis phenotype of cystic fibrosis transmembrane 
conductance regulator mouse models. J Biol Chem, 2004. 279: p. 22276-22283. 
 
100. Uchida S, et al., Molecular cloning of a chloride channel that is regulated by 
dehydration and expressed predominantly in kidney medulla. J Biol Chem, 1993. 
268: p. 3821-3824. 
 
101. Kieferle S, et al., Two highly homologous members of the ClC chloride channel 
family in both rat and human kidney. Proc Natl Acad Sci U S A, 1994. 91: p. 
6943-6947. 
 
102. Adachi S, et al., Two isoforms of a chloride channel predominantly expressed in 
thick ascending limb of Henle's loop and collecting ducts of rat kidney. J Biol 
Chem, 1994. 269: p. 17677-17683. 
 
103. Waldegger S & Jentsch TJ, Functional and structural analysis of ClC-K chloride 
channels involved in renal disease. J Biol Chem, 2000. 275: p. 24527-24533. 
 
104. Uchida S, et al., Localization and functional characterization of rat kidney-
specific chloride channel, ClC-K1. J Clin Invest, 1995. 95: p. 104-113. 
 
105. Estevez R, et al., Barttin is a Cl- channel beta-subunit crucial for renal Cl- 
reabsorption and inner ear K+ secretion. Nature, 2001. 414: p. 558-561. 
 
106. Waldegger S, et al., Barttin increases surface expression and changes current 
properties of ClC-K channels. Pflugers Arch, 2002. 444: p. 411-418. 
 
107. Scholl U, et al., Barttin modulates trafficking and function of ClC-K channels. 
Proc Natl Acad Sci U S A, 2006. 103: p. 11411-11416. 
 
 205
108. Jeck N, et al., A common sequence variation of the CLCNKB gene strongly 
activates ClC-Kb chloride channel activity. Kidney Int, 2004. 65: p. 190-197. 
 
109. Sauve R, et al., pH and external Ca(2+) regulation of a small conductance Cl(-) 
channel in kidney distal tubule. Biochim Biophys Acta, 2000. 1509: p. 73-85. 
 
110. Lourdel S, et al., A chloride channel at the basolateral membrane of the distal-
convoluted tubule: a candidate ClC-K channel. J Gen Physiol, 2003. 121: p. 287-
300. 
 
111. Kobayashi K, et al., Developmental expression of CLC-K1 in the postnatal rat 
kidney. Histochem Cell Biol, 2001. 116: p. 49-56. 
 
112. Yoshikawa M, et al., Localization of rat CLC-K2 chloride channel mRNA in the 
kidney. Am J Physiol, 1999. 276: p. F552-558. 
 
113. Kobayashi K, et al., Intrarenal and cellular localization of CLC-K2 protein in the 
mouse kidney. J Am Soc Nephrol, 2001. 12: p. 1327-1334. 
 
114. Qu C, et al., Expression of CLC-K chloride channels in the rat cochlea. Hear Res, 
2006. 213: p. 79-87. 
 
115. Mummery JL, Killey J, & Linsdell P, Expression of the chloride channel CLC-K 
in human airway epithelial cells. Can J Physiol Pharmacol, 2005. 83: p. 1123-
1128. 
 
116. Hebert SC, Bartter syndrome. Curr Opin Nephrol Hypertens, 2003. 12: p. 527-
532. 
 
117. Sile S, Vanoye CG, & George AL, Jr., Molecular physiology of renal ClC 
chloride channels/transporters. Curr Opin Nephrol Hypertens, 2006. 15: p. 511-
516. 
 
118. Schlingmann KP, et al., Salt wasting and deafness resulting from mutations in 
two chloride channels. N Engl J Med, 2004. 350: p. 1314-1319. 
 
119. Simon DB, et al., Mutations in the chloride channel gene, CLCNKB, cause 
Bartter's syndrome type III. Nat Genet, 1997. 17: p. 171-178. 
 
120. Konrad M, et al., Mutations in the chloride channel gene CLCNKB as a cause of 
classic Bartter syndrome. J Am Soc Nephrol, 2000. 11: p. 1449-1459. 
 
121. Birkenhager R, et al., Mutation of BSND causes Bartter syndrome with 
sensorineural deafness and kidney failure. Nat Genet, 2001. 29: p. 310-314. 
 
 206
122. Hayama A, Rai T, Sasaki S, & Uchida S, Molecular mechanisms of Bartter 
syndrome caused by mutations in the BSND gene. Histochem Cell Biol, 2003. 
119: p. 485-493. 
 
123. Frey A, et al., Influence of gain of function epithelial chloride channel ClC-Kb 
mutation on hearing thresholds. Hear Res, 2006. 214: p. 68-75. 
 
124. Matsumura Y, et al., Overt nephrogenic diabetes insipidus in mice lacking the 
CLC-K1 chloride channel. Nat Genet, 1999. 21: p. 95-98. 
 
125. Maduke M, Pheasant DJ, & Miller C, High-level expression, functional 
reconstitution, and quaternary structure of a prokaryotic ClC-type chloride 
channel. J Gen Physiol, 1999. 114: p. 713-722. 
 
126. Accardi A & Miller C, Secondary active transport mediated by a prokaryotic 
homologue of ClC Cl- channels. Nature, 2004. 427: p. 803-807. 
 
127. Accardi A, Kolmakova-Partensky L, Williams C, & Miller C, Ionic currents 
mediated by a prokaryotic homologue of CLC Cl- channels. J Gen Physiol, 2004. 
123: p. 109-119. 
 
128. Nguitragool W & Miller C, Uncoupling of a CLC Cl-/H+ exchange transporter by 
polyatomic anions. J Mol Biol, 2006. 362: p. 682-690. 
 
129. Accardi A, et al., Synergism between halide binding and proton transport in a 
CLC-type exchanger. J Mol Biol, 2006. 362: p. 691-699. 
 
130. Walden M, et al., Uncoupling and turnover in a Cl-/H+ exchange transporter. J 
Gen Physiol, 2007. 129: p. 317-329. 
 
131. Kuang Z, Mahankali U, & Beck TL, Proton pathways and H+/Cl- stoichiometry in 
bacterial chloride transporters. Proteins, 2007. 68: p. 26-33. 
 
132. Accardi A, et al., Separate ion pathways in a Cl-/H+ exchanger. J Gen Physiol, 
2005. 126: p. 563-570. 
 
133. Nguitragool W & Miller C, CLC Cl- /H+ transporters constrained by covalent 
cross-linking. Proc Natl Acad Sci U S A, 2007. 104: p. 20659-20665. 
 
134. Iyer R, Iverson TM, Accardi A, & Miller C, A biological role for prokaryotic ClC 
chloride channels. Nature, 2002. 419: p. 715-718. 
 
135. Sasaki S, et al., ClC family in the kidney. Jpn J Physiol, 1994. 44 Suppl 2: p. S3-
8. 
 
 207
136. Borsani G, et al., Characterization of a human and murine gene (CLCN3) sharing 
similarities to voltage-gated chloride channels and to a yeast integral membrane 
protein. Genomics, 1995. 27: p. 131-141. 
 
137. Ogura T, et al., ClC-3B, a novel ClC-3 splicing variant that interacts with EBP50 
and facilitates expression of CFTR-regulated ORCC. FASEB J, 2002. 16: p. 863-
865. 
 
138. Kawasaki M, et al., Stable and functional expression of the CIC-3 chloride 
channel in somatic cell lines. Neuron, 1995. 14: p. 1285-1291. 
 
139. Duan D, et al., Molecular identification of a volume-regulated chloride channel. 
Nature, 1997. 390: p. 417-421. 
 
140. Li X, Shimada K, Showalter LA, & Weinman SA, Biophysical properties of ClC-
3 differentiate it from swelling-activated chloride channels in Chinese hamster 
ovary-K1 cells. J Biol Chem, 2000. 275: p. 35994-35998. 
 
141. Li X, Wang T, Zhao Z, & Weinman SA, The ClC-3 chloride channel promotes 
acidification of lysosomes in CHO-K1 and Huh-7 cells. Am J Physiol Cell 
Physiol, 2002. 282: p. C1483-1491. 
 
142. Huang P, et al., Regulation of human CLC-3 channels by multifunctional 
Ca2+/calmodulin-dependent protein kinase. J Biol Chem, 2001. 276: p. 20093-
20100. 
 
143. Robinson NC, et al., Identification of an N-terminal amino acid of the CLC-3 
chloride channel critical in phosphorylation-dependent activation of a CaMKII-
activated chloride current. J Physiol, 2004. 556: p. 353-368. 
 
144. Matsuda JJ, et al., Overexpression of CLC-3 in HEK293T cells yields novel 
currents that are pH dependent. Am J Physiol Cell Physiol, 2008. 294: p. C251-
262. 
 
145. Hara-Chikuma M, et al., ClC-3 chloride channels facilitate endosomal 
acidification and chloride accumulation. J Biol Chem, 2005. 280: p. 1241-1247. 
 
146. Wang XQ, et al., CLC-3 channels modulate excitatory synaptic transmission in 
hippocampal neurons. Neuron, 2006. 52: p. 321-333. 
 
147. Stobrawa SM, et al., Disruption of ClC-3, a chloride channel expressed on 
synaptic vesicles, leads to a loss of the hippocampus. Neuron, 2001. 29: p. 185-
196. 
 
 208
148. Arreola J, et al., Secretion and cell volume regulation by salivary acinar cells 
from mice lacking expression of the Clcn3 Cl- channel gene. J Physiol, 2002. 545: 
p. 207-216. 
 
149. Jentsch TJ, Chloride and the endosomal-lysosomal pathway: emerging roles of 
CLC chloride transporters. J Physiol, 2007. 578: p. 633-640. 
 
150. Zhao Z, et al., The ClC-3 chloride transport protein traffics through the plasma 
membrane via interaction of an N-terminal dileucine cluster with clathrin. J Biol 
Chem, 2007. 282: p. 29022-29031. 
 
151. Salazar G, et al., AP-3-dependent mechanisms control the targeting of a chloride 
channel (ClC-3) in neuronal and non-neuronal cells. J Biol Chem, 2004. 279: p. 
25430-25439. 
 
152. Dickerson LW, et al., Altered GABAergic function accompanies hippocampal 
degeneration in mice lacking ClC-3 voltage-gated chloride channels. Brain Res, 
2002. 958: p. 227-250. 
 
153. Yoshikawa M, et al., CLC-3 deficiency leads to phenotypes similar to human 
neuronal ceroid lipofuscinosis. Genes Cells, 2002. 7: p. 597-605. 
 
154. Wohlke A, Distl O, & Drogemuller C, Characterization of the canine CLCN3 
gene and evaluation as candidate for late-onset NCL. BMC Genet, 2006. 7: p. 13. 
 
155. Wang GX, et al., Functional effects of novel anti-ClC-3 antibodies on native 
volume-sensitive osmolyte and anion channels in cardiac and smooth muscle 
cells. Am J Physiol Heart Circ Physiol, 2003. 285: p. H1453-1463. 
 
156. Hume JR, et al., Anion transport in heart. Physiol Rev, 2000. 80: p. 31-81. 
 
157. Duan DY, et al., Functional role of anion channels in cardiac diseases. Acta 
Pharmacol Sin, 2005. 26: p. 265-278. 
 
158. Weylandt KH, et al., ClC-3 expression enhances etoposide resistance by 
increasing acidification of the late endocytic compartment. Mol Cancer Ther, 
2007. 6: p. 979-986. 
 
159. Moreland JG, et al., Anion channels, including ClC-3, are required for normal 
neutrophil oxidative function, phagocytosis, and transendothelial migration. J Biol 
Chem, 2006. 281: p. 12277-12288. 
 
160. Miller FJ, Jr., et al., Cytokine activation of nuclear factor kappa B in vascular 
smooth muscle cells requires signaling endosomes containing Nox1 and ClC-3. 
Circ Res, 2007. 101: p. 663-671. 
 
 209
161. van Slegtenhorst MA, et al., A gene from the Xp22.3 region shares homology 
with voltage-gated chloride channels. Hum Mol Genet, 1994. 3: p. 547-552. 
 
162. Friedrich T, Breiderhoff T, & Jentsch TJ, Mutational analysis demonstrates that 
ClC-4 and ClC-5 directly mediate plasma membrane currents. J Biol Chem, 1999. 
274: p. 896-902. 
 
163. Vanoye CG & George AL, Jr., Functional characterization of recombinant human 
ClC-4 chloride channels in cultured mammalian cells. J Physiol, 2002. 539: p. 
373-383. 
 
164. Hebeisen S, et al., Anion permeation in human ClC-4 channels. Biophys J, 2003. 
84: p. 2306-2318. 
 
165. Picollo A & Pusch M, Chloride/proton antiporter activity of mammalian CLC 
proteins ClC-4 and ClC-5. Nature, 2005. 436: p. 420-423. 
 
166. Scheel O, Zdebik AA, Lourdel S, & Jentsch TJ, Voltage-dependent electrogenic 
chloride/proton exchange by endosomal CLC proteins. Nature, 2005. 436: p. 424-
427. 
 
167. Zdebik AA, et al., Determinants of anion-proton coupling in mammalian 
endosomal CLC proteins. J Biol Chem, 2008. 283: p. 4219-4227. 
 
168. Suzuki T, et al., Intracellular localization of ClC chloride channels and their 
ability to form hetero-oligomers. J Cell Physiol, 2006. 206: p. 792-798. 
 
169. Mohammad-Panah R, et al., The chloride channel ClC-4 contributes to endosomal 
acidification and trafficking. J Biol Chem, 2003. 278: p. 29267-29277. 
 
170. Mohammad-Panah R, et al., The chloride channel ClC-4 co-localizes with cystic 
fibrosis transmembrane conductance regulator and may mediate chloride flux 
across the apical membrane of intestinal epithelia. J Biol Chem, 2002. 277: p. 
566-574. 
 
171. Fisher SE, et al., Isolation and partial characterization of a chloride channel gene 
which is expressed in kidney and is a candidate for Dent's disease (an X-linked 
hereditary nephrolithiasis). Hum Mol Genet, 1994. 3: p. 2053-2059. 
 
172. Fisher SE, et al., Cloning and characterization of CLCN5, the human kidney 
chloride channel gene implicated in Dent disease (an X-linked hereditary 
nephrolithiasis). Genomics, 1995. 29: p. 598-606. 
 
173. Steinmeyer K, et al., Cloning and functional expression of rat CLC-5, a chloride 
channel related to kidney disease. J Biol Chem, 1995. 270: p. 31172-31177. 
 
 210
174. Sakamoto H, et al., Identification of a new outwardly rectifying Cl- channel that 
belongs to a subfamily of the ClC Cl- channels. J Biol Chem, 1996. 271: p. 
10210-10216. 
 
175. Meyer S, Savaresi S, Forster IC, & Dutzler R, Nucleotide recognition by the 
cytoplasmic domain of the human chloride transporter ClC-5. Nat Struct Mol 
Biol, 2007. 14: p. 60-67. 
 
176. Wellhauser L, et al., Nucleotides bind to the C-terminus of ClC-5. Biochem J, 
2006. 398: p. 289-294. 
 
177. Devuyst O, et al., Intra-renal and subcellular distribution of the human chloride 
channel, CLC-5, reveals a pathophysiological basis for Dent's disease. Hum Mol 
Genet, 1999. 8: p. 247-257. 
 
178. Thakker RV, Pathogenesis of Dent's disease and related syndromes of X-linked 
nephrolithiasis. Kidney Int, 2000. 57: p. 787-793. 
 
179. Jentsch TJ, Chloride transport in the kidney: lessons from human disease and 
knockout mice. J Am Soc Nephrol, 2005. 16: p. 1549-1561. 
 
180. Piwon N, et al., ClC-5 Cl- -channel disruption impairs endocytosis in a mouse 
model for Dent's disease. Nature, 2000. 408: p. 369-373. 
 
181. Gunther W, Piwon N, & Jentsch TJ, The ClC-5 chloride channel knock-out 
mouse - an animal model for Dent's disease. Pflugers Arch, 2003. 445: p. 456-
462. 
 
182. Gunther W, et al., ClC-5, the chloride channel mutated in Dent's disease, 
colocalizes with the proton pump in endocytotically active kidney cells. Proc Natl 
Acad Sci U S A, 1998. 95: p. 8075-8080. 
 
183. Vandewalle A, et al., Tissue distribution and subcellular localization of the ClC-5 
chloride channel in rat intestinal cells. Am J Physiol Cell Physiol, 2001. 280: p. 
C373-381. 
 
184. Christensen EI, et al., Loss of chloride channel ClC-5 impairs endocytosis by 
defective trafficking of megalin and cubilin in kidney proximal tubules. Proc Natl 
Acad Sci U S A, 2003. 100: p. 8472-8477. 
 
185. Jentsch TJ, Poet M, Fuhrmann JC, & Zdebik AA, Physiological functions of CLC 
Cl- channels gleaned from human genetic disease and mouse models. Annu Rev 
Physiol, 2005. 67: p. 779-807. 
 
186. Wang Y, et al., ClC-5: role in endocytosis in the proximal tubule. Am J Physiol 
Renal Physiol, 2005. 289: p. F850-862. 
 211
 
187. Carr G, Simmons N, & Sayer J, A role for CBS domain 2 in trafficking of 
chloride channel CLC-5. Biochem Biophys Res Commun, 2003. 310: p. 600-605. 
 
188. Fuchs R, et al., Rat liver endocytic coated vesicles do not exhibit ATP-dependent 
acidification in vitro. Proc Natl Acad Sci U S A, 1994. 91: p. 4811-4815. 
 
189. Hara-Chikuma M, et al., Impaired acidification in early endosomes of ClC-5 
deficient proximal tubule. Biochem Biophys Res Commun, 2005. 329: p. 941-946. 
 
190. Moulin P, et al., Altered polarity and expression of H+-ATPase without 
ultrastructural changes in kidneys of Dent's disease patients. Kidney Int, 2003. 63: 
p. 1285-1295. 
 
191. Schwake M, Friedrich T, & Jentsch TJ, An internalization signal in ClC-5, an 
endosomal Cl-channel mutated in dent's disease. J Biol Chem, 2001. 276: p. 
12049-12054. 
 
192. Hryciw DH, et al., Cofilin interacts with ClC-5 and regulates albumin uptake in 
proximal tubule cell lines. J Biol Chem, 2003. 278: p. 40169-40176. 
 
193. Hryciw DH, et al., Regulation of albumin endocytosis by PSD95/Dlg/ZO-1 
(PDZ) scaffolds. Interaction of Na+-H+ exchange regulatory factor-2 with ClC-5. 
J Biol Chem, 2006. 281: p. 16068-16077. 
 
194. Lloyd SE, et al., Characterisation of renal chloride channel, CLCN5, mutations in 
hypercalciuric nephrolithiasis (kidney stones) disorders. Hum Mol Genet, 1997. 6: 
p. 1233-1239. 
 
195. Silva IV, Blaisdell CJ, Guggino SE, & Guggino WB, PTH regulates expression of 
ClC-5 chloride channel in the kidney. Am J Physiol Renal Physiol, 2000. 278: p. 
F238-245. 
 
196. Wang SS, et al., Mice lacking renal chloride channel, CLC-5, are a model for 
Dent's disease, a nephrolithiasis disorder associated with defective receptor-
mediated endocytosis. Hum Mol Genet, 2000. 9: p. 2937-2945. 
 
197. Carr G, Simmons NL, & Sayer JA, Disruption of clc-5 leads to a redistribution of 
annexin A2 and promotes calcium crystal agglomeration in collecting duct 
epithelial cells. Cell Mol Life Sci, 2006. 63: p. 367-377. 
 
198. Weng TX, et al., Oxidant and antioxidant modulation of chloride channels 
expressed in human retinal pigment epithelium. Am J Physiol Cell Physiol, 2002. 
283: p. C839-849. 
 
 212
199. Davies N, et al., Chloride channel gene expression in the rabbit cornea. Mol Vis, 
2004. 10: p. 1028-1037. 
 
200. Edmonds RD, et al., ClC-5: ontogeny of an alternative chloride channel in 
respiratory epithelia. Am J Physiol Lung Cell Mol Physiol, 2002. 282: p. L501-
507. 
 
201. Brandt S & Jentsch TJ, ClC-6 and ClC-7 are two novel broadly expressed 
members of the CLC chloride channel family. FEBS Lett, 1995. 377: p. 15-20. 
 
202. Kida Y, et al., Localization of mouse CLC-6 and CLC-7 mRNA and their 
functional complementation of yeast CLC gene mutant. Histochem Cell Biol, 
2001. 115: p. 189-194. 
 
203. Eggermont J, et al., Alternative splicing of ClC-6 (a member of the CIC chloride-
channel family) transcripts generates three truncated isoforms one of which, ClC-
6c, is kidney-specific. Biochem J, 1997. 325 ( Pt 1): p. 269-276. 
 
204. Buyse G, et al., Expression of human pICln and ClC-6 in Xenopus oocytes 
induces an identical endogenous chloride conductance. J Biol Chem, 1997. 272: p. 
3615-3621. 
 
205. Buyse G, et al., Evidence for the intracellular location of chloride channel (ClC)-
type proteins: co-localization of ClC-6a and ClC-6c with the sarco/endoplasmic-
reticulum Ca2+ pump SERCA2b. Biochem J, 1998. 330 ( Pt 2): p. 1015-1021. 
 
206. Ignoul S, et al., Human ClC-6 is a late endosomal glycoprotein that associates 
with detergent-resistant lipid domains. PLoS ONE, 2007. 2: p. e474. 
 
207. Poet M, et al., Lysosomal storage disease upon disruption of the neuronal chloride 
transport protein ClC-6. Proc Natl Acad Sci U S A, 2006. 103: p. 13854-13859. 
 
208. Ernest NJ, Weaver AK, Van Duyn LB, & Sontheimer HW, Relative contribution 
of chloride channels and transporters to regulatory volume decrease in human 
glioma cells. Am J Physiol Cell Physiol, 2005. 288: p. C1451-1460. 
 
209. Kornak U, Bosl MR, & Kubisch C, Complete genomic structure of the CLCN6 
and CLCN7 putative chloride channel genes(1). Biochim Biophys Acta, 1999. 
1447: p. 100-106. 
 
210. Diewald L, et al., Activation by acidic pH of CLC-7 expressed in oocytes from 
Xenopus laevis. Biochem Biophys Res Commun, 2002. 291: p. 421-424. 
 
211. Graves AR, Curran PK, Smith CL, & Mindell JA, The Cl(-)/H(+) antiporter ClC-
7 is the primary chloride permeation pathway in lysosomes. Nature, 2008. 
 
 213
212. Kornak U, et al., Loss of the ClC-7 chloride channel leads to osteopetrosis in 
mice and man. Cell, 2001. 104: p. 205-215. 
 
213. Henriksen K, et al., Characterization of osteoclasts from patients harboring a 
G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. Am J 
Pathol, 2004. 164: p. 1537-1545. 
 
214. Kornak U, et al., Polymorphisms in the CLCN7 gene modulate bone density in 
postmenopausal women and in patients with autosomal dominant osteopetrosis 
type II. J Clin Endocrinol Metab, 2006. 91: p. 995-1000. 
 
215. Henriksen K, et al., Degradation of the organic phase of bone by osteoclasts: a 
secondary role for lysosomal acidification. J Bone Miner Res, 2006. 21: p. 58-66. 
 
216. Waguespack SG, Hui SL, Dimeglio LA, & Econs MJ, Autosomal dominant 
osteopetrosis: clinical severity and natural history of 94 subjects with a chloride 
channel 7 gene mutation. J Clin Endocrinol Metab, 2007. 92: p. 771-778. 
 
217. Cleiren E, et al., Albers-Schonberg disease (autosomal dominant osteopetrosis, 
type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol 
Genet, 2001. 10: p. 2861-2867. 
 
218. Kasper D, et al., Loss of the chloride channel ClC-7 leads to lysosomal storage 
disease and neurodegeneration. EMBO J, 2005. 24: p. 1079-1091. 
 
219. Lange PF, Wartosch L, Jentsch TJ, & Fuhrmann JC, ClC-7 requires Ostm1 as a 
beta-subunit to support bone resorption and lysosomal function. Nature, 2006. 
440: p. 220-223. 
 
220. Chalhoub N, et al., Grey-lethal mutation induces severe malignant autosomal 
recessive osteopetrosis in mouse and human. Nat Med, 2003. 9: p. 399-406. 
 
221. Quarello P, et al., Severe malignant osteopetrosis caused by a GL gene mutation. 
J Bone Miner Res, 2004. 19: p. 1194-1199. 
 
222. Pangrazio A, et al., Mutations in OSTM1 (grey lethal) define a particularly severe 
form of autosomal recessive osteopetrosis with neural involvement. J Bone Miner 
Res, 2006. 21: p. 1098-1105. 
 
223. Yin X, Denton J, Yan X, & Strange K, Characterization of a novel voltage-
dependent outwardly rectifying anion current in Caenorhabditis elegans oocytes. 
Am J Physiol Cell Physiol, 2007. 292: p. C269-277. 
 
224. He L, Denton J, Nehrke K, & Strange K, Carboxy terminus splice variation alters 
ClC channel gating and extracellular cysteine reactivity. Biophys J, 2006. 90: p. 
3570-3581. 
 214
 
225. Denton J, et al., Altered gating and regulation of a carboxy-terminal ClC channel 
mutant expressed in the Caenorhabditis elegans oocyte. Am J Physiol Cell 
Physiol, 2006. 290: p. C1109-1118. 
 
226. Denton J, et al., Alternative splicing of N- and C-termini of a C. elegans ClC 
channel alters gating and sensitivity to external Cl- and H+. J Physiol, 2004. 555: 
p. 97-114. 
 
227. Strange K, Of mice and worms: novel insights into ClC-2 anion channel 
physiology. News Physiol Sci, 2002. 17: p. 11-16. 
 
228. Rutledge E, et al., CLH-3, a ClC-2 anion channel ortholog activated during 
meiotic maturation in C. elegans oocytes. Curr Biol, 2001. 11: p. 161-170. 
 
229. von der Fecht-Bartenbach J, et al., Function of the anion transporter AtCLC-d in 
the trans-Golgi network. Plant J, 2007. 50: p. 466-474. 
 
230. Marmagne A, et al., Two members of the Arabidopsis CLC (chloride channel) 
family, AtCLCe and AtCLCf, are associated with thylakoid and Golgi 
membranes, respectively. J Exp Bot, 2007. 58: p. 3385-3393. 
 
231. De Angeli A, et al., The nitrate/proton antiporter AtCLCa mediates nitrate 
accumulation in plant vacuoles. Nature, 2006. 442: p. 939-942. 
 
232. Ludewig U, Pusch M, & Jentsch TJ, Two physically distinct pores in the dimeric 
ClC-0 chloride channel. Nature, 1996. 383: p. 340-343. 
 
233. Schmidt-Rose T & Jentsch TJ, Transmembrane topology of a CLC chloride 
channel. Proc Natl Acad Sci U S A, 1997. 94: p. 7633-7638. 
 
234. Mindell JA, Maduke M, Miller C, & Grigorieff N, Projection structure of a ClC-
type chloride channel at 6.5 A resolution. Nature, 2001. 409: p. 219-223. 
 
235. Engh AM & Maduke M, Cysteine accessibility in ClC-0 supports conservation of 
the ClC intracellular vestibule. J Gen Physiol, 2005. 125: p. 601-617. 
 
236. Ramjeesingh M, Li C, She YM, & Bear CE, Evaluation of the membrane-
spanning domain of ClC-2. Biochem J, 2006. 396: p. 449-460. 
 
237. Doyle DA, et al., The structure of the potassium channel: molecular basis of K+ 
conduction and selectivity. Science, 1998. 280: p. 69-77. 
 
238. Morais-Cabral JH, Zhou Y, & MacKinnon R, Energetic optimization of ion 
conduction rate by the K+ selectivity filter. Nature, 2001. 414: p. 37-42. 
 
 215
239. Dutzler R, Campbell EB, & MacKinnon R, Gating the selectivity filter in ClC 
chloride channels. Science, 2003. 300: p. 108-112. 
 
240. Faraldo-Gomez JD & Roux B, Electrostatics of ion stabilization in a ClC chloride 
channel homologue from Escherichia coli. J Mol Biol, 2004. 339: p. 981-1000. 
 
241. Chen TY, Coupling gating with ion permeation in ClC channels. Sci STKE, 2003. 
2003: p. pe23. 
 
242. Accardi A & Pusch M, Conformational changes in the pore of CLC-0. J Gen 
Physiol, 2003. 122: p. 277-293. 
 
243. Bykova EA, Zhang XD, Chen TY, & Zheng J, Large movement in the C terminus 
of CLC-0 chloride channel during slow gating. Nat Struct Mol Biol, 2006. 13: p. 
1115-1119. 
 
244. Markovic S & Dutzler R, The structure of the cytoplasmic domain of the chloride 
channel ClC-Ka reveals a conserved interaction interface. Structure, 2007. 15: p. 
715-725. 
 
245. Meyer S & Dutzler R, Crystal structure of the cytoplasmic domain of the chloride 
channel ClC-0. Structure, 2006. 14: p. 299-307. 
 
246. Alioth S, Meyer S, Dutzler R, & Pervushin K, The cytoplasmic domain of the 
chloride channel ClC-0: structural and dynamic characterization of flexible 
regions. J Mol Biol, 2007. 369: p. 1163-1169. 
 
247. Corry B, O'Mara M, & Chung SH, Conduction mechanisms of chloride ions in 
ClC-type channels. Biophys J, 2004. 86: p. 846-860. 
 
248. Cohen J & Schulten K, Mechanism of anionic conduction across ClC. Biophys J, 
2004. 86: p. 836-845. 
 
249. McDonough S (2003) in Calcium Channel Pharmacology, ed. McDonough S 
(Kluwer-Academic-Plenum Publishing, New York). 
 
250. Clark S, Jordt SE, Jentsch TJ, & Mathie A, Characterization of the 
hyperpolarization-activated chloride current in dissociated rat sympathetic 
neurons. J Physiol, 1998. 506 ( Pt 3): p. 665-678. 
 
251. Kurz LL, et al., Identification of three cysteines as targets for the Zn2+ blockade 
of the human skeletal muscle chloride channel. J Biol Chem, 1999. 274: p. 11687-
11692. 
 
 216
252. Duffield MD, Rychkov GY, Bretag AH, & Roberts ML, Zinc inhibits human 
ClC-1 muscle chloride channel by interacting with its common gating mechanism. 
J Physiol, 2005. 568: p. 5-12. 
 
253. Osteen JD & Mindell J, Insights into the ClC-4 transport mechanism from studies 
of Zn2+ inhibition. Biophys J, 2008. 
 
254. Pusch M, et al., Mechanism of block of single protopores of the Torpedo chloride 
channel ClC-0 by 2-(p-chlorophenoxy)butyric acid (CPB). J Gen Physiol, 2001. 
118: p. 45-62. 
 
255. Traverso S, Elia L, & Pusch M, Gating competence of constitutively open CLC-0 
mutants revealed by the interaction with a small organic Inhibitor. J Gen Physiol, 
2003. 122: p. 295-306. 
 
256. Liantonio A, et al., Structural requisites of 2-(p-chlorophenoxy)propionic acid 
analogues for activity on native rat skeletal muscle chloride conductance and on 
heterologously expressed CLC-1. Br J Pharmacol, 2003. 139: p. 1255-1264. 
 
257. Pusch M, et al., Pharmacological characterization of chloride channels belonging 
to the ClC family by the use of chiral clofibric acid derivatives. Mol Pharmacol, 
2000. 58: p. 498-507. 
 
258. Aromataris EC, et al., Modulation of the gating of CIC-1 by S-(-) 2-(4-
chlorophenoxy) propionic acid. Br J Pharmacol, 1999. 126: p. 1375-1382. 
 
259. Aromataris EC, et al., Fast and slow gating of CLC-1: differential effects of 2-(4-
chlorophenoxy) propionic acid and dominant negative mutations. Mol Pharmacol, 
2001. 60: p. 200-208. 
 
260. Estevez R, et al., Conservation of chloride channel structure revealed by an 
inhibitor binding site in ClC-1. Neuron, 2003. 38: p. 47-59. 
 
261. Liantonio A, et al., Investigations of pharmacologic properties of the renal CLC-
K1 chloride channel co-expressed with barttin by the use of 2-(p-
Chlorophenoxy)propionic acid derivatives and other structurally unrelated 
chloride channels blockers. J Am Soc Nephrol, 2004. 15: p. 13-20. 
 
262. Picollo A, et al., Molecular determinants of differential pore blocking of kidney 
CLC-K chloride channels. EMBO Rep, 2004. 5: p. 584-589. 
 
263. Gentzsch M, et al., The PDZ-binding chloride channel ClC-3B localizes to the 
Golgi and associates with cystic fibrosis transmembrane conductance regulator-
interacting PDZ proteins. J Biol Chem, 2003. 278: p. 6440-6449. 
 
 217
264. Matulef K, et al., Discovery of potent CLC chloride channel inhibitors. ACS 
Chem Biol, 2008. 3: p. 419-428. 
 
265. Matulef K & Maduke M, Side-dependent inhibition of a prokaryotic ClC by 
DIDS. Biophys J, 2005. 89: p. 1721-1730. 
 
266. Linsdell P & Hanrahan JW, Disulphonic stilbene block of cystic fibrosis 
transmembrane conductance regulator Cl- channels expressed in a mammalian 
cell line and its regulation by a critical pore residue. J Physiol, 1996. 496 ( Pt 3): 
p. 687-693. 
 
267. Qu Z, Wei RW, & Hartzell HC, Characterization of Ca2+-activated Cl- currents in 
mouse kidney inner medullary collecting duct cells. Am J Physiol Renal Physiol, 
2003. 285: p. F326-335. 
 
268. Liantonio A, et al., Activation and inhibition of kidney CLC-K chloride channels 
by fenamates. Mol Pharmacol, 2006. 69: p. 165-173. 
 
269. Picollo A, et al., Mechanism of interaction of niflumic acid with heterologously 
expressed kidney CLC-K chloride channels. J Membr Biol, 2007. 216: p. 73-82. 
 
270. Liantonio A, et al., Molecular switch for CLC-K Cl- channel block/activation: 
optimal pharmacophoric requirements towards high-affinity ligands. Proc Natl 
Acad Sci U S A, 2008. 105: p. 1369-1373. 
 
271. Liantonio A, et al., Niflumic acid inhibits chloride conductance of rat skeletal 
muscle by directly inhibiting the CLC-1 channel and by increasing intracellular 
calcium. Br J Pharmacol, 2007. 150: p. 235-247. 
 
272. Catterall WA, et al., Voltage-gated ion channels and gating modifier toxins. 
Toxicon, 2007. 49: p. 124-141. 
 
273. McDonough SI, Gating modifier toxins of voltage-gated calcium channels. 
Toxicon, 2007. 49: p. 202-212. 
 
274. Swartz KJ, Tarantula toxins interacting with voltage sensors in potassium 
channels. Toxicon, 2007. 49: p. 213-230. 
 
275. Rodriguez de la Vega RC & Possani LD, Current views on scorpion toxins 
specific for K+-channels. Toxicon, 2004. 43: p. 865-875. 
 
276. Tsetlin VI & Hucho F, Snake and snail toxins acting on nicotinic acetylcholine 
receptors: fundamental aspects and medical applications. FEBS Lett, 2004. 557: p. 
9-13. 
 
 218
277. Kristipati R, et al., Characterization of the binding of omega-conopeptides to 
different classes of non-L-type neuronal calcium channels. Mol Cell Neurosci, 
1994. 5: p. 219-228. 
 
278. Anderson CS, MacKinnon R, Smith C, & Miller C, Charybdotoxin block of single 
Ca2+-activated K+ channels. Effects of channel gating, voltage, and ionic strength. 
J Gen Physiol, 1988. 91: p. 317-333. 
 
279. Goldstein SA & Miller C, Mechanism of charybdotoxin block of a voltage-gated 
K+ channel. Biophys J, 1993. 65: p. 1613-1619. 
 
280. Gross A & MacKinnon R, Agitoxin footprinting the shaker potassium channel 
pore. Neuron, 1996. 16: p. 399-406. 
 
281. Naranjo D & Miller C, A strongly interacting pair of residues on the contact 
surface of charybdotoxin and a Shaker K+ channel. Neuron, 1996. 16: p. 123-130. 
 
282. Hidalgo P & MacKinnon R, Revealing the architecture of a K+ channel pore 
through mutant cycles with a peptide inhibitor. Science, 1995. 268: p. 307-310. 
 
283. Ranganathan R, Lewis JH, & MacKinnon R, Spatial localization of the K+ 
channel selectivity filter by mutant cycle-based structure analysis. Neuron, 1996. 
16: p. 131-139. 
 
284. Jiang Y, et al., X-ray structure of a voltage-dependent K+ channel. Nature, 2003. 
423: p. 33-41. 
 
285. Long SB, Campbell EB, & Mackinnon R, Crystal structure of a mammalian 
voltage-dependent Shaker family K+ channel. Science, 2005. 309: p. 897-903. 
 
286. Swartz KJ & MacKinnon R, Hanatoxin modifies the gating of a voltage-
dependent K+ channel through multiple binding sites. Neuron, 1997. 18: p. 665-
673. 
 
287. Chen H, Gordon D, & Heinemann SH, Modulation of cloned skeletal muscle 
sodium channels by the scorpion toxins Lqh II, Lqh III, and Lqh alphaIT. Pflugers 
Arch, 2000. 439: p. 423-432. 
 
288. Ruta V, et al., Functional analysis of an archaebacterial voltage-dependent K+ 
channel. Nature, 2003. 422: p. 180-185. 
 
289. Lee HC, Wang JM, & Swartz KJ, Interaction between extracellular Hanatoxin and 
the resting conformation of the voltage-sensor paddle in Kv channels. Neuron, 
2003. 40: p. 527-536. 
 
 219
290. Alabi AA, et al., Portability of paddle motif function and pharmacology in 
voltage sensors. Nature, 2007. 450: p. 370-375. 
 
291. Lee SY & MacKinnon R, A membrane-access mechanism of ion channel 
inhibition by voltage sensor toxins from spider venom. Nature, 2004. 430: p. 232-
235. 
 
292. Campos FV, Chanda B, Beirao PS, & Bezanilla F, beta-Scorpion toxin modifies 
gating transitions in all four voltage sensors of the sodium channel. J Gen Physiol, 
2007. 130: p. 257-268. 
 
293. Siemens J, et al., Spider toxins activate the capsaicin receptor to produce 
inflammatory pain. Nature, 2006. 444: p. 208-212. 
 
294. DeBin JA, Maggio JE, & Strichartz GR, Purification and characterization of 
chlorotoxin, a chloride channel ligand from the venom of the scorpion. Am J 
Physiol, 1993. 264: p. C361-369. 
 
295. Fuller MD, et al., Inhibition of CFTR channels by a peptide toxin of scorpion 
venom. Am J Physiol Cell Physiol, 2004. 287: p. C1328-1341. 
 
296. Maertens C, et al., Chlorotoxin does not inhibit volume-regulated, calcium-
activated and cyclic AMP-activated chloride channels. Br J Pharmacol, 2000. 
129: p. 791-801. 
 
297. Deshane J, Garner CC, & Sontheimer H, Chlorotoxin inhibits glioma cell invasion 
via matrix metalloproteinase-2. J Biol Chem, 2003. 278: p. 4135-4144. 
 
298. Fuller MD, et al., State-dependent inhibition of cystic fibrosis transmembrane 
conductance regulator chloride channels by a novel peptide toxin. J Biol Chem, 
2007. 282: p. 37545-37555. 
 
299. Fuller MD, Zhang ZR, Cui G, & McCarty NA, The block of CFTR by scorpion 
venom is state-dependent. Biophys J, 2005. 89: p. 3960-3975. 
 
300. Hechenberger M, et al., A family of putative chloride channels from Arabidopsis 
and functional complementation of a yeast strain with a CLC gene disruption. J 
Biol Chem, 1996. 271: p. 33632-33638. 
 
301. Jentsch TJ, Neagoe I, & Scheel O, CLC chloride channels and transporters. Curr 
Opin Neurobiol, 2005. 15: p. 319-325. 
 
302. Devuyst O & Guggino WB, Chloride channels in the kidney: lessons learned from 
knockout animals. Am J Physiol Renal Physiol, 2002. 283: p. F1176-1191. 
 
 220
303. Sherry AM, et al., Localization of ClC-2 Cl- channels in rabbit gastric mucosa. 
Am J Physiol Cell Physiol, 2001. 280: p. C1599-1606. 
 
304. Murray CB, Chu S, & Zeitlin PL, Gestational and tissue-specific regulation of 
C1C-2 chloride channel expression. Am J Physiol, 1996. 271: p. L829-837. 
 
305. Li-Smerin Y & Swartz KJ, Gating modifier toxins reveal a conserved structural 
motif in voltage-gated Ca2+ and K+ channels. Proc Natl Acad Sci U S A, 1998. 95: 
p. 8585-8589. 
 
306. DeBin JA & Strichartz GR, Chloride channel inhibition by the venom of the 
scorpion Leiurus quinquestriatus. Toxicon, 1991. 29: p. 1403-1408. 
 
307. McCarty NA & Zhang ZR, Identification of a region of strong discrimination in 
the pore of CFTR. Am J Physiol Lung Cell Mol Physiol, 2001. 281: p. L852-867. 
 
308. Machaca K & Hartzell HC, Asymmetrical distribution of Ca-activated Cl 
channels in Xenopus oocytes. Biophys J, 1998. 74: p. 1286-1295. 
 
309. Qu Z & Hartzell HC, Anion permeation in Ca(2+)-activated Cl(-) channels. J Gen 
Physiol, 2000. 116: p. 825-844. 
 
310. Swartz KJ & MacKinnon R, Mapping the receptor site for hanatoxin, a gating 
modifier of voltage-dependent K+ channels. Neuron, 1997. 18: p. 675-682. 
 
311. Norton RS & Pallaghy PK, The cystine knot structure of ion channel toxins and 
related polypeptides. Toxicon, 1998. 36: p. 1573-1583. 
 
312. McDonough SI, Boland LM, Mintz IM, & Bean BP, Interactions among toxins 
that inhibit N-type and P-type calcium channels. J Gen Physiol, 2002. 119: p. 
313-328. 
 
313. McDonough SI, Lampe RA, Keith RA, & Bean BP, Voltage-dependent inhibition 
of N- and P-type calcium channels by the peptide toxin omega-grammotoxin-SIA. 
Mol Pharmacol, 1997. 52: p. 1095-1104. 
 
314. Sidach SS & Mintz IM, Kurtoxin, a gating modifier of neuronal high- and low-
threshold ca channels. J Neurosci, 2002. 22: p. 2023-2034. 
 
315. Fahlke C, et al., Pore-forming segments in voltage-gated chloride channels. 
Nature, 1997. 390: p. 529-532. 
 
316. Adjadj E, et al., Solution structure of Lqh-8/6, a toxin-like peptide from a 
scorpion venom--structural heterogeneity induced by proline cis/trans 
isomerization. Eur J Biochem, 1997. 246: p. 218-227. 
 
 221
317. Maduke M, Miller C, & Mindell JA, A decade of CLC chloride channels: 
structure, mechanism, and many unsettled questions. Annu Rev Biophys Biomol 
Struct, 2000. 29: p. 411-438. 
 
318. Fahlke C, Ion permeation and selectivity in ClC-type chloride channels. Am J 
Physiol Renal Physiol, 2001. 280: p. F748-757. 
 
319. Jentsch TJ, Lorenz C, Pusch M, & Steinmeyer K, Myotonias due to CLC-1 
chloride channel mutations. Soc Gen Physiol Ser, 1995. 50: p. 149-159. 
 
320. Possani LD, et al., Peptides and genes coding for scorpion toxins that affect ion-
channels. Biochimie, 2000. 82: p. 861-868. 
 
321. Blanc E, et al., Solution structure of P01, a natural scorpion peptide structurally 
analogous to scorpion toxins specific for apamin-sensitive potassium channel. 
Proteins, 1996. 24: p. 359-369. 
 
322. Chang NS, et al., Predominant interactions between mu-conotoxin Arg-13 and the 
skeletal muscle Na+ channel localized by mutant cycle analysis. Biochemistry, 
1998. 37: p. 4407-4419. 
 
323. Buisine E, et al., Characterization of a new family of toxin-like peptides from the 
venom of the scorpion Leiurus quinquestriatus hebraeus. 1H-NMR structure of 
leiuropeptide II. J Pept Res, 1997. 49: p. 545-555. 
 
324. Mouhat S, De Waard M, & Sabatier JM, Contribution of the functional dyad of 
animal toxins acting on voltage-gated Kv1-type channels. J Pept Sci, 2005. 11: p. 
65-68. 
 
325. Zerrouk H, et al., Characterization of PO1, a new peptide ligand of the apamin-
sensitive Ca2+ activated K+ channel. Int J Pept Protein Res, 1996. 48: p. 514-521. 
 
326. Chicchi GG, et al., Purification and characterization of a unique, potent inhibitor 
of apamin binding from Leiurus quinquestriatus hebraeus venom. J Biol Chem, 
1988. 263: p. 10192-10197. 
 
327. Kharrat R, et al., Chemical synthesis and characterization of maurotoxin, a short 
scorpion toxin with four disulfide bridges that acts on K+ channels. Eur J 
Biochem, 1996. 242: p. 491-498. 
 
328. Abdel-Mottaleb Y, et al., The first potassium channel toxin from the venom of the 
Iranian scorpion Odonthobuthus doriae. FEBS Lett, 2006. 580: p. 6254-6258. 
 
329. Hui K, McIntyre D, & French RJ, Conotoxins as sensors of local pH and 
electrostatic potential in the outer vestibule of the sodium channel. J Gen Physiol, 
2003. 122: p. 63-79. 
 222
 
330. Yang XY, et al., siRNA-mediated silencing of ClC-2 gene inhibits proliferation of 
human U-87 glioma cells. Ai Zheng, 2006. 25: p. 805-810. 
 
331. Lewis RJ & Garcia ML, Therapeutic potential of venom peptides. Nat Rev Drug 
Discov, 2003. 2: p. 790-802. 
 
 
 
